JOURNAL OF PHARMACEUTICAL SCIENCES

A publication of the American Pharmaceutical Association—
the National Professional Society of Pharmacists

INDEX TO AUTHORS
INDEX TO SUBJECTS

VOLUME 66
JANUARY TO DECEMBER, 1977

Published monthly under the supervision of the Board of Trustees

MARY H. FERGUSON
Editor

SHELLY ELLIOTT
Production Editor

JANET D. SHOFF
Copy Editor

EDWARD G. FELDMANN
Contributing Editor

SAMUEL W. GOLDSTEIN
Contributing Editor

DAVID BOHARDT
Director of Publications

L. LUAN CORRIGAN
Assistant Director of Publications

EDITORIAL ADVISORY BOARD

John Autian
Norman R. Farnsworth
William O. Foye
William J. Jusko
Harry B. Kostenbauder
Herbert A. Lieberman
David E. Mann, Jr.
Gerald J. Papariello

© Copyright 1977 by the American Pharmaceutical Association; all rights reserved.

AUTHOR INDEX

A

Aarons, D. H., Rossi, G. V., and Orzechowski, R. F., cardiovascular actions of three harmala alkaloids: harmine, harmaline, and harmalol, 1244
Aarons, L. J., and Rowland, M., use of *in vitro* dissolution data to predict plasma drug profiles, 1359
Abbas, R., Willette, R. E., and Edwards, J. M., piperidine derivatives: synthesis of potential analgesics in 3-substituted 4-phenylpiperidine series, 1583
Abdel-Monem, M. M., and Ohno, K., polyamine metabolism II: *N*-(monoaminoalkyl)- and *N*-(polyaminoalkyl)acetamides in human urine, 1195
——and Ohno, K., polyamine metabolism I: synthesis of dansyl derivatives of *N*-(monoaminoalkyl)- and *N*-(polyaminoalkyl)acetamides and elucidation in urine of a cancer patient, 1089
——*see* Chen, C.-H., 931
——*see* Weeks, C. E., 1586
Abdou, H., *see* Bailey, L. C., 564
Abou-Gharbia, M., and Joullié, M. M., synthesis and hydrolysis of fluorene-9-spiro-2′-(*N*-aryl-3′,3′-dichloroaziridines), 1653
Abramson, H. N., Huang, C. L., Ho, C. C., Walny, L. L., and Hsu, Y.-M., thiocardenolides II: synthesis and pharmacological evaluation of 3β-thioacetyl-14β-hydroxy-5β-card-20(22)-enolide, 602
——*see* Wormser, H. C., 1208
Abu-Shady, H. A., *see* Loutfy, M. A., 1623
Aceto, M. D., *see* Rice, K. C., 193
Adams, K., *see* Mehta, A., 1462
Adir, J., and Barr, W. H., effect of sleep on bioavailability of tetracycline, 1000
Aghazarian, S. M., *see* Bikhazi, A. B., 1515
Agrawal, A. K., Parmar, S. S., Dwivedi, C., and Harbison, R. D., synthesis of 5-substituted 2-oxazolidinethiones and their antagonism to uterotropic effect of diethylstilbestrol, 887
Ahlquist, R. P., *see* Matheny, J. L., 93
Airoldi, L., *see* Mussini, E., 1482
Akers, W., *see* Skinner, W. A., 1764
Akhtar, B., *see* Nasir, S. S., 370
Albonico, S. M., *see* Rodriguez, M. R., 121
Alexander, K. S., Mauger, J. W., Petersen, H., Jr., and Paruta, A. N., solubility profiles and thermodynamics of parabens in aliphatic alcohols, 42
Allen, L. V., Jr., Yanchick, V. A., and Maness, D. D., dissolution rates of corticosteroids utilizing sugar glass dispersions, 494
Amaro, A. A., *see* Chowhan, Z. T., 1249, 1254
Ambre, J. J., *see* Van Hamme, M. J., 1344
Amirjahed, A. K., simplified method to study stability of pharmaceutical preparations, 785
Ando, H. Y., Ho, N. F. H., and Higuchi, W. I., *in vitro* estimates of topical bioavailability, 755
——Ho, N. F. H., and Higuchi, W. I., skin as an active metabolizing barrier I: theoretical analysis of topical bioavailability, 1525
Andrzejewski, D., *see* Hills, E. B., 1497
Ansel, H. C., *see* Cadwallader, D. E., 1357
Antonini, I., Cardellini, M., Claudi, F., Franchetti, P., Gulini, U., De Caro, G., and Venturi, F., indolizine derivatives with biological activity III: 3-(3-aminopropyl)-2-methylindolizine, 3-(3-aminopropyl)-2-methyl-5,6,7,8-tetrahydroindolizine, and their *N*-alkyl derivatives, 1692
Anttila, M., fluorometric determination of naproxen in serum, 433
Arambulo, A., *see* Hussain, M., 907
Arcelli, E., *see* Benzi, G., 1278
Arrigoni, E., *see* Benzi, G., 1278
Assadi, F., *see* Shafiee, A., 1050
Assinder, D. F., Chasseaud, L. F., and Taylor, T., plasma isosorbide dinitrate concentrations in human subjects after administration of standard and sustained-release formulations, 775
Augsburger, L. L., *see* David, S. T., 155
——*see* Small, L. E., 504, 1508
Avdovich, H. W., *see* Wilson, W. L., 1079
Axelson, J. E., *see* Jamali, F., 1540
Ayres, J. W., and Lindstrom, F. T., diffusion model for drug release from suspensions I: theoretical considerations, 654
——*see* Laskar, P. A., 1073, 1076
——*see* Lindstrom, F. T., 662
Azarnoff, D. L., *see* Bochner, F., 644

B

Baer, D. T., *see* Manion, C. V., 981
Baeyens, W., and De Moerloose, P., fluorescence properties of glafenine, 1771
——De Moerloose, P., and De Taeye, L., fluorescence characteristics of azaperone and of an azaperone mononitrogen oxide, 1787
Bailey, L. C., and Abdou, H., high-performance liquid chromatographic analysis of isoniazid and its dosage forms, 564
Bainbridge, C. A., Kelly, E. L., and Walkling, W. D., *in vitro* adsorption of acetaminophen onto activated charcoal, 480
Baizman, E. R., and Jenkins, H. J., mechanism of methacholine-induced rise in intraocular pressure in the dog, 1013
Baker, J. C., *see* Fuller, R. W., 271
Balagot, R., *see* Takruri, H., 283
Baley, G. J., Peck, G. E., and Banker, G. S., bactericidal properties of quaternary ammonium compounds in dispersed systems, 696
Ballbach, R. L., Brown, D. J., and Walters, S. M., determination of diphenoxylate hydrochloride and atropine sulfate in solutions and tablets, 1553
Ballerini, R., Cambi, A., and Del Soldato, P., new and simple method for determination of 2-(3-benzoylphenyl)propionic acid in body fluid, 281
Banerjee, S., Mitra, C., and Mukherjee, A. K., smooth muscle relaxant properties and vasomotor actions of 2-amino-1-*p*-nitrophenylpropane-1,3-diol, 1239
——*see* Gucluyildiz, H., 407
Banker, G. S., *see* Baley, G. J., 696
——*see* Mo, Y., 713
Bansal, P. C., and Monkhouse, D. C., stability of aqueous solutions of pirbuterol, 819
Bare, C. E., *see* Vincent, P. G., 1716
Barletta, M., *see* Staab, R. J., 1483
Barr, W. H., *see* Adir, J., 1000
Barry, B. W., *see* Woodford, R., 99
Bathala, M. S., *see* Kramer, W. G., 1720
Baugh, R., Calvert, R. T., and Fell, J. T., stability of phenylbutazone in presence of pharmaceutical colors, 733
Baweja, R., Sokoloski, T. D., and Patil, P. N., competitive binding between cocaine and various drugs to synthetic levodopa melanin, 1544
Bayne, W., *see* Theeuwes, F., 1388
Beasley, T. H., Sr., and Ziegler, H. W., high-performance liquid chromatographic analysis of methadone hydrochloride oral solution, 1749
Beaudoin, N., *see* Sved, S., 1761
Bechgaard, H., and Jespersen, S., GI absorption of niacin in humans, 871
Bechtol, L. D., *see* Kleber, J. W., 992
Beck, W. T., *see* Chou, J. T., 1556
Becker, C. H., *see* Newton, D. W., 1327
Bedford, J. A., *see* Borne, R. F., 119
Beecher, H., *see* Gumtow, R. H., 1777
Behl, C. R., *see* Owada, E., 216
Beihn, G. A., *see* Digenis, G. A., 442
Beisler, J. A., Peng, G. W., and Driscoll, J. S., potential antitumor agents: procarbazine analogs and other methylhydrazine derivatives, 849
Belair, E. J., *see* Melamed, S., 899
Beliveau, J., *see* Simon, D. Z., 431
Benet, L. Z., *see* Ronfeld, R. A., 178
Benhaim, S., *see* Tansy, M. F., 613
Benson, G. A., and Spillane, W. J., metabolic studies with the nonnutritive sweetener cycloheptylsulfamate, 881
Benzi, G., Villa, R. F., Montani, A., Pastoris, O., Arcelli, E., Strada, P., and Arrigoni, E., influence of training and pharmacological treatment on muscular enzymatic activities, 1278
Berge, S. M., Bighley, L. D., and Monkhouse, D. C., pharmaceutical salts, 1
Berlin, D., *see* Pottier, J., 1030
Besner, J. G., *see* Caille, G., 1383
Bevill, R. F., Dittert, L. W., and Bourne, D. W. A., disposition of sulfonamides in food-producing animals IV: pharmacokinetics of sulfamethazine in cattle following administration of an intravenous dose and three oral dosage forms, 619
——Koritz, G. D., Dittert, L. W., and Bourne, D. W. A., disposition of sulfonamides in food-producing animals V: disposition of sulfathiazole in tissue, urine, and plasma of sheep following intravenous administration, 1297
——*see* Sharma, J. P., 1319
Bhargava, H. N., improved recovery of morphine from biological tissue using siliconized glassware, 1044
Bibler, D. A., *see* Pikal, M. J., 1293
Biehl, E. R., *see* Graham, R. E., 965
——*see* Oteiza, R. M., 1385
Bighley, L. D., and Spivey, R. J., chelates of dicumarol I: preparation and structure identification of magnesium chelate, 1124
——*see* Berge, S. M., 1
Bikhazi, A. B., Aghazarian, S. M., and Tayim, H. A., degradation kinetics of a novel antimitogenic and antiviral palladium(II) coordination compound, 1515
——Nadir, N. S., and Hajjar, J.-J., calcium–prostaglandin aggregation and its effect on prostaglandin uptake by isolated rabbit intestine, 1308
——Shiatis, J. A., and Haddad, A. F., quantitative estimation of particulate matter in pharmaceutical preparations intended for intravenous administration, 181
Bilous, R., *see* Munson, J. W., 1403, 1775
Bjornsson, T. D., Blaschke, T. F., and Meffin, P. J., high-pressure liquid chromatographic analysis of drugs in biological fluids I: warfarin, 142
Blake, M. I., *see* Hsiao, C. H., 1157
——*see* Mrtek, M. B., 1019
Blanchard, J., Fink, W. T., and Duffy, J. P., effect of sorbitol on interaction of phenolic preservatives with polysorbate 80, 1470
——Schwartz, J. A., and Byrne, D. M., effects of agitation on size distribution of particulate matter in large-volume parenterals, 935
——Schwartz, J. A., and Byrne, D. M., parameter for assessing parenteral cleanliness based on particle-size distributions, 1083
Blaschke, T. F., *see* Bjornsson, T. D., 142
——*see* Meffin, P. J., 135
Blei, I., effects of adenine nucleotides on oxidation of phenothiazine tranquilizers, 1575
Bloss, J., *see* Sanvordeker, D. R., 82
Bochner, F., Huffman, D. H., Shen, D. D., and Azarnoff, D. L., bioavailability of digoxin–hydroquinone complex: a new oral digoxin formulation, 644
Bodnar, J. E., Evans, W. G., and Mays, D. L., spectrophotometric determination of cephapirin, a cephalosporin antibacterial, 1108
Boelstra, J. P., *see* Lerk, C. F., 1480
Bollinger, J. N., Lewis, D., and Mendex, V. M., benzoyl peroxide stability in pharmaceutical gel preparations, 718
Born, G. S., *see* Farid, N. A., 536
——*see* Heeg, J. F., 96
Born, J. L., and Harsin, C. E., anomalous chemical shifts and methyl groups of 2,4-dimethylbenzo[*g*]-quinoline, 1200
——and Vaughn, D., binding of pyridine derivatives to cytochrome P-450, 1046
Borne, R. F., Bedford, J. A., Buelke, J. L., Craig, C. B., Hardin, T. C., Kibbe, A. H., and Wilson, M. C., bio-

logical effects of cocaine derivatives I: improved synthesis and pharmacological evaluation of norcocaine, 119
——Law, S.-J., Wirth, P. W., and Murphy, J. C., synthesis of 5,6-benzo-2-azabicyclo[2.2.2]octane derivatives as potential benzomorphan-type analgesic agents, 594
Borodkin, S., Macy, L., Thompson, G., and Schmits, R., stable nonaqueous pentobarbital sodium solutions for use in laboratory animals, 693
——*see* Winkler, V. W., 816
Bortesi, F., Cavalli, S., and Mangia, A., preparation, identification, and quantitative NMR determination of silyl derivatives of 6-aminopenicillanic acid, 7-amino-3-methyl-Δ^3-cephem-4-carboxylic acid, and 7-amino-3-acetoxymethyl-Δ^3-cephem-4-carboxylic acid, 1767
Bottari, F., Di Colo, G., Nannipieri, E., Saettone, M. F., and Serafini, M. F., release of drugs from ointment bases II: *in vitro* release of benzocaine from suspension-type aqueous gels, 926
Bourne, D. W. A., Higuchi, T., and Repta, A. J., acetylacroninium salts as soluble prodrugs of the *antineoplastic agent acronine*, 628
——*see* Bevill, R. F., 619, 1297
——*see* Mercer, H. D., 1198
Bowen, M. H., *see* Hoar, D. R., 725
Bowman, P. B., see Hartman, P. A., 789
Boyden, G. R., *see* Johnson, R. N., 1212
Boze, L., *see* Meadows, G. G., 1503
Brady, M. E., and Hayton, W. L., GI drug absorption in rats exposed to cobalt-60 γ-radiation I: extent of absorption, 361
——and Hayton, W. L., GI drug absorption in rats exposed to cobalt-60 γ-radiation III: *in situ* intestinal absorption, 680
——and Hayton, W. L., GI drug absorption in rats exposed to cobalt-60 γ-radiation II: *in vivo* rate of absorption, 366
Breck, G. D., *see* Nelson, S. D., 1180
Broersma, P., *see* Lerk, C. F., 1480
Brooke, D., and Washkuhn, R. J., zero-order drug delivery system: theory and preliminary testing, 159
——*see* Mauger, J. W., 553
Brookman, S., and Kourounakis, P., alterations induced in distribution and *in vivo* metabolism of *imipramine by pregnenolone-16α-carbonitrile*, 1492
——*see* Simon, D. Z., 431
Brown, C. C., *see* Horrom, N. J., 739
Brown, D. J., *see* Ballbach, R. L., 1553
Brown, K. F., *see* Veng Pedersen, P., 1435, 1458
Brown, R., *see* Finn, A. M., 275
Brown, R. G., see Haney, W. G., 1602
——*see* Huerta, P. L., 1120
Browning, R. S., *see* Dombrowski, L. J., 1413
Bruce, R. B., *see* Teng, L., 1615
Bruckner, J. V., *see Chu, C. K., 238*
Bruemmer, G. A., see Tan, H. S. I., 1037
Brukwinski, W., *see* Hills, E. B., 1497
Bruno, A., *see* Ibrahim, H. G., 669
Brunson, M. K., see Kleber, J. W., 992
***Bryant, P. J.,** see Valentine, J. L., 1263*
Buchanan, G. W., *see* Wilson, W. L., 1079
Budd, R. D., *see* Jain, N. C., 66
***Buelke, J. L.,** see* Borne, R. F., 119
Burgschat, H., and Netter, K. J., simultaneous determination of *4-nitroanisole, 4-nitrophenol, and 4-nitrocatechol* by phase-sensitive ac polarography, 90
***Burke, D. H.,** and O'Hara, G. P., sodium nitroprusside-induced hypothermia in mice, 1658*
Burke, M., *see* Hills, E. B., 1497
Burns, L. B., Stedman, R. J., and Tuckerman, M. M., polynitro aromatic compounds in analytical chemistry I: *reaction with ouabain and digitoxin, 753*
Burrous, S. E., *see* White, R. L., 277
Bush, J. H., see Fujii, A., 844
***Butterfield, A. G.,** and Sears, R. W., high-performance* liquid chromatographic determination of perphenazine and amitriptyline hydrochloride in two-component tablet formulations, 1117
——Matsui, F. F., Smith, S. J., and Sears, R. W., *high-performance liquid chromatographic determination* of chlordiazepoxide and major related impurities in pharmaceuticals, 684
Byrne, D. M., *see* Blanchard, J., 935, 1083

C

Cadwallader, D. E., Lee, B. H., and Ansel, H. C., nitrofurantoin solubility in aqueous pyridoxine hydrochloride solutions, 1357
Caille, G., Lelorier, J., Latour, Y., and Besner, J. G., GLC determination of lidocaine in human plasma, 1383
Cairns, E. R., *see* McCallum, N. K., 114
Callery, P. S., and Leslie, J., thermal decomposition of 1,3-dimethyl derivative of phenobarbital in trimethylanilinium hydroxide, 578
Calvert, R. T., *see* Baugh, R., 733
Cambi, A., *see* Ballerini, R., 281
Cammarata, A., *see* Menon, G. K., 304
Cardellini, M., Claudi, F., Grifantini, M., Gulini, U., and Martelli, S., indolizine derivatives with biological activity I: *N'-substituted hydrazides of indolizine-2-carboxylic acid*, 259
——*see* Antonini, I., 1692
Cardone, M. J., quantitative IR spectrophotometric calculations, 1211
Carless, J. E., *see* Summers, M. P., 1172
Carlson, G. R., *see* Melamed, S., 899
Carney, C. F., and Hurwitz, A. R., pH partition behavior of *ampicillin*, 294
Carrano, R. A., *see* Heindel, N. D., 772
Carrier, G. O., *see* Matheny, J. L., 93
Carstensen, J. T., and Chan, P. C., flow rates and repose angles of wet-processed granulations, 1235
——Lai, T., and Prasad, V. K., USP dissolution test I: adequacy of mixing, 607
——*see* Mehta, A., 1462
Carter, G. G., *see* Mercer, H. D., 1198
Carter, J. E., Petersen, R. V., and Roll, D. B., synthesis and PMR and mass spectra of potential metabolites and other derivatives of *bis(2-ethylhexyl) phthalate*, 546
Cary, L., *see* Johnson, H. L., 1660
Catenazzo, G., *see* Ghirardi, P., 267
Caudal, F., see Sioufi, A., 1166
Cavalli, S., *see* Bortesi, F., 1767
Cecil, J. T., *see* Chib, J. S., 1052
Cella, J. A., and Kelley, J. A., preparation of spin-labeled opiates: *morphine and codeine, 1054*
Chafetz, L., and Tsilifonis, D. C., selective photometric determination of betamethasone benzoate and other *21-hydroxycorticosteroids*, 1145
——*see* Frank, J., 439
Chan, P. C., *see* Carstensen, J. T., 1235
Chang, B.-L., El-Feraly, F. S., and Doorenbos, N. J., cudranone: a novel benzophenone derivative from *Cudrania chochinchinensis* var. *gerontogea, 908*
Chang, C.-H., Mann, D. E., Jr., and Gautieri, R. F., teratogenicity of zinc chloride, 1,10-phenanthroline, and a zinc–1,10-phenanthroline complex in mice, 1755
Chang, S. F., Miller, A. M., and Ober, R. E., determination of an anti-inflammatory methanesulfonanilide in plasma by high-speed liquid chromatography, *1700*
Chao, A., Kim, C.-K., Kildsig, D. O., and Kramer, P. A., mathematical description of solute velocities during dissolution from a horizontal surface, 741
Charles, H. C., see Domer, F. R., 269
***Chasseaud, L. F.,** see Assinder, D. F., 775*
——*see* Taylor, T., 1638
Chatten, L. G., *see* Olliff, C. J., 1564
***Chatterji, D. C.,** and Gallelli, J. F., high-pressure liquid* chromatographic analysis of methotrexate in presence of its degradation products, 1219
Chaudhary, M., *see* Parmar, S. S., 971
Chaudhary, S. K., see Parmar, S. S., 971
***Chen, C.-H.,** Abdel-Monem, M. M., and Krick, T. P.,* metabolism of *N*-ethyl-3-piperidyl benzilate in rats, 931
***Chen, L.,** see Vallner, J. J., 420*
Cheng, C. C., Engle, R. R., Hodgson, J. R., Ing, R. B., Wood, H. B. Jr., Yan, S.-J., and Zee-Cheng, R. K. Y., absence of mutagenicity of coralyne and related antileukemic agents: structural comparison with the *potent carcinogen 7,12-dimethylbenz[a]anthracene*, 1781
——*see* Lee, J. W., 986
Chernish, S. M., *see* Kleber, J. W., 992
Cheung, A. P., and Lim, P., contaminants in commercial dapsone, 1723
Chiang, C.-W., *see* Lausier, J. M., 1636
Chib, J. S., Stempien, M. F., Jr., Cecil, J. T., Ruggieri, G. D., and Nigrelli, R. F., physiologically active substances from marine sponges IV: heterocyclic compounds, 1052
Chihal, D. M., *see* Domer, F. R., 269
Child, R. G., Osterberg, A. C., Sloboda, A. E., and Tomcufcik, A. S., fenbufen, a new anti-inflammatory analgesic: synthesis and structure–activity relationships of analogs, 466
Chin, D. A., Prue, D. G., Michelucci, J., Kho, B. T., and Warner, C. R., quantitative determination of isosorbide dinitrate and two metabolites in plasma, 1143
Chiou, C. Y., cytolysis of neuroblastoma cells *in vitro* and treatment of neuronal tumors *in vivo* with bromoacetylcholine, 837
Chiou, W. L., pharmaceutical applications of solid dispersion systems: X-ray diffraction and aqueous solubility studies on *griseofulvin–polyethylene glycol* 6000 systems, 989
——*see* Niazi, S., 49
Cho, A. K., *see* Gal, J., 866
Cho, M. J., Krueger, W. C., and Oesterling, T. O., nucleophilic addition of *bisulfite ion to prostaglandins* E_2 and A_2: implication in aqueous stability, 149
Choi, J. J., *see* Robinson, C. P., 879
Choong, T.-C., Thompson, B. L., and Shough, H. R., synthesis of 10α-methoxy-$\Delta^{8,9}$-lysergaldehyde from elymoclavine, 1340
Chou, C. H., Johnson, J. R., and Rippie, E. G., polydisperse particulate solids mixing and segregation: nonstationary Markov chains, 104
Chou, J. T., Beck, W. T., Khwaja, T., Mayer, K., and Lien, E. J., synthesis and anticancer activity of novel cyclic *N*-hydroxyureas, 1556
Chowhan, Z. T., and Amaro, A. A., everted rat intestinal sacs as an *in vitro* model for assessing absorptivity of new drugs, 1249
——and Amaro, A. A., powder inhalation aerosol studies I: selection of a suitable drug entity for bronchial delivery of new drugs, 1254
Chu, C. K., Stella, V. J., Bruckner, J. V., and Jiang, W. D., effects of long-term exposure to environmental levels of polychlorinated biphenyls on pharmacokinetics of pentobarbital in rats, 238
Chun, A. H. C., *see* Sun, S.-R., 477
Cilento, R. D., methods for evaluating hermetic closures for screw-capped bottles, 333
Ciurczak, E. W., *see* Theimer, E. E., 139
Clarke, J. M., Ramsay, L. E., Shelton, J. R., Tidd, M. J., Murray, S., and Palmer, R. F., factors influencing comparative bioavailability of spironolactone tablets, 1429
Claudi, F., Grifantini, M., Gulini, U., Martelli, S., and Natalini, P., indolizine derivatives with biological activity II: *N'-substituted hydrazides of 2-methyl-3-indolizinecarboxylic acid*, 1355
——*see* Antonini, I., 1692
——*see Cardellini, M., 259*
Cleary, G. W., and Zatz, J. L., interaction of hydrocortisone with model membranes containing phospholipid and cholesterol, 975
Cohen, D. M., see Wong, C. K., 736
***Cohen, V. I.,** Rist, N., and Duponchel, C., synthesis and* antituberculosis activity of thiocarboxamide derivatives of Schiff bases, 1332
***Colaizzi, J. L.,** see* Strum, J. D., 539
Colburn, W. A., and Gibaldi, M., pharmacokinetic analysis of drug concentration data obtained during repetitive drug administration, 530
Cole, J. R., see Hoffmann, J. J., 586, 883, 1336
——*see Ionescu, F., 1489*
——*see* Jolad, S. D., 889, 892
——*see* Torrance, S. J., 1348
Combs, A. B., *see* Newburger, J., 1561
Cone, E. J., Phelps, B. A., and Gorodetzky, C. W., urinary excretion of *hydromorphone and metabolites* in humans, rats, dogs, guinea pigs, and rabbits, 1709
***Congdon, W. C.,** see Levy, R. H., 1154*
Conney, A. H., *see* Garland, W. A., 340

Conrad, J. M., and Robinson, J. R., aqueous chamber drug distribution volume measurement in rabbits, 219
Conway, W. D., *see* Singhvi, S. M., 1488
Cook, E. S., *see* Fujii, A., 844
Cooke, G. G., *see* Rickard, E. C., 379
Cooper, J. K., *see* Midha, K. K., 799, 1596
Cooper, J. W., Jr., *see* Schwartz, P. A., 994
Cosyns-Duyck, M.-C., *see* De Leenheer, A. P., 1190
Craig, C. B., *see* Borne, R. F., 119
Craig, W. A., *see* Welling, P. G., 549
Crane, F. A., *see* Dobberstein, R. H., 600
Crawford, H. T., *see* Skinner, W. A., 587
Crooks, M. J., *see* Veng Pedersen, P., 1458
Cross, J. M., *see* Fleischner, A. M., 1206
Curran, N. M., *see* McErlane, K. M., 523, 1015

D

Dahl, S. G., and Garle, M., identification of nonpolar methotrimeprazine metabolites in plasma and urine by GLC–mass spectrometry, 190
Dalton, C., and Pool, W. R., serum lipid-lowering properties of 6-chloro-9-[2-(6-methyl-3-pyridyl)-ethyl]-1,2,3,4-tetrahydrocarbazole-2-carboxylic acid, 348
Damewood, E. Z., *see* Mauger, J. W., 553
Dandekar, K. A., and Kostenbauder, H. B., effect of sodium salicylate on renal elimination of a quaternary ammonium compound, 56
Danzinger, R. G., *see* Molokhia, A. M., 1101
Darling, C. M., *see* McNeil, H. R., 1642
David, S. T., and Augsburger, L. L., plastic flow during compression of directly compressible fillers and its effect on tablet strength, 155
Dawson, J. E., Hajratwala, B. R., and Taylor, H., kinetics of indomethacin degradation II: presence of alkali plus surfactant, 1259
——*see* Hajratwala, B. R., 27
Day, J. L., *see* Tterlikkis, L., 1454
De, A. U., and Pal, D., possible antineoplastic agents II, 232
Dean, C. R., *see* Lui, E. M. K., 950
DeAngelis, R. L., Kearney, M. F., and Welch, R. M., determination of triprolidine in human plasma by quantitative TLC, 841
de Blaey, C. J., and van der Graaff, H., dissolution kinetics of soluble nondisintegrating disks, 1696
De Caro, G., *see* Antonini, I., 1692
De Clercq, H., Massart, D. L., and Dryon, L., evaluation and optimal combination of TLC systems for qualitative identification I: sulfonamides, 1269
De Fabrizio, F., UV spectrophotometric determination of aminophylline, amobarbital, and ephedrine hydrochloride in an antiasthma capsule preparation, 811
DeGraw, J. I., *see* Johnson, H. L., 1660
Delis, T. L., Gapski, G. R., and Whiteley, J. M., fluorescent inhibitors of thymidylate synthetase, 434
de la Lastra, M., *see Forcelledo, M. L., 1773*
De Leenheer, A. P., Cosyns-Duyck, M.-C., and Van Vaerenbergh, P. M., application of ion-pair methods to extraction of fluorouracil from aqeuous fluids, 1190
Delgado, J. N., *see* Haney, W. G., 1602
——*see* Huerta, P. L., 1120
Del Soldato, P., TLC determination of iodochlorhydroxyquin and its conjugate in plasma, 1334
——*see* Ballerini, R., 281
De Moerloose, P., *see* Baeyens, W., 1771, 1787
DePalma, P. D., *see* Loux, J. J., 674
Dermody, W. C., Pastushok, C. A., Sakowski, R., Vaitkus, J. W., and Reel, J. R., potency of synthetic luteinizing hormone releasing hormone preparations in rat anterior pituitary cell cultures, 386
Derr, G. R., *see Sims, B. E., 823*
DeSante, K. A., Stoll, R. G., Kaiser, D. G., and DiSanto, A. R., generic propoxyphene: need for clinical bioavailability evaluation, 1713
de Silva, J. A. F., Strojny, N., Rubio, F., Meyer, J. C., and Koechlin, B. A., spectrofluorometric determination of substituted tetrahydrocarbazoles by a methylene blue sensitized photolytic reaction, 353
De Taeye, L., *see* Baeyens, W., 1787
Diab, A. M., *see* Karawya, M. S., 1317, 1331
Di Bitetto, M., *see* Silingardi, S., 1769
Di Carlo, F. J., *see* Leinweber, F.-J., 1570
——*see* Loh, A., 1056
Di Colo, G., *see* Bottari, F., 926
Digenis, G. A., Beihn, R. M., Theodorakis, M. C., and Shambhu, M. B., use of ^{99m}Tc-labeled triethylenetetramine–polystyrene resin for measuring the gastric emptying rate in humans, 442
Dimattio, A. S., *see* Tan, H. S. I., 766
Dimmock, J. R., *see* Repta, A. J., 1501
Dinçer, S., and Özdurmuş, S., mathematical model for enteric film coating of tablets, 1070
DiSanto, A. R., *see* DeSante, K. A., 1713
Dittert, L. W., *see* Bevill, R. F., 619, 1297
——*see* Mercer, H. D., 1198
Ditzler, C. A., *see* Hare, L. E., 414, 486
Dixon, W. R., Young, R. L., Ning, R., and Liebman, A., radioimmunoassay of the anticonvulsant agent clonazepam, 235
Dobberstein, R. H., Tin-Wa, M., Fong, H. H. S., Crane, F. A., and Farnsworth, N. R., flavonoid constituents from *Eupatorium altissimum* L. (Compositae), 600
Dobrinska, M. R., and Welling, P. G., pharmacokinetics of methsuximide and a major metabolite in dogs, 688
Dolman, L., *see* Sellers, E. M., 1640
Dombrowski, L. J., Browning, R. S., and Pratt, E. L., direct spectrophotometric determination of sulfathiazole in presence of sulfadiazine and sulfamerazine, 1413
Domer, F. R., Chihal, D. M., and Charles, H. C., cardiovascular and neuromuscular effects of dimethyl sulfoxide in anesthetized rabbits, 269
Doorenbos, N. J., *see* Chang, B.-L., 908
——*see* Kinghorn, A. D., 1362
Dorato, M. A., Lynch, V. D., and Ward, C. O., effect of lysine and diethanolamine–rutin on blood levels, withdrawal reaction, and acute toxicity of ethanol in mice, 35
Douglas, J. F., and Philopoulous, Y., determination of anthranilic acid in plasma, 1645
Driscoll, J. S., *see* Beisler, J. A., 849
Dryden, W. F., *see Harvey, A. L., 913*
Dryon, L., *see* De Clercq, H., 1269
Duffy, J. P., *see* Blanchard, J., 1470
Duggan, D. E., *see* Hare, L. E., 414, 486
Dunn, W. J., III, and Greenberg, M. J., synthesis, physicochemical properties, and antitumor activities of analogs of 1-phenyl-3-benzyl-3-methyltriazenes, 1416
Dunning, L. K., *see Teng, L., 1615*
Duponchel, C., *see* Cohen, V. I., 1332
Dwivedi, C., *see* Agrawal, A. K., 887
Dwuma-Badu, D., *Okarter, T. U., Tackie, A. N., Lopez, J. A., Slatkin, D. J., Knapp, J. E., and Schiff, P. L., Jr., constituents of West African medicinal plants XIX: funiferine N-oxide, a new alkaloid from Tiliacora funifera* (Menispermaceae), 1242
Dykstra, W. G., Jr., *see Warner, V. D., 418*

E

Ebert, W. R., *see* Horn, F. S., 710
Eby, R. Z., *see Loux, J. J., 674*
Ecanow, B., *see* Takruri, H., 283
Eckelman, W. C., *see* Karesh, S. M., 225
Edwards, J. M., *see Abbas, R., 1583*
Egerton, J. R., *see* Fisher, M. H., 1349
——*see* Wu, M. T., 1150
El-Feraly, F. S., *see* Chang, B.-L., 908
Ellin, R. I., *see* Groff, W. A., 389
Ellis, M., *see Johnson, H. L., 1660*
Elmer, G. W., *see* Meadows, G. G., 1503
El-Rabbat, N. A., *see* Omar, N. M., 597
Elshabouri, S. R., *see Youssef, A. F., 116*
Emele, J. F., see Ramachander, G., 1047
Enever, R. P., *Li Won Po, A., and Shotton E., factors* influencing decomposition rate of amitriptyline hydrochloride in aqueous solution, 1087
——*see Summers, M. P., 825, 1172*
Engle, R. R., see Cheng, C. C., 1781
Erb, R. J., *see* Smolen, V. F., 297
Erni, W., *see* Ritschel, W. A., 1438
Escalona-Castillo, H., see Smith, R. V., 132
Esezobo, S., and Pilpel, N., formulation factors affecting strength and dissolution of uncoated oxytetracycline tablets, 852
Evans, F. J., *see* Fairbairn, J. W., 1300
Evans, M. A., and Harbison, R. D., GLC microanalyses of phenacetin and acetaminophen plasma levels, 1628
——and Harbison, R. D., micromethod for determination of meperidine in plasma, 599
Evans, W. G., *see* Bodnar, J. E., 1108
Eyer, C. L., and Johnson, W. E., chronotropic and cylic adenosine monophosphate response of fetal rat heart in organ culture to isoproterenol, quinidine, and a dysrhythmogenic agent, 1450

F

Facchinetti, T., *see Mussini, E., 1482*
Fairbairn, J. W., Evans, F. J., and Phillipson, J. D., cascarosides A and B, 1300
Fang, S. M., Lin, C. S., and Lyon, V., progesterone retention by rat uterus I: pharmacokinetics after uterine intraluminal instillation, 1744
Farag, H. H., Youssef, A. F., and Omran, L. A., synthesis and antiparasitic activity of certain 2-imino-3-[(*N*-arylcarbamoyl)methyl]-2,3,4,5-tetrahydrothiazoles, 423
Farid, N. A., Born, G. S., Kessler, W. V., Russell, H. T., Shaw, S. M., and Lange, W. E., synthesis of ^{14}C-meglumine salicylate and its disposition in humans after oral administration, 536
Farmer, P. S., *see* Lui, E. M. K., 950
Farng, K. F., and Nelson, K. G., effects of polyelectrolytes on drug transport II: permeation, 1611
Farnsworth, N. R., *see* Dobberstein, R. H., 600
Fazakerley, G. V., and Jackson, G. E., metal-ion interaction with penicillins: kinetics of complexation of nickel(II), 533
Feld, K., *see* Molokhia, A. M., 1101
Fell, J. T., *see* Baugh, R., 733
Ferguson, G. G., *see* Keller, W. J., 1048
Fink, W. T., *see Blanchard, J., 1470*
Finn, A. M., Brown, R., and Sadée, W., tissue distribution of ^{3}H-canrenoate potassium in rabbits, 275
Finnegan, R. A., and Merkel, K. E., NMR solvent shift data for methoxylated xanthones, 884
Fisher, G., and Gillard, R., GLC determination of opium alkaloids in papaveretum, 421
Fisher, M. H., *Lusi, A., and Egerton, J. R., anthelmintic* dihydroquinoxalino[2,3-*b*]quinoxalines, 1349
——*see* Wu, M. T., 1150
Fives, W. P., *see Heindel, N. D., 772*
Flamm, B. L., *see* Gal, J., 866
Flanagan, C., *see* Sturgeon, R. J., 1346
Flanagan, D. R., and Yalkowsky, S. H., corrective diffusional analysis for drug transport through a tubular polymeric membrane, 337
——*see* Yu, A. B. C., 213
Fleischner, A. M., Cross, J. M., Segelman, A. B., and van Es, T., new compounds: synthesis of D-arabinofuranosylurea derivatives, 1206
Flynn, G. L., *see Hwang, S., 778, 781*
——*see* Owada, E., 216
Flynn, N. W., see Melikian, A. P., 228
Fong, H. H. S., *see Dobberstein, R. H., 600*
Forcelledo, M. L., and de la Lastra, M., gonadotropin-inhibitory contaminants in partially purified pharmaceutical preparations of human chorionic gonadotropin, 1773
Forrest, T. P., *see Yung, D. K., 1009*
Foye, W. O., and Sane, J. N., sulfur-containing derivatives of amphetamine: thioureas, methanesulfonamides, and trifluoromethanesulfonamides, 923
——and Tovivich, P., *N*-glucopyranosyl-5-aralkylidenerhodanines: synthesis and antibacterial and antiviral activities, 1607
Franchetti, P., *see Antonini, I., 1692*
Frank, J., and Chafetz, L., IR spectrophotometric assay of carbachol solutions, 439
Free, S. M., *see* Intoccia, A. P., 85
Freedman, R., see Snyder, H. R., Jr., 1204
Fu, C.-C., *and Sibley, M. J., quantitative high-pressure* liquid chromatographic determination of epinephrine in pharmaceutical formulations, 425

——and Sibley, M. J., quantitative high-pressure liquid chromatographic determination of thimerosal in pharmaceutical formulations, 738
Fu, P. P., *see* Ma, J. K. H., 209
Fujii, A., Bush, J. H., Shores, K. E., Johnson, R. G., Garascia, R. J., and Cook, E. S., probiotics: antistaphylococcal activity of 4-aminocyclohexanecarboxylic acid, aminobenzoic acid, and their derivatives and structure–activity relationships, 844
Fuller, R. W., Baker, J. C., and Molloy, B. B., biological disposition of rigid analogs of amphetamine, 271
Furusawa, E., *see* Lenney, J. F., 702

G

Gal, J., stereochemistry of metabolism of amphetamines: use of (−)-α-methoxy-α-(trifluoromethyl)phenylacetyl chloride for GLC resolution of chiral amines, 169
——Hodshon, B. J., Pintauro, C., Flamm, B. L., and Cho, A. K., pharmacokinetics of methylphenidate in the rat using single-ion monitoring GLC–mass spectrometry, 866
Gallelli, J. F., see Chatterji, D. C., 1219
Galloway, J. A., *see* Kleber, J. W., 635
Gan, O. H. M., *see* Valentine, J. L., 1263
Gapski, G. R., see Deits, T. L., 434
Garascia, R. J., *see Fujii, A., 844*
Garattini, S., *see* Mussini, E., 1482
Garland, W. A., quantitative determination of amitriptyline and its principal metabolite, nortriptyline, 77
——Hsiao, K. C., Pantuck, E. J., and Conney, A. H., quantitative determination of phenacetin and its metabolite acetaminophen by GLC–chemical ionization mass spectrometry, 340
——*see* Nelson, S. D., 1180
Garle, M., *see* Dahl, S. G., 190
Garrett, E. R., *and Hinderling, P. H., pharmacokinetics* of β-methyldigoxin in healthy humans IV: comparisons of radioimmunoassays, total radioactivity, and specific assays of β-methyldigoxin and digoxin in plasma, 806
——*and Hunt, C. A., pharmacokinetics of* Δ^9*-tetrahydrocannabinol in dogs*, 395
——and Hunt, C. A., separation and analysis of Δ^9-tetrahydrocannabinol in biological fluids by high-pressure liquid chromatography and GLC, 20
——Hurst, G. H., and Green, J. R., Jr., kinetics and mechanisms of drug action on microorganisms XXIII: microbial kinetic assay for fluorouracil in biological fluids and its application to human pharmacokinetics, 1422
——*see* Hinderling, P. H., 242, 314, 326
——*see Vilallonga, F. A., 1229*
Garrett, R. J. B., see Lubawy, W. C., 111
Gautieri, R. F., *see* Chang, C.-H., 1755
——*see* Zellers, J. E., 1727
Gearien, J. E., see Mrtek, M. B., 1019
Gentner, W. A., *see Vincent, P. G., 1716*
Genton, D., and Kesselring, U. W., effect of temperature and relative humidity on nitrazepam stability in solid state, 676
George, R. E., *see* McBride, M. H. D., 870
Gerlach, E. D., *see* Tan, H. S. I., 766
Ghanekar, A. G., *see Gupta, V. D., 895*
Ghirardi, P., Catenazzo, G., Mantero, O., Merotti, G. C., and Marzo, A., bioavailability of digoxin in a new soluble pharmaceutical formulation in capsules, 267
Ghoneim, M. M., *see Van Hamme, M. J., 1344*
Gibaldi, M., and McNamara, P. J., tissue binding of drugs, 1211
——*see Colburn, W. A., 530*
——*see* Grundhofer, B., 1433
——*see* Harrison, L. I., 1138, 1679
——*see* Singhvi, S. M., 1488
Gilbertson, T. J., see Royer, M. E., 1266
Gillard, R., *see Fisher, G., 421*
Gillchriest, W. C., *see* Roscoe, C. W., 1505
Gilroy, M. L., see Yung, D. K., 1009
Giroux, E., *and Prakash, N. J., influence of zinc–ligand* mixtures on serum zinc levels in rats, 391
Glogowski, D., *see* Gumtow, R. H., 1777
Godefroi, V. C., *see Hills, E. B., 1497*
Goehl, T. J., Pittick, W. H., Shiu, G. K., and Pirakitikulr, P., rapid GLC determination of therapeutic plasma glycerin levels, 1027
Gomez, R., *see* Rubia, L. B., 1656
Goodhart, F. W., *see* Gucluyildiz, H., 265
Gorodetzky, C. W., *see* Cone, E. J., 1709
——*see Yeh, S. Y., 201, 1288*
Gouda, M. W., Khalafalah, N., and Khalil, S. A., effect of surfactants on absorption through membranes V: concentration-dependent effect of a bile salt (sodium deoxycholate) on absorption of a poorly absorbable drug, phenolsulfonphthalein, in humans, 727
Govil, G., *see* Kulkarni, V. M., 483
Grady, L. T., *see* Reif, V. D., 1112
Graham, R. E., Biehl, E. R., and Kenner, C. T., effect of laboratory light on tetrazolium reaction and on stability of formazans in various solvents, 965
——*see* Oteiza, R. M., 1385
Green, J. R., Jr., see Garrett, E. R., 1422
Greenberg, M. J., *see Dunn, W. J., III, 1416*
Greene, D. S., and Tice, A. D., effect of hemodialysis on cefazolin protein binding, 1508
——*Quintiliani, R., and Nightingale, C. H., binding rate* of antibacterials to serum proteins, 1663
Greenough, R. C., *see* Leinweber, F.-J., 1570
Grifantini, M., *see* Cardellini, M., 259
——see Claudi, F., 1355
Grimault, D., *see Sioufi, A., 1166*
Grindel, J. M., Tilton, P. F., and Shaffer, R. D., quantitation of the antimalarial agent, mefloquine, in blood, plasma, and urine using high-pressure liquid chromatography, 834
Groff, W. A., Ellin, R. I., and Skalsky, R. L., quantitative assay of physostigmine in human whole blood, 389
Gross, J. F., *see Himmelstein, K. J., 1441*
Grundhofer, B., and Gibaldi, M., biopharmaceutic factors that influence effects of anticholinergic drugs: comparison of propantheline, hexocyclium, and isopropamide, 1433
Gucluyildiz, H., Banker, G. S., and Peck, G. E., determination of porosity and pore-size distribution of aspirin tablets relevant to drug stability, 407
——*Goodhart, F. W., and Ninger, F. C., rapid determination of nitroglycerin volatility using thermogravimetric analysis*, 265
Gulini, U., *see Antonini, I., 1692*
——see Cardellini, M., 259
——*see* Claudi, F., 1355
Gumtow, R. H., Beecher, H., Hartnett, D., and Glogowski, D., in vitro evaluation of an anticholinergic agent in a timed-release solid dosage formulation, 1777
Gupta, V. D., quantitative determination of benzoic acid and salicylic acid in ointments by high-pressure liquid chromatography, 110
——and Ghanekar, A. G., quantitative determinations of codeine phosphate, guaifenesin, pheniramine maleate, phenylpropanolamine hydrochloride, and pyrilamine maleate in an expectorant by high-pressure liquid chromatography, 895
——and Sachanandani, S., quantitative determinations of antipyrine and benzocaine in ear drops by high-pressure liquid chromatography, 897
Gural, R. P., *see* Mercer, H. D., 1198
Gutin, P. H., Prockop, L. D., Yip, K. F., Weinstein, J. D., and Tsou, K. C., perfusion and molecular modification of idoxuridine to alter its cerebrospinal fluid metabolism, 1338
Gutshall, P. L., see Valentine, J. L., 1263

H

Hachey, D. L., *Kreek, M. J., and Mattson, D. H.,* quantitative analysis of methadone in biological fluids using deuterium-labeled methadone and GLC–chemical-ionization mass spectrometry, 1579
Haddad, A. F., *see Bikhazi, A. B., 181*
Hajjar, J.-J., *see* Bikhazi, A. B., 1308
Hajratwala, B. R., and Dawson, J. E., kinetics of indomethacin degradation I: presence of alkali, 27
——and Hennig, A. J., influence of sunscreening agents on color stability of tablets coated with certified dyes III: FD&C yellow No. 6, 107
——see Dawson, J. E., 1259
Hall, I. H., *see Lee, K.-H., 1194*
Hall, L. H., and Kier, L. B., structure–activity studies using valence molecular connectivity, 642
Han, S. K., *see* Schott, H., 165
Han, W. W., Yakatan, G. J., and Maness, D. D., kinetics and mechanisms of hydrolysis of 1,4-benzodiazepines III: nitrazepam, 795
——Yakatan, G. J., and Maness, D. D., kinetics and mechanisms of hydrolysis of 1,4-benzodiazepines II: oxazepam and diazepam, 573
Haney, W. G., Brown, R. G., Isaacson, E. I., and Delgado, J. N., synthesis and structure–activity relationships of selected isomeric oxime *O*-ethers as anticholinergic agents, 1602
——*see* Sood, S. P., 40
Hanin, I., see Poust, R. I., 609
Hanna, S., Rosen, M., Rasero, L., and Lachman, L., analysis of homatropine methylbromide dosage forms, 123
Hansen, L. G., *and Welborn, M. E., distribution, dilution,* and elimination of polychlorinated biphenyl analogs in growing swine, 497
Harapat, S. R., *see* Meffin, P. J., 583
Harbison, R. D., see Agrawal, A. K., 887
——*see* Evans, M. A., 599, 1628
Hardin, T. C., *see* Borne, R. F., 119
Hare, L. E., Ditzler, C. A., and Duggan, D. E., radioimmunoassay of indomethacin in biological fluids, 486
——Ditzler, C. A., Hichens, M., Rosegay, A., and Duggan, D. E., analysis of sulindac and metabolites by combined isotope dilution–radioimmunoassay, 414
Harjes, K. K., *see* Kinghorn, A. D., 1362
Harrison, D. C., see Meffin, P. J., 583
Harrison, L. I., *and Gibaldi, M., physiologically based* pharmacokinetic model for digoxin disposition in dogs and its preliminary application to humans, 1679
——and Gibaldi, M., physiologically based pharmacokinetic model for digoxin distribution and elimination in the rat, 1138
Harsin, C. E., *see* Born, J. L., 1200
Hartman, P. A., *and Bowman, P. B., simple GLC* determination of ethylene oxide and its reaction products in drugs and formulations, 789
Hartnett, D., *see* Gumtow, R. H., 1777
Haruna, M., see Lee, K.-H., 1194
Harvey, A. L., *and Dryden, W. F., electrophysiological* and pharmacological properties of skeletal muscle in culture, 913
Hasan, F. B., *see Neville, G. A., 638*
Hayton, W. L., *see* Brady, M. E., 361, 366, 680
Hazlett, J. R., *see* Kramer, P. A., 542
Hedberg, S., *see* Miller, G. H., 88
Heeg, J. F., Born, G. S., Kessler, W. V., Shaw, S. M., and Lange, W. E., absorption, distribution, and excretion of ^{14}C-meglumine in rats and dogs after administration of ^{14}C-meglumine salicylate, 96
Hegde, G. P., *see Kent, J. S., 1665*
Heindel, N. D., Fives, W. P., and Carrano, R. A., new synthesis of 1,4,2-dioxazoles and their pharmacological properties, 772
——*see* Leiby, R. W., 605
Hem, S. L., *see* Kerkhof, N. J., 1528, 1533
Hennig, A. J., *see* Hajratwala, B. R., 107
Herbst, D., detection of penicillin G and ampicillin as contaminants in tetracyclines and penicillamine, 1646
Herczeg, T., see Lee, J. K., 832
Heyd, A., *see Mo, Y., 713*
Hichens, M., *see* Hare, L. E., 414
Hiestand, E. N., Wells, J. E., Peot, C. B., and Ochs, J. F., physical processes of tableting, 510
Higuchi, T., see Bourne, D. W. A., 628
Higuchi, W. I., *see* Ando, H. Y., 755, 1525
——*see* Hwang, S., 778, 781
——see Kwan, K. H., 1094, 1105
——*see Lipper, R. A., 163*
——*see* Molokhia, A. M., 1101
——see Owada, E., 216
Hill, J. L., *see Joseph, A. A., 490*
Hills, E. B., Godefroi, V. C., O'Leary, I. A., Burke, M., Andrzejewski, D., Brukwinski, W., and Horwitz, J. P., GLC determination for ftorafur in biological fluids, 1497

Himmelhoch, J. M., see Poust, R. I., 609
Himmelstein, K. J., and Gross, J. F., mathematical model for cyclocytidine pharmacokinetics, 1441
Hinderling, P. H., and Garrett, E. R., pharmacokinetics of β-methyldigoxin in healthy humans III: pharmacodynamic correlations, 326
——Garrett, E. R., and Wester, R. C., pharmacokinetics of β-methyldigoxin in healthy humans I: intravenous studies, 242
——Garrett, E. R., and Wester, R. C., pharmacokinetics of β-methyldigoxin in healthy humans II: oral studies and bioavailability, 314
——*see* Garrett, E. R., 806
Hindmarsh, K. W., see Midha, K. K., 1596
Hirayama, F., *see* Uekama, K., 706
Ho, C.-C., see Abramson, H. N., 602
Ho, N. F. H., see Ando, H. Y., 755, 1525
——*see* Hwang, S., 778, 781
——*see* Owada, E., 216
Hoar, D. R., and Bowen, M. H., GLC determination of free triclocarban in blood, 725
Hodgson, J. R., *see* Cheng, C. C., 1781
Hodshon, B. J., *see* Gal, J., 866
Hoener, B., see Sokoloski, T. D., 1159
Hoff, D. R., see Wu, M. T., 1150
Hoffman, D. J., rapid GLC determination of ibuprofen in serum, 749
Hoffmann, J. J., and Cole, J. R., phytochemical investigation of Adenium obesum Forskal (Apocynaceae): isolation and identification of cytotoxic agents, 1336
——Torrance, S. J., Wiedhopf, R. M., and Cole, J. R., *cytotoxic agents from Michelia champaca and Talauma ovata:* parthenolide and costunolide, 883
——Wiedhopf, R. M., and Cole, J. R., cytotoxic and *tumor inhibitory agent from Polygala macradenia* Gray (Polygalaceae): 4′-demethyldeoxypodophyllotoxin, 586
Hofmann, A. F., *see* Kwan, K. H., 1094, 1105
——see Molokhia, A. M., 1101
Hom, F. S., and Ebert, W. R., determination of meclizine hydrochloride by ion-pair extraction with methyl orange, 710
Hong, W. H., Johnston, C., and Szulczewski, D., equilibrium reaction of pyrazolodiazepinones in aqueous solution, 1703
Honigberg, I. L., *see* Saxena, S. J., 286, 751, 813
Hoppe, R. C., see Intoccia, A. P., 85
Horrom, N. J., and Brown, C. C., sex differences in drug evaluations, 739
Horwitz, J. P., *see* Hills, E. B., 1497
Howard, S. A., Mauger, J. W., and Phusanti, L., dissolution profiles for multisized prednisolone acetate suspensions, 557
Hsia, D. C., Kim, C.-K., and Kildsig, D. O., determination of energy change associated with dissolution *of a solid, 961*
Hsiao, K. C., see Garland, W. A., 340
Hsu, T. F., *see* Newburger, J., 1561
Hsu, Y.-M., *see* Abramson, H. N., 602
Huang, C. L., see Abramson, H. N., 602
Huang, H., see Welling, P. G., 549
Huang, H.-C., *see* Lee, K.-H., 1194
Huang, M. L., and Niazi, S., polymorphic and dissolution properties of mercaptopurine, 608
Huerta, P. L., Isaacson, E. I., Brown, R. G., and Delgado, J. N., synthesis of various geometric and *enantiomeric oxime O-(α- and β-methylcholinyl)* ethers as potential anticholinergic agents, 1120
Huffman, D. H., *see* Bochner, F., 644
Hughes, D. W., see Wilson, W. L., 1079
Humphrey, D. W., see Smith, R. V., 132
Hunt, C. A., see Garrett, E. R., 20, 395
Hunt, J. S., *see* Vilallonga, F. A., 1229
Hurst, G. H., see Garrett, E. R., 1422
Hurwitz, A. R., and Liu, S. T., determination of aqueous solubility and pKa values of estrogens, 624
——*see* Carney, C. F., 294
Hussain, A., see Munson, J. W., 1775
Hussain, M., Niazi, S., Arambulo, A., and Long, D. M., *perfluorooctyl bromide: a potential antiobesity* compound, 907
Huynh-Ngoc, T., and Sirois, G., comparison of two spectrofluorometric procedures for quinidine determination in biological fluids, 591
Hwang, S., Owada, E., Suhardja, L., Ho, N. F. H., Flynn, G. L., and Higuchi, W. I., systems approach to vaginal delivery of drugs V: *in situ* vaginal absorption *of 1-alkanoic acids, 781*
——Owada, E., Suhardja, L., Ho, N. F. H., Flynn, G. L., and Higuchi, W. I., systems approach to vaginal delivery of drugs IV: methodology for determination of membrane surface pH, 778
——*see* Owada, E., 216

I

Ibrahim, H. G., Pisano, F., and Bruno, A., polymorphism of phenylbutazone: properties and compressional behavior of crystals, 669
Ibrahim, S. A., *see* Youssef, A. F., 116
Ikeda, K., *see* Uekama, K., 706
Inaba, K., *see* Uekama, K., 706
Ing, R. B., see Cheng, C. C., 1781
Innes, D. L., see Tansy, M. F., 902
Intoccia, A. P., Walkenstein, S. S., Wittendorf, R. W., Hoppe, R. C., and Free, S. M., use of anemic piglet *to assess bioavailability of iron from oral iron* preparations, 85
——*see* Randolph, W. C., 1148
Ionescu, F., Jolad, S. D., and Cole, J. R., dehydrodiisoeugenol: a naturally occurring lignan from *Aristolochia taliscana (Aristolochiaceae), 1489*
——*see* Kingston, D. G. I., 1135
Isaacson, E. I., *see* Hanley, W. G., 1602
——*see* Huerta, P. L., 1120
Ismaiel, S. A., *see* Sood, S. P., 40
Itatani, Y., *see* Tsuji, A., 1004
Ivashkiv, E., fluorometric determination of nadolol in human serum and urine, 1168

J

Jackson, G. E., see Fazakerley, G. V., 533
Jacobson, A. E., *see* May, E. L., 285
——*see* Rice, K. C., 193
Jaffe, J. M., *see* Strum, J. D., 539
Jain, N. C., Sneath, T. C., Leung, W. J., and Budd, R. D., *mass screening and confirmation of codeine and* morphine in urine by radioimmunoassay–GLC, 66
Jamali, F., and Axelson, J. E., influence of metoclo*pramide and propantheline on GI absorption of* griseofulvin in rats, 1540
Janssen, L. H. M., and Perrin, J. H., estimation of free energy change associated with conformational transition of proteins showing cooperative binding *properties, 146*
Jarowski, C. I., *see* Kim, K. H., 1536
Jenkins, H. J., *see* Baizman, E. R., 1013
Jennings, E. C., and Langdraf, W. C., multiple sulfa compounds: high-pressure liquid chromatographic assay and mobile phase correlation, 1784
Jespersen, S., *see* Bechgaard, H., 871
Jiang, W. D., see Chu, C. K., 238
Johnson, B. J., complement: a host defense mechanism ready for pharmacological manipulation?, 1367
——*and Kucich, U. N., interrelation between two* anticomplement cobra venom factors isolated from crude *Naja naja* cobra venom, 947
——*and Thames, K. E., complement fixing site of* human IgGl, 427
——*see* Kempner, D. H., 876
Johnson, H., *see* Skinner, W. A., 1764
Johnson, H. L., Thomas, D. W., Ellis, M., Cary, L., and DeGraw, J. I., *application of* ^{13}C-NMR *spectroscopy* to *in vitro* analysis of enzyme kinetics, 1660
Johnson, J. R., see Chou, C. H., 104
Johnson, R. G., see Fujii, A., 844
Johnson, R. N., and Boyden, G. R., characterization of biotin trimethylsilyl derivative, 1212
Johnson, W. E., see Eyer, C. L., 1450
Johnston, C., see Hong, W. H., 1703
Johnston, K. T., *see* Royer, M. E., 1266
Johnston, M. M., Li, H., and Mufson, D., chlorthalidone analysis using carbonic anhydrase inhibition, *1735*
——*see* Li, H., 1732
Jolad, S. D., Wiedhopf, R. M., and Cole, J. R., cytotoxic agents from *Bursera klugii* (Burseraceae) I: isolation of sapelins A and B, 889
——*Wiedhopf, R. M., and Cole, J. R., cytotoxic agents* from *Bursera morelensis* (Burseraceae): deoxypodophyllotoxin *and a new lignan, 5′-desmethoxy-deoxypodophyllotoxin, 892*
——*see* Ionescu, F., 1489
Jones, C. L., *see* Kates, R. E., 1490
Joseph, A. A., Hill, J. L., Patel, J., Patel, S., and Kincl, F. A., sustained-release hormonal preparations XV: release of progesterone from cholesterol pellets *in vivo,* 490
Joullié, M. M., see Abou-Gharbia, M., 1653
*Judis, J., binding of codeine, morphine, and metha-*done to human serum proteins, 802
Jun, H. W., *see* Strom, J. G., Jr., 589
Juneau, R., single-dose assay of ferrous ion in pharmaceuticals, 140
Jurkar, J. V., *see* Sokoloski, T. D., 1159

K

Kaiser, D. G., *see* DeSante, K. A., 1713
Kaminski, J. J., *see* Repta, A. J., 1501
Karamian, N. A., and Waters, P. F., spectrophotometry as a tool for assaying endotoxins, 723
Karawya, M. S., and Diab, A. M., colorimetric assay of quinine and quinidine in raw materials, formulations, and biological fluids, 1317
——*and Diab, A. M., selective estimation of aconitine* in presence of aconine and benzoylaconine, 1331
Karesh, S. M., Eckelman, W. C., and Reba, R. C., biological distribution of chemical analogs of fatty acids and long chain hydrocarbons containing a strong chelating agent, *225*
Karim, A., see Phelps, D. L., 1203
Kates, R. E., and Jones, C. L., rapid GLC determination of propranolol in human plasma samples, 1490
Kau, S. T., and Rama Sastry, B. V., distribution and *pharmacokinetics of triamterene in rats, 53*
Kavanagh, F., microbiological turbidimetric methods: linearization of antibiotic and vitamin standard curves, 1520
Kearney, M. F., see DeAngelis, R. L., 841
Keene, G. R., see Saxena, S. J., 286, 813
Keller, W. J., and Ferguson, G. G., effects of 3,4-dimethoxyphenethylamine derivatives on mono*amine oxidase, 1048*
Kelley, J. A., see Cella, J. A., 1054
Kelly, E. L., *see* Bainbridge, C. A., 480
Kempner, D. H., and Johnson, B. J., lipid–protein interactions: detergent binding to L-glutamic acid *dehydrogenase, 876*
Kendall, F. M., *see* Tansy, M. F., 613, 902
Kenner, C. T., *see* Graham, R. E., 965
——*see Oteiza, R. M., 1385*
Kent, J. S., and Yost, M. T., strain-gauge Wheatstone bridge design for automatic capsule-filling machine, 1507
——Wong, P. P., and Hegde, G. P., design and evaluation of an automated system for *in vitro* dissolution testing utilizing a high-pressure liquid chromatographic multiport switching valve, 1665
Kerkhof, N. J., Vanderlaan, R. K., White, J. L., and Hem, S. L., pH-stat titration of aluminum hydroxide gel, 1528
——*White, J. L., and Hem, S. L., role of carbonate in* acid neutralization of aluminum hydroxide gel, 1533
Kesselring, U. W., *see* Genton, D., 676
Kessler, W. V., see Farid, N. A., 536
——*see Heeg, J. F., 96*
——*see* McBride, M. H. D., 870
Khalafalah, N., *see* Gouda, M. W., 727
Khalafi, F., see Shafiee, A., 873, 1050
Khalil, S. A., *see* Gouda, M. W., 727
Khalil, S. A. H., effect of chloroquine adsorption on acid reactivity of magnesium trisilicate, 289
Khalil, S. K. W., high-speed liquid chromatographic *determination of pilocarpine in pharmaceutical* dosage forms, 1625
Kho, B. T., see Chin, D. A., 1143
——*see Mannan, C. A., 1618*
Khouw, V., *see* Sellers, E. M., 1640
Khwaja, T., *see* Chou, J. T., 1556

Kibbe, A. H., *see* Borne, R. F., 119
Kier, L. B., see Hall, L. H., 642
Kildsig, D. O., *see* Chao, A., 741
——*see* Hsia, D. C., 961
——*see* Kramer, P. A., 542
Kim, B. K., and Koda, R. T., fluorometric determination of methyldopa in biological fluids, 1632
Kim, C.-K., *see* Chao, A., 741
——*see* Hsia, D. C., 961
Kim, K. H., and Jarowski, C. I., surface tension lowering and dissolution rate of hydrocortisone from solid solutions of selected *n*-acyl esters of cholesterol, 1536
Kinel, F. A., *see* Joseph, A. A., 490
Kinghorn, A. D., Harjes, K. K., and Doorenbos, N. J., screening procedure for phorbol esters using brine shrimp (*Artemia salina*) larvae, 1362
Kingston, D. G. I., Li, B. T., and Ionescu, F., plant anticancer agents III: isolation of indole and bisindole alkaloids from *Tabernaemontana holstii* roots, 1135
Kish, N. G., *see* Repke, D. B., 743
Kiya, E., *see* Yamana, T., 861
Kjaer, T. B., Welling, P. G., and Madsen, P. O., pharmacokinetics of ampicillin and methoxymethyl ester of hetacillin in dogs, 345
Kleber, J. W., Bechtol, L. D., Brunson, M. K., and Chernish, S. M., GLC determination of ethinamate and its hydroxy derivative in biological fluids, 992
——Galloway, J. A., and Rodda, B. E., GLC determination of acetohexamide and hydroxyhexamide in biological fluids, 635
Klee, W. A., *see* Rice, K. C., 193
Knapp, J. E., *see* Dwuma-Badu, D., 1242
Ko, H., *see* Royer, M. E., 1266
Ko, P. H., direct analysis of salicylic acid in keratolytic plaster by gas–solid chromatography, 731
Koch, K., *see* Neubert, P., 1131
Koch, P. A., *see* Welling, P. G., 549
Koda, R. T., *see* Kim, B. K., 1632
Koechlin, B. A., *see* de Silva, J. A. F., 353
Koernigen, C., and Margulis, T. N., X-ray analysis of sulfur-containing colchicine derivatives, 1127
Kolibash, A. J., *see* Kramer, W. G., 1720
Koritz, G. D., *see* Bevill, R. F., 1297
——*see* Sharma, J. P., 1319
Kornet, M. J., Thio, A. P., and Thorstenson, J. H., synthesis and cytotoxic activity of latentiated derivatives of 3-methyleneoxindole, 1022
Kostenbauder, H. B., *see* Dandekar, K. A., 56
Kourounakis, P., *see* Brookman, S., 1492
Kram, T. C., identification of an impurity in illicit amphetamine tablets, 443
Kramer, P. A., use of pharmacological data for bioavailability and pharmacokinetic analyses, 580
——Hazlett, J. R., and Kildsig, D. O., mechanism of histamine binding II: effect of alkali metal and alkaline earth cations of histamine binding to peptide H, 542
——*see* Chao, A., 741
——*see* Simmons, S. P., 984
Kramer, W. G., Kolibash, A. J., Bathala, M. S., Visconti, J. A., Lewis, R. P., and Reuning, R. H., digoxin bioavailability: evaluation of a generic tablet and proposed FDA guidelines, 1720
Krebs, H. A., *see* Yeh, S. Y., 1288
Kreek, M. J., *see* Hachey, D. L., 1579
Kreilgård, B., *see* Rajata, A. J., 1501
Krick, T. P., *see* Chen, C.-H., 931
Krol, G. J., *see* Mannan, C. A., 1618
Krueger, W. C., *see* Cho, M. J., 149
Krygier, H. E., *see* Lewis, D. A., 1651
Kubo, O., *see* Tsuji, A., 1675
——*see* Yamana, T., 747
Kucich, U. N., *see* Johnson, B. J., 947
Kujundžić, N., *see* Pečar, M., 330
Kulkarni, V. M., and Govil, G., conformational studies of antiradiation agents by NMR: cysteamine and its derivatives, 483
Kumar, S., *see* Parmar, S. S., 971
Kwan, K. H., Higuchi, W. I., Molokhia, A. M., and Hofmann, A. F., cholesterol gallstone dissolution rate accelerators I: exploratory investigations, 1105
——Higuchi, W. I., Molokhia, A. M., and Hofmann, A. F., dissolution kinetics of cholesterol in simulated bile I: influence of bile acid type and concentration, bile acid–lecithin ratio, and added electrolyte, 1094

L

Lach, J. L., *see* McGinity, J. W., 63
Lachman, L., *see* Hanna, S., 123
Lagas, M., *see* Lerk, C. F., 1480
Lal, C.-M., and Levy, G., comparative pharmacokinetics of coumarin anticoagulants XXX: relationship between total clearance and serum protein binding of dicumarol in rats, 1739
——*see* Yacobi, A., 1741
Lal, T., *see* Carstensen, J. T., 607
Lajevardi, S., *see* Shafiee, A., 873
Lalezari, I., *see* Shafiee, A., 593, 873, 1050
Lalka, D., *see* Manion, C. V., 981
Landgraf, W. C., *see* Jennings, E. C., 1784
Landin, W. E., *see* Tansy, M. F., 613
Landolt, R. R., *see* Scheu, J. D., 172
Lang, J. E., *see* Pikal, M. J., 1312
Lange, W. E., *see* Farid, N. A., 536
——*see* Heeg, J. F., 96
Laskar, P. A., and Ayres, J. W., degradation of carmustine in aqueous media, 1073
——and Ayres, J. W., degradation of carmustine in mixed solvent and nonaqueous media, 1076
Latour, Y., *see* Caille, G., 1383
Lau-Cam, C., *see* Staab, R. J., 1483
Lausier, J. M., Chang, C.-W., Zompa, H. A., and Rhodes, C. T., aging of tablets made with dibasic calcium phosphate dihydrate as matrix, 1636
Law, S.-J., *see* Borne, R. F., 594
Lawrence, R. C., *see* Watson, J. R., 560
Lee, B. H., *see* Cadwallader, D. E., 1357
Lee, J. K., Smyth, R. D., Polk, A., Herczeg, T., Tsuei, C. T., and Reavey-Cantwell, N. H., quantitative determination of fenclorac in serum, 832
Lee, J. W., MacFarlane, J. O., Zee-Cheng, R. K. Y., and Cheng, C. C., inhibition of catechol *O*-methyltransferase and transfer RNA methyltransferases by coralyne, nitidine, and related compounds, 986
Lee, K.-H., Haruna, M., Huang, H.-C., Wu, B.-S., and Hall, I. H., antitumor agents XXIII: helenalin, an antitumor principle from *Anaphalis morrisonicola* HAY, 1194
Leiby, R. W., and Heindel, N. D., new compounds: synthesis of 2-amino-5*H*-1,3,4-benzotriazepin-5-ones, 605
Leinweber, F.-J., Greenough, R. C., and Di Carlo, F. J., bunolol metabolism by dogs: identification of basic metabolites and their conjugates, 1570
Lelorier, J., *see* Caille, G., 1383
Lenney, J. F., Siddiqui, W. A., Schnell, J. V., Furusawa, E., and Read, G. W., antimicrobial action of compound 48/80 against protozoa, bacteria, and fungi, 702
Lerk, C. F., Lagas, M., Boelstra, J. P., and Broersma, P., contact angles of pharmaceutical powders, 1480
Le Roux, Y., and Richard, J., determination of acenocoumarol in plasma and urine by double radioisotope derivative analysis, 997
Leslie, D. T., *see* Repke, D. B., 113, 743
Leslie, J., *see* Callery, P. S., 578
Leung, W. J., *see* Jain, N. C., 66
Levy, G., *see* Lai, C.-M., 1739
——*see* Slattery, J. T., 943, 1060
——*see* Wingard, L. B., Jr., 1790
——*see* Yacobi, A., 145, 567, 941, 1025, 1275, 1285, 1741
Levy, R. H., Lockard, J. S., Patel, I. H., and Congdon, W. C., time-dependent kinetics III: diurnal oscillations in steady-state plasma valproic acid levels in rhesus monkeys, 1154
——*see* Patel, I. H., 650
——*see* Pitlick, W. H., 647
Lewis, D., *see* Bollinger, J. N., 718
Lewis, D. A., and Krygier, H. E., interactions of indomethacin with lysosomes and proteins, 1651
Lewis, R. P., *see* Kramer, W. G., 1720
Li, B. T., *see* Kingston, D. G. I., 1135
Li, H., Johnston, M. M., and Mufson, D., GLC determination of urinary chlorthalidone levels, 1732
——*see* Johnston, M. M., 1735
Li, N. C., *see* Ma, J. K. H., 1684
Liebman, A., see Dixon, W. R., 235
Lien, E. J., *see* Chou, J. T., 1556
Lim, P., *see* Cheung, A. P., 1723
Lin, C. S., *see* Fang, S. M., 1744
Lin, S. K., Moss, A. A., and Riegelman, S., iodipamide kinetics: capacity-limited biliary excretion with simultaneous pseudo-first-order renal excretion, 1670
Lindstrom, F. T., and Ayres, J. W., diffusion model for drug release from suspensions II: release to a perfect sink, 662
——*see* Ayres, J. W., 654
Lipper, R. A., and Higuchi, W. I., analysis of theoretical behavior of a proposed zero-order drug delivery system, 163
Liu, S. T., *see* Hurwitz, A. R., 624
Li Wan Po, A., *see* Enever, R. P., 1087
Lockard, J. S., *see* Levy, R. H., 1154
——*see* Patel, I. H., 650
Loh, A., Zuleski, F. R., and Di Carlo, F. J., radiochemical GLC assay for nortriptyline in human plasma, 1056
Long, D. M., *see* Hussain, M., 907
Lopez, J. A., *see* Dwuma-Badu, D., 1242
Loutfy, M. A., and Abu-Shady, H. A., preparation and skin-photosensitizing activity of substituted psoralens, 1623
Loux, J. J., DePalma, P. D., Eby, R. Z., and Yankell, S. L., antipyretic testing of commercial aspirin formulations in rats, 674
Lovegreen, P. D., *see* Valentine, J. L., 1263
Lovering, E. G., *see* McErlane, K. M., 1015
Lubawy, W. C., and Garrett, R. J. B., effects of aspirin and acetaminophen on fetal and placental growth in rats, 111
Lui, E. M. K., Farmer, P. S., and Dean, C. R., functional modification of indole binding site with indomethacin congeners, 950
Lukes, A. L., *see* Pikal, M. J., 1312
Lusi, A., *see* Fisher, M. H., 1349
Luzzi, L. A., *see* Ma, J. K. H., 209, 1684
Lynch, D. M., *see* Warner, V. D., 418
Lynch, V. D. P., *see* Dorato, M. A., 35
——*see* Staab, R. J., 1483
Lyon, V., *see* Fang, S. M., 1744

M

Ma, J. K. H., Fu, P. P., and Luzzi, L. A., protein binding of benz[*a*]anthracene and benzo[*a*]pyrene, 209
——Luzzi, L. A., Ma, J. Y. C., and Li, N. C., fluorescence studies of oxygen binding in *Limulus* hemocyanin, 1684
Ma, J. Y. C., *see* Ma, J. K. H., 1684
MacFarlane, J. O., *see* Lee, J. W., 986
Machkovech, S. M., *see* Rowe, E. L., 273
Macy, L., *see* Borodkin, S., 693
Madsen, P. O., *see* Kjaer, T. B., 345
——*see* Welling, P. G., 549
Maeda, T., Takenaka, H., Yamahira, Y., and Noguchi, T., use of rabbits for GI drug absorption studies, 69
Mahjour, M., *see* Shafiee, A., 593
Maibach, H. I., *see* Skinner, W. A., 587, 1764
Malbica, J. O., Monson, K., Neilson, K., and Sprissler, R., electron-capture GLC determination of nanogram to picogram amounts of isosorbide dinitrate, 384
Malick, A. W., and Weiner, N. D., effect of lipids on enzymatic activity of pig heart mitochondrial malate dehydrogenase monomolecular films, 1465
——and Weiner, N. D., enzymatic activity of pig heart mitochondrial malate dehydrogenase monomolecular films by surface exchange technique, 792
Mallinger, A. G., *see* Poust, R. I., 609
Mallinger, J., *see* Poust, R. I., 609
Malone, M. H., *see* Watson, W. C., 1304
Mandell, D. M., *see* Repke, D. B., 743
Maness, D. D., *see* Allen, L. V., Jr., 494
——*see* Han, W. W., 573, 795
Mangia, A., *see* Bortesi, F., 1767
——*see* Silingardi, S., 1769
Manion, C. V., Lalka, D., Baer, D. T., and Meyer, M. B., absorption kinetics of procainamide in humans, 981

Manius, G., and Viswanathan, V., GLC determination of lasalocid and its bromo analog as their silyl derivatives, 769
Mann, D. E., Jr., *see* Chang, C.-H., 1755
Mannan, C. A., Krol, G. J., and Kho, B. T., high-speed liquid chromatographic analysis of dapsone and related compounds, 1618
Mannebach, J. T., *see* Winkler, V. W., 816
Mantero, O., see Ghirardi, P., 267
Manzer, A. R., *see* Yung, D. K., 1009
Marcucci, F., *see* Mussini, E., 1482
Margosis, M., GLC determination of *N,N*-dimethylaniline in penicillins, 1634
Margulis, T. N., *see* Koerntgen, C., 1127
Martelli, S., *see* Cardellini, M., 259
——*see* Claudi, F., 1355
Martin, F. G., *see* Russi, G. D., 1652
Martin, J. S., *see* Tansy, M. F., 613, 902
Martineau, P. C., *see* Strum, J. D., 539
Marzo, A., *see* Ghirardi, P., 267
Mason, W. D., *see* Weddle, O. H., 874
Massart, D. L., *see* De Clercq, H., 1269
——*see* Michotte, Y., 1630
Masui, K., *see* Naito, S.-I., 254
Matheny, J. L., Carrier, G. O., and Ahlquist, R. P., role of neuronal and extraneuronal uptake in responses of rabbit iris dilator muscle to levarterenol and phenylephrine, 93
Matheson, L. E., Jr., *see* Parrott, E. L., 955
Matsui, F. F., *see* Butterfield, A. G., 684
Mattson, D. H., *see* Hachey, D. L., 1579
Mauger, J. W., Brooke, D., and Damewood, E. Z., dissolution profile for multisized drug particles: new approximate expression, 553
——*see* Alexander, K. S., 42
——*see* Howard, S. A., 557
Maulding, H. V., and Zoglio, M. A., degradation kinetics of a substituted carbinolamine in aqueous media, 1175
May, E. L., and Jacobson, A. E., chemistry and pharmacology of homologs of 6-acetyl- and 3,6-diacetylmorphine, 285
Mayer, K., *see* Chou, J. T., 1556
Mays, D. L., *see* Bodnar, J. E., 1108
McBride, M. H. D., George, R. E., Kessler, W. V., and Shaw, S. M., stannous-ion quantitation in pyrophosphate and polyphosphate radiopharmaceutical kits using differential pulse polarography, 870
McCall, J. M., *see* Royer, M. E., 1266
McCallum, N. K., and Cairns, E. R., simple device for GLC separations of cannabinoids using a surface-coated open tube column without stream splitting, 114
McCreery, R. L., oxidative reactions of hydroxylated chlorpromazine metabolites, 357
McErlane, K. M., and Curran, N. M., GLC assay of conjugated estrogen formulations, 523
——Curran, N. M., and Lovering, E. G., impurities in drugs I: imipramine, desipramine, and their formulations, 1015
McGilveray, I. J., *see* Midha, K. K., 1596
——*see* Sved, S., 1761
McGinity, J. W., and Lach, J. L., sustained-release applications of montmorillonite interaction with amphetamine sulfate, 63
McHugh, W. C., Jr., *see* Sandmann, R. A., 890
McLaughlin, J. L., *see* Pummangura, S., 1485
McMullen, J. N., *see* Newton, D. W., 1327
McNamara, P. J., *see* Gibaldi, M., 1211
McNeil, H. R., Williams, B. B., Jr., and Darling, C. M., tetrazole analogs of phenylalanine derivatives as tyrosine hydroxylase inhibitors, 1642
McQuinn, R. L., *see* Yeh, S. Y., 201
Meadows, G. G., Boze, L., and Elmer, G. W., new rapid determination of pyridoxal phosphate using tyrosine phenol-lyase, 1503
Meffin, P. J., Harapat, S. R., and Harrison, D. C., high-pressure liquid chromatographic analysis of drugs in biological fluids II: determination of an antiarrhythmic drug, tocainide, as its dansyl derivative using a fluorescence detector, 583
——Williams, R. L., Blaschke, T. F., and Rowland, M., application of salivary concentration data to pharmacokinetic studies with antipyrine, 135
——*see* Bjornsson, T. D., 142
Mehta, A., Adams, K., Zoglio, M. A., and Carstensen, J. T., influences of granulation liquid flow rate on particle-size distribution in spray-granulated products, 1462
Melamed, S., Carlson, G. R., Moss, J. N., Belair, E. J., and Tansy, M. F., GI pharmacology of polyethyleneimine I: effects on gastric emptying in rats, 899
——*see* Tansy, M. F., 902
Melikian, A. P., Flynn, N. W., Petty, F., and Wander, J. D., chemical ionization mass spectra of phenothiazine derivatives and their oxygenated analogs, 228
Mendez, V. M., *see* Bollinger, J. N., 718
Menon, G. K., and Cammarata, A., pattern recognition II: investigation of structure–activity relationships, 304
Mercer, H. D., Rollins, L. D., Carter, G. G., Gural, R. P., Bourne, D. W. A., and Dittert, L. W., factors affecting serum oxytetracycline levels in beef calves, 1198
Merkel, K. E., *see* Finnegan, R. A., 884
Merotti, G. C., *see* Ghirardi, P., 267
Meszoely, C. A., *see* Warner, V. D., 418
Meyer, J. C., *see* de Silva, J. A. F., 353
Meyer, M. B., *see* Manion, C. V., 981
Michelucci, J., *see* Chin, D. A., 1143
Michotte, Y., and Massart, D. L., molecular connectivity and retention indexes, 1630
Midha, K. K., and Cooper, J. K., GLC determinations of plasma acenocoumarol levels, 799
——Hindmarsh, K. W., McGilveray, I. J., and Cooper, J. K., identification of urinary catechol and methylated catechol metabolites of phenytoin in humans, monkeys, and dogs by GLC and GLC–mass spectrometry, 1596
Miller, A. M., *see* Chang, S. F., 1700
Miller, G. H., Smith, H. L., Rock, W. L., and Hedberg, S., antibacterial structure–activity relationships obtained with resistant microorganisms I: inhibition of R-factor resistant *Escherichia coli* by tetracyclines, 88
Mitra, C., *see* Banerjee, S., 1239
Mitscher, L. A., *see* Sokoloski, T. D., 1159
Miyamoto, E., *see* Tsuji, A., 1675
——*see* Yamana, T., 747, 861
Mlodozeniec, A.R., *see* Shah, A. C., 1377
Mo, Y., Peck, G. E., Heyd, A., and Banker, G. S., recording pH method of characterizing composition and monitoring dissolution profile of an anhydride–acid copolymer and its salt derivatives, 713
Molloy, B. B., *see* Fuller, R. W., 271
Molokhia, A. M., Hofmann, A. F., Higuchi, W. I., Tuchinda, M., Feld, K., Prakongpan, S., and Danzinger, R. G., dissolution rates of model gallstones in human and animal biles and importance of interfacial resistance, 1101
——*see* Kwan, K. H., 1094, 1105
Monkhouse, D. C., *see* Bansal, P. C., 819
——*see* Berge, S. M., 1
Monson, K., *see* Malbica, J. O., 384
Montani, A., *see* Benzi, G., 1278
Moore, D. E., photosensitization by drugs, 1282
——*see* Wiebe, J. A., 186
Moore, E. C., *see* Parker, G. R., 1040
Moss, A. A., *see* Lin, S. K., 1670
Moss, J. N., *see* Melamed, S., 899
——*see* Tansy, M. F., 902
Moxon, G. H., and Slifkin, M. A., kinetic spectrophotometric study of effect of triazolopyrazines on *p*-benzoquinone complexes, 205
Mrtek, M. B., Gearien, J. E., and Blake, M. I., chemical and spectroscopic analysis of a phenobarbital–ephedrine complex, 1019
Mufson, D., *see* Johnston, M. M., 1735
——*see* Li, H., 1732
Mukherjee, A. K., *see* Banerjee, S., 1239
Munnelly, K. P., *see* Wong, C. K., 736
Munson, J. W., and Bilous, R., colorimetric determination of aliphatic acids, 1403
——Hussain, A., and Bilous, R., precautionary note for use of bisulfite in pharmaceutical formulations, 1775
Murphy, J. C., *see* Borne, R. F., 594
Murray, S., *see* Clarke, J. M., 1429
Murray, W. J., molecular connectivity and steric parameters, 1352
Murthy, K. S., and Samyn, J. C., effect of shear mixing on *in vitro* drug release of capsule formulations containing lubricants, 1215
Mussini, E., Marcucci, F., Airoldi, L., Facchinetti, T., and Garattini, S., hydroxylation of three benzodiazepines *in vitro*, 1482
Musto, J. D., Sane, J. N., and Warner, V. D., quantitative determination of phenol by high-pressure liquid chromatography, 1201

N

Nadir, N. S., *see* Bikhazi, A. B., 1308
Naik, D. V., *see* Sturgeon, R. J., 1346
Naito, S.-I., Masui, K., and Shiraki, T., prediction of tableting problems such as capping and sticking: theoretical calculations, 254
Nannipieri, E., *see* Bottari, F., 926
Nasir, S. S., Wilken, L. O., Jr., and Akhtar, B., application of gluconolactone in direct tablet compression, 370
Natalini, P., *see* Claudi, F., 1355
Neil, J. F., *see* Poust, R. I., 609
Neilson, K., *see* Malbica, J. O., 384
Nelson, K. G., and Shah, A. C., application of a convective diffusion model to membrane transport, 137
——and Wang, L. Y., determination of time course of tablet disintegration I: numerical method, 1758
——*see* Farng, K. F., 1611
Nelson, S. D., Garland, W. A., Breck, G. D., and Trager, W. F., quantification of lidocaine and several metabolites utilizing chemical-ionization mass spectrometry and stable isotope labeling, 1180
Nesbitt, R. U., Jr., and Sandmann, B. J., solubility studies of silver sulfadiazine, 519
Netter, K. J., *see* Burgschat, H., 60
Neubert, P., and Koch, K., simultaneous automated determination of spironolactone metabolites in serum, 1131
Neville, G. A., Hasan, F. B., and Smith, I. C. P., quantitative analysis of degradation products in pilocarpine hydrochloride ophthalmic formulations, 638
Newburger, J., Combs, A. B., and Hsu, T.-F., *in vitro* photodecomposition of uric acid in presence of riboflavin II, 1561
Newton, D. W., McMullen, J. N., and Becker, C. H., characteristics of medicated and unmedicated microglobules recovered from complex coacervates of gelatin–acacia, 1327
Niazi, S., and Chiou, W. L., fluorocarbon aerosol propellants XI: pharmacokinetics of dichlorodifluoromethane in dogs following single and multiple dosing, 49
——*see* Huang, M. L., 608
——*see* Hussain, M., 907
Nichols, D. E., *see* Pummangura, S., 1485
Nightingale, C. H., *see* Greene, D. S., 1663
——*see* Yu, A. B. C., 213
Nigrelli, R. F., *see* Chib, J. S., 1052
Ning, R., *see* Dixon, W. R., 235
Ninger, F. C., *see* Gucluyildiz, H., 265
Niu, H. C., *see* Valentine, J. L., 1263
Njau, E., nature of acid-induced fluorescence of 17α-methyltestosterone, 1478
Noguchi, T., *see* Maeda, T., 69

O

Ober, R. E., *see* Chang, S. F., 1700
Ochs, J. F., *see* Hiestand, E. N., 510
Ode, R. H., *see* Pettit, G. R., 757
Oesterling, T. O., *see* Cho, M. J., 149
——*see* Stehle, R. G., 1590
O'Hara, G. P., *see* Burke, D. H., 1658
Ohno, K., *see* Abdel-Monem, M. M., 1089, 1195
Oie, S., *see* Yacobi, A., 1025
Okarter, T. U., *see* Dwuma-Badu, D., 1242
O'Leary, I. A., *see* Hills, E. B., 1497
Olliff, C. J., and Chatten, L. G., ac polarography for tetracycline analysis, 1564
Omar, N. M., and El-Rabbat, N. A., polarographic study of new antibacterial isoxazolium salts: 2,3-dialkyl-5-arylisoxazolium perchlorates, 597
Omran, L. A., *see* Farag, H. H., 423

O'Neill, P. J., and Rahwan, R. G., modified electron-capture GLC assay for salsolinol in brain tissue, 893
Ortega, E., *see* Tterlikkis, L., 1454
Orth, R. E., Swidler, H. J., and Zarakov, M. S., survival of pleomorphic sarcoma-37 transplanted virgin female DBA/2J mice: effects produced by high blood glucose levels alone and in combination with drugs, 279
——Swidler, H. J., and Zarakov, M. S., survival of pleomorphic sarcoma-37 transplanted virgin female DBA/2J mice: hyperthermia and hyperglycemia, alone and in combination with drugs, 437
Orzechowski, R. F., *see* Aarons, D. H., 1244
——*see* Siegl, P. K. S., 938
Osborne, V. L., *see* Randolph, W. C., 1148
Osterberg, A. C., *see* Child, R. G., 466
Oteiza, R. M., Wooten, R. S., Kenner, C. T., Graham, R. E., and Biehl, E. R., kinetics and mechanism of blue tetrazolium reaction with corticosteroids, 1385
Owada, E., Behl, C. R., Hwang, S. S.,Suhardja, L., Flynn, G. L., Ho, N. F. H., and Higuchi, W. I., vaginal drug absorption in rhesus monkeys I: development of methodology, 216
——*see* Hwang, S., 778, 781
Owen, B. J., and Wilkie, S. V., separation and quantitative determination of 2,4-disulfamyl-5-trifluoromethylaniline in hydroflumethiazide using high-pressure liquid chromatography, 877
Özdurmuş, S., *see* Dinçer, S., 1070

P

Pal, D., *see* De, A. U., 232
Palermo, B. T., *see* Phillips, B. M., 124
Palmer, R. F., *see* Clarke, J. M., 1429
Pantuck, E. J., *see* Garland, W. A., 340
Park, J. Y., and Rippie, E. G., micellar distribution equilibria: ultracentrifugal study of apparent partition coefficients, 858
Parker, G. R., and Moore, E. C., solvent-dependent conformational system of hydroxyureas in octanol–water and in inhibition of ribonucleotide reductase, 1040
Parkhurst, R. M., *see* Skinner,W. A., 1764
Parmar, S. S., Chaudhary, M., Chaudhary, S. K., Kumar, S., and Spiro, H. R., anticonvulsant activity and selective inhibition of NAD-dependent oxidations in rat brain homogenates by newer mercaptotriazoles, 971
——*see* Agrawal, A. K., 887
Parrott, E. L., and Matheson, L. E., Jr., rectal absorption of nitrofurantoin, 955
Paruta, A. N., *see* Alexander, K. S., 42
Pastoris, O., *see* Benzi, G., 1278
Pastushok, C. A., *see* Dermody, W. C., 386
Patchett, A. A., *see* Wu, M. T., 1150
Patel, D. M., *see* Won, C. M., 73
Patel, I. H., Levy, R. H., and Lockard, J. S., time-dependent kinetics II: diurnal oscillations in steady-state plasma ethosuximide levels in rhesus monkeys, 650
——*see* Levy, R. H., 1154
Patel, J., *see* Joseph, A. A., 490
Patel, S., *see* Joseph, A. A., 490
Patil, P. N., *see* Baweja, R., 1544
Patton, T. F., pharmacokinetic evidence for improved ophthalmic drug delivery by reduction of instilled volume, 1058
Paul, C. J., *see* Whitehouse, L. W., 1399
Paul, W. L., *see* Schulman, S. G., 1473
Pazman, J., *see* Pečar, M., 330
Pečar, M., Kujundžić, N., and Pazman, J., stability of (pyrrolidone-5-hydroxamato)iron(III) chelates, 330
Peck, G. E., *see* Baley, G. J., 696
——*see* Gucluyildiz, H., 407
——*see* Mo, Y., 713
——*see* Scheu, J. D., 172
Peng, G. W., *see* Beisler, J. A., 849
Pento, J. T., *see* Robinson, C. P., 879
Peot, C. B., *see* Hiestand, E. N., 510
Perkins, E. G., *see* Sharma, J. P., 1319
Perrin, J. H., *see* Janssen, L. H. M., 146
——*see* Roseboom, H., 1392, 1395
Petersen, H., Jr., *see* Alexander, K. S., 42
Petersen, R. V., *see* Carter, J. E., 546
Pettit, G. R., and Ode, R. H., antineoplastic agents L: isolation and characterization of sphyrnastatins 1 and 2 from the hammerhead shark *Sphyrna lewini,* 757
Petty, F., *see* Melikian, A. P., 228
Phelps, B. A., *see* Cone, E. J., 1709
Phelps, D. L., and Karim, A., spironolactone: relationship between concentrations of dethioacetylated metabolite in human serum and milk, 1203
Phillips, B. M., and Palermo, B. T., physical form as a determinant of effect of buffered acetylsalicylate formulations on GI microbleeding, 124
Phillips, J. W., *see* Roscoe, C. W., 1505
Phillipson, J. D., *see* Fairbairn, J. W., 1300
Philopoulous, Y., *see* Douglas, J. F., 1645
Phusanti, L., *see* Howard, S. A., 557
Pikal, M. J., Bibier, D. A., and Rutherford, B., polymer sorption of nitroglycerin and stability of molded nitroglycerin tablets in unit-dose packaging, 1293
——Lukes, A. L., and Lang, J. E., thermal decomposition of amorphous β-lactam antibacterials, 1312
Pilpel, N., *see* Esezobo, S., 852
Pintauro, C., *see* Gal, J., 866
Pirakitikulr, P., *see* Goehl, T. J., 1027
Pisano, F., *see* Ibrahim, H. G., 669
Pitlick, W. H., and Levy, R. H., time-dependent kinetics I: exponential autoinduction of carbamazepine in monkeys, 647
——*see* Goehl, T. J., 1027
Pizzorno, M. T., *see* Rodriguez, M. R., 121
Plakogiannis, F. M., and Saad, A. M., simultaneous GLC determination of acetaminophen, dichloralantipyrine, and isometheptene mucate, 604
Polk, A., *see* Lee, J. K., 832
Pool, W., *see* Sheth, P. R., 1567
Pool, W. R., *see* Dalton, C., 348
Post, A., *see* Zappala, A. F., 292
Pottier, J., Berlin, D., and Raynaud, J. P., pharmacokinetics of the anti-inflammatory tiaprofenic acid in humans, mice, rats, rabbits, and dogs, 1030
Poust, R. I., Mallinger, A. G., Mallinger, J., Himmelhoch, J. M., Neil, J. F., and Hanin, I., absolute availability of lithium, 609
——*see* Strum, J. D., 539
Prakash, N. J., *see* Giroux, E., 391
Prakongpan, S., *see* Molokhia, A. M., 1101
Prasad, V. K., *see* Carstensen, J. T., 607
Pratt, E. L., *see* Dombrowski, L. J., 1413
Price, J. C., *see* Warren, J. W., Jr., 1406, 1409
Prockop, L. D., *see* Gutin, P. H., 1338
Prue, D. G., *see* Chin, D. A., 1143
Pummangura, S., Nichols, D. E., and McLaughlin, J. L., cactus alkaloids XXXIII: β-phenethylamines from the Guatemalan cactus *Pilosocereus maxonii,* 1485

Q

Quintiliani, R., *see* Greene, D. S., 1663

R

Rahwan, R. G., *see* O'Neill, P. J., 893
Raje, R. R., *see* Shah, P. R., 291
Ramachander, G., Williams, F. D., and Emele, J. F., determination of dextrorphan in plasma and evaluation of bioavailability of dextromethorphan hydrobromide in humans, 1047
Raman, P. V., *see* Shah, R. C., 1551
Rama Sastry, B. V., *see* Kau, S. T., 53
Ramsay, L. E., *see* Clarke, J. M., 1429
Randolph, W. C., Osborne, V. L., Walkenstein, S. S., and Intoccia, A. P., high-pressure liquid chromatographic analysis of cimetidine, a histamine H_2-receptor antagonist, in blood and urine, 1148
Rasero, L., *see* Hanna, S., 123
Raynaud, J. P., *see* Pottier, J., 1030
Read, G. W., *see* Lenney, J. F., 702
Reamer, J. T., *see* Reif, V. D., 1112
Rearick, D. E., *see* Sundberg, R. J., 263
Reavey-Cantwell, N. H., *see* Lee, J. K., 832
——*see* Won, C. M., 73
Reba, R. C., *see* Karesh, S. M., 225
Reel, J. R., *see* Dermody, W. C., 386
Reif, V. D., Reamer, J. T., and Grady, L. T., chromatographic assays for folic acid, 1112
Repke, D. B., and Leslie, D. T., baeocystin in *Psilocybe semilanceata,* 113
——Leslie, D. T., Mandell, D. M., and Kish, N. G., GLC–mass spectral analysis of psilocin and psilocybin, 743
Repta, A. J., Dimmock, J. R., Kreilgård, B., and Kaminski, J. J., hydrolysis mechanism of 7-acetylacroninium perchlorate, a novel prodrug of acronine, 1501
——*see* Bourne, D. W. A., 628
Reuning, R. H., *see* Kramer, W. G., 1720
Rhodes, C. T., *see* Lausier, J. M., 1636
——*see* Schwartz, P. A., 994
Rhodes, H. J., *see* Hsiao, C. H., 1157
Rice, K. C., Klee, W. A., Aceto, M. D., Swain, H. H., and Jacobson, A. E., potential long acting opiate antagonists: preparation, pharmacological activity, and opiate–receptor binding of *N*-substituted 2′-hydroxy-5-methyl-9α-propyl-6,7-benzomorphans, 193
Richard, J., *see* Le Roux, Y., 997
Rickard, E. C., and Cooke, G. G., electrochemical analysis of the cephalosporin cefamandole nafate, 379
Riegelman, S., *see* Lin, S. K., 1670
——*see* Wallace, S. M., 527, 729
Rippie, E. G., *see* Chou, C. H., 104
——*see* Park, J. Y., 858
Rist, N., *see* Cohen, V. I., 1332
Ritschel, W. A., and Erni, W., bioavailability of sulfadiazine in rabbits using tablets prepared by direct compression and fluidized-bed granulation, 1438
Robinson, C. P., Choi, J. J., and Pento, J. T., enhancement of intestinal glucose transport following chronic parathion poisoning, 879
Robinson, J. R., *see* Conrad, J. M., 219
——*see* Sieg, J. W., 1222
Rock, W. L., *see* Miller, G. H., 88
Rodda, B. E., *see* Kleber, J. W., 635
Rodriguez, M. R., Pizzorno, M. T., and Albonico, S. M., NMR determination of trimethoprim and sulfamethoxazole in tablets and powders, 121
Roll, D. B., *see* Carter, J. E., 546
Rollins, L. D., *see* Mercer, H. D., 1198
Ronfeld, R. A., and Benet, L. Z., interpretation of plasma concentration–time curves after oral dosing, 178
Roscoe, C. W., Phillips, J. W., and Gillchriest, W. C., new compounds: organoboron derivatives of tetracyclines I: synthesis of carboxamido derivative of tetracycline with perhydro-2-phenyl-1,3,6,2-dioxazaborocine, 1505
Roseboom, H., and Perrin, J. H., mechanism for phenothiazine oxidation, 1395
——and Perrin, J. H., oxidation kinetics of phenothiazine and 10-methylphenothiazine in acidic medium, 1392
Rosegay, A., *see* Hare, L. E., 414
Rosen, M., *see* Hanna, S., 123
Rosler, K.-H. A., *see* Sullivan, G., 828
Rossi, G. V., *see* Aarons, D. H., 1244
Rowe, E. L., and Machkovech, S. M., rapid acetylation of a dihydroxy compound by 4-(dimethylamino)-pyridine catalysis: application to GLC determination of clindamycin palmitate hydrochloride, 273
Rowland, M., *see* Aarons, L. J., 1359
——*see* Meffin, P. J., 135
——*see* Thiessen, J. J., 1063
Royer, M. E., Ko, H., Gilbertson, T. J., McCall, J. M., Johnston, K. T., and Stryd, R., radioimmunoassay of minoxidil in human serum, 1266
Rubia, L. B., and Gomez, R., TLC sensitivity of six modifications of Dragendorff's reagent, 1656
Rubio, F., *see* da Silva, J. A. F., 353
Ruggieri, G. D., *see* Chib, J. S., 1052
Russell, H. F., *see* Sundberg, R. J., 263
Russell, H. T., *see* Farid, N. A., 536
Russi, G. D., and Martin, F. G., effect of pentazocine on pressor responses of epinephrine and levarterenol, 1652
Rutherford, B., *see* Pikal, M. J., 1293

S

Saad, A. M., *see* Plakogiannis, F. M., 604

Sachanandani, S., *see* Gupta, V. D., 897
Sadée, W., *see* Finn, A. M., 275
Saettone, M. F., *see* Bottari, F., 926
Sakowski, R., *see* Dermody, W. C., 386
Salvador, R. L., *see* Simon, D. Z., 431
Samyn, J. C., *see* Murthy, K. S., 1215
Sanchez de Ramos, M. E., *see* Tuckerman, M. M., 1341
Sandmann, B. J., *see* Nesbitt, R. U., Jr., 519
Sandmann, R. A., and McHugh, W. C., Jr., quinuclidine chemistry: autocondensation reactions of 3-quinuclidinone, 890
Sane, J. N., *see* Foye, W. O., 923
——*see* Musto, J. D., 1201
Sanvordeker, D. R., and Bloss, J., vehicle effects on activity of an anticonvulsant compound, 82
Saxena, S. J., Honigberg, I. L., Stewart, J. T., and Vallner, J. J., liquid chromatography in pharmaceutical analysis VII: determination of dantrolene sodium in biological fluids, 751
——Honigberg, I. L., Stewart, J. T., Keene, G. R., and Vallner, J. J., liquid chromatography in pharmaceutical analysis VI: determination of dantrolene sodium in a dosage form, 286
——Stewart, J. T., Honigberg, I. L., Washington, J. G., and Keene, G. R., liquid chromatography in pharmaceutical analysis VIII: determination of isoniazid and acetyl derivative in plasma and urine samples, 813
Scheu, J. D., Sperandio, G. J., Shaw, S. M., Landolt, R. R., and Peck, G. E., use of microcapsules as timed-release parenteral dosage form: application as radiopharmaceutical imaging agent, 172
Schiff, P. L., Jr., *see* Dwuma-Badu, D., 1242
Schmits, R., *see* Borodkin, S., 693
Schnell, J. V., *see* Lenney, J. F., 702
Schott, H., relationship between zero point of charge and solubility product for hydroxides of polyvalent cations, 1548
——and Han, S. K., effect of symmetrical tetraalkylammonium salts on cloud point of nonionic surfactants, 165
Schulman, S. G., Paul, W. L., and Sturgeon, R. J., binding of *N*-substituted anthracenecarboxamides to double-stranded DNA: an electronic spectral study, 1473
——*see* Sturgeon, R. J., 958, 1346
Schwan, T. J., *see* White, R. L., 277
Schwartz, J. A., *see* Blanchard, J., 935, 1083
Schwartz, P. A., Rhodes, C. T., and Cooper J. W., Jr., solubility and ionization characteristics of phenytoin, 994
Sears, R. W., *see* Butterfield, A. G., 684, 1117
Segelman, A. B., Segelman, F. P., Varma, S. D., Wagner, H., and Seligmann, O., *Cannabis sativa* L. (marijuana) IX: lens aldose reductase inhibitory activity of marijuana flavone C-glycosides, 1358
——*see* Fleischner, A. M., 1206
Segelman, F. P., *see* Segelman, A. B., 1358
Seligmann, O., *see* Segelman, A. B., 1358
Sellers, E. M., Khouw, V., and Dolman, L., comparative drug adsorption by activated charcoal, 1640
Serafini, M. F., *see* Bottari, F., 926
Sethi, M. L., *in vitro* inhibition of viral DNA polymerase activity by litmomycin, 130
Shaar, S., *see* Singhvi, S. M., 1488
Shaffer, R. D., *see* Grindel, J. M., 834
Shafiee, A., Lalezari, I., and Mahjour, M., alkaloids of *Glaucium oxylobum* Boiss and Buhse, population Ab-Ali, 593
——Lalezari, I., Assadi, F., and Khalafi, F., alkaloids of *Papaver orientale* L., 1050
——Lalezari, I., Lajevardi, S., and Khalafi, F., alkaloids of *Glaucium flavum* Grantz, populations Isfahan and Kazerun, 873
Shah, A. C., and Mlodozeniec, A. R., mechanism of surface lubrication: influence of duration of lubricant–excipient mixing on processing characteristics of powders and properties of compressed tablets, 1377
——*see* Nelson, K. G., 137
Shah, J. J., synthesis of sulfonates of 4-chloro-3,5-dimethylphenol and 5-chloro-7-iodo-8-quinolinol, 440
Shah, N. H., *see* Sheth, P. R., 1567
Shah, P. R., and Raje, R. R., hydrazones of isoniazid for colorimetric analysis, 291
Shah, R. C., Raman, P. V., and Sheth, P. V., polyethylene glycol as a binder for tablets, 1551
Shah, V. P., *see* Wallace, S. M., 527
Shambhu, M. B., *see* Digenis, G. A., 442
Sharma, J. P., Koritz, G. D., Perkins, E. G., and Bevill, R. F., high-pressure liquid chromatographic determination of tetracyclines in urine, 1319
Shaw, S. M., *see* Farid, N. A., 536
——*see* Heeg, J. F., 96
——*see* McBride, M. H. D., 870
——*see* Scheu, J. D., 172
Shelton, D., *see* Tan, H. S. I., 1037
Shelton, J. R., *see* Clarke, J. M., 1429
Shen, D. D., *see* Bochner, F., 644
Sheth, P. R., Shah, N. H., and Pool, W., evaluation of drug formulations using LD_{50} testing in mice, 1567
Sheth, P. V., *see* Shah, R. C., 1551
Shlatis, J. A., *see* Bikhazi, A. B., 181
Shiraki, T., *see* Naito, S.-I., 254
Shiu, G. K., *see* Goehl, T. J., 1027
Shores, K. E., *see* Fujii, A., 844
Shotton, E., *see* Enever, R. P., 1087
Shough, H. R., *see* Choong, T.-C., 1340
Sibley, M. J., *see* Fu, C.-C., 425, 738
Siddiqui, W. A., *see* Lenney, J. F., 702
Sieg, J. W., and Robinson, J. R., vehicle effects on ocular drug bioavailability II: evaluation of pilocarpine, 1222
Siegl, P. K. S., and Orzechowski, R. F., actions of mescaline on isolated rat atria, 938
Silingardi, S., Di Bitetto, M., and Mangia, A., GLC determination of 6-aminopenicillanic acid and 7-amino-3-methyl-Δ^3-cephem-4-carboxylic acid, 1769
Simmons, S. P., and Kramer, P. A., liposomal entrapment of floxuridine, 984
Simon, D. Z., Brookman, S., Beliveau, J., and Salvador, R. L., synthetic acetylenic antifungal agents, 431
Sims, B. E., and Derr, G. R., prostaglandin monolayers II: monomolecular film behavior of dinoprost C-15 alkyl esters, 823
Singhvi, S. M., estimation of pharmacokinetic parameters from postinfusion blood level data obtained after simultaneous administration of intravenous priming and infusion doses, 1499
——Conway, W. D., Gibaldi, M., and Shaar, S., effect of coadministered salicylamide on terbutaline metabolism in rats, 1488
Sioufi, A., Caudal, F., and Grimault, D., GLC determination of free and conjugated triclosan in human plasma and urine, 1166
Sirois, G., *see* Huynh-Ngoc, T., 591
Skalsky, R. L., *see* Groff, W. A., 389
Skidmore, D., *see* Skinner, W. A., 587, 1764
Skinner, W. A., Crawford, H. T., Skidmore, D., and Maibach, H. I., topical mosquito repellents X: 2-oxazolidones, 587
——Tong, H. C., Johnson, H., Parkhurst, R. M., Thomas, D., Spencer, T., Akers, W., Skidmore, D., and Maibach, H., influence of human skin surface lipids on protection time of topical mosquito repellent, 1764
Slatkin, D. J., *see* Dwuma-Badu, D., 1242
Slattery, J. T., and Levy, G., effect of ibuprofen on protein binding of warfarin in human serum, 1060
——Yacobi, A., and Levy, G., comparative pharmacokinetics of coumarin anticoagulants XXV: warfarin–ibuprofen interaction in rats, 943
——*see* Yacobi, A., 941
Slifkin, M. A., *see* Moxon, G. H., 205
Sloboda, A. E., *see* Child, R. G., 466
Small, L. E., and Augsburger, L. L., clarification of nomenclature, 1508
——and Augsburger, L. L., instrumentation of an automatic capsule-filling machine, 504
Smith, H. L., *see* Miller, G. H., 88
Smith, I. C. P., *see* Neville, G. A., 638
Smith, R. V., Humphrey, D. W., and Escalona-Castillo, H., GLC determination of indoprofen in plasma, 132
Smith, S. J., *see* Butterfield, A. G., 684
Smolen, V. F., and Erb, R. J., predictive conversion of *in vitro* drug dissolution data into *in vivo* drug response *versus* time profiles exemplified for plasma levels of warfarin, 297
Smyth, R. D., *see* Lee, J. K., 832
Sneath, T. C., *see* Jain, N. C., 66
Snyder, H. R., Jr., Spencer, C. F., and Freedman, R., imidazo[4,5-*f*]quinolines III: antibacterial 7-methyl-9-(substituted arylamino)imidazo[4,5-*f*]-quinolines, 1204
Sokoloski, T. D., Mitscher, L. A., Yuen, P. H., Juvarkar, J. V., and Hoener, B., rate and proposed mechanism of anhydrotetracycline epimerization in acid solution, 1159
——*see* Baweja, R., 1544
——*see* Yuen, P. H., 1648
Soliva, M., *see* Voellmy, C., 631
Solomon, R., *see* Tterlikkis, L., 1454
Solomonraj, G., *see* Thomas, B. H., 1322
Sood, S. P., Wittmer, D. P., Ismaiel, S. A., and Haney, W. G., simultaneous high-pressure liquid chromatographic determination of niacin and niacinamide in multivitamin preparations: reversed-phase, ion-pairing approach, 40
Speiser, P., *see* Voellmy, C., 631
Spencer, C. F., *see* Snyder, H. R., Jr., 1204
Spencer, T., *see* Skinner, W. A., 1764
Sperandio, G. J., *see* Scheu, J. D., 172
Spillane, W. J., *see* Benson, G. A., 881
Spiro, H. R., *see* Parmar, S. S., 971
Spivey, R. J., *see* Bighley, L. D., 1124
Sprissler, R., *see* Malbica, J. O., 384
Srivastava, P. K., and Upadhyaya, J. S., new compounds: potential antituberculous agents I: alkylaryl 4-arylformamidinothiosemicarbazones, 904
Staab, R. J., Lynch, V. de P., Lau-Cam, C., and Barletta, M., small animal model for myocardial infarction, 1483
Stedman, R. J., *see* Burns, L. B., 753
Stehle, R. G., and Oesterling, T. O., stability of prostaglandin E_1 and dinoprostone (prostaglandin E_2) under strongly acidic and basic conditions, 1590
Stella, V. J., use of trimethylanilinium hydroxide–tetramethylammonium hydroxide as on-column methylating agent for GLC analysis of phenytoin, 1510
——*see* Chu, C. K., 238
Stempien, M. F., Jr., *see* Chib, J. S., 1052
Stewart, J. T., *see* Saxena, S. J., 286, 751, 813
Stiles, F. D., *see* Sullivan, G., 828
Stoll, R. G., *see* DeSante, K. A., 1713
Story, M. J., enteric-coated pellets: theoretical analysis of effect of dispersion in the stomach on blood level profiles, 1495
Strada, P., *see* Benzi, G., 1278
Streng, W. H., correction to "ionization constants of cephalosporin zwitterionic compounds," 1357
Strojny, N., *see* de Silva, J. A. F., 353
Strom, J. G., Jr., and Jun, H. W., GLC determination of methenamine in tablets, 589
Strum, J. D., Colaizzi, J. L., Jaffe, J. M., Martineau, P. C., and Poust, R. I., comparative bioavailability of four commercial quinidine sulfate tablets, 539
Stryd, R., *see* Royer, M. E., 1266
Sturgeon, R. J., and Schulman, S. G., electronic absorption spectra and protolytic equilibria of doxorubicin: direct spectrophotometric determination of microconstants, 958
——Flanagan, C., Naik, D. V., and Schulman, S. G., *in vitro* adsorption of doxorubicin hydrochloride on insoluble calcium phosphate, 1346
——*see* Schulman, S. G., 1473
Suhardja, L., *see* Hwang, S., 778, 781
——*see* Owada, E., 216
Sullivan, G., Stiles, F. D., and Rosler, K.-H. A., phytochemical investigation of xanthones of *Eustoma grandiflorum* (Raf.) Shinners, 828
Summers, M. P., and Enever, R. P., effect of primidone concentration on glass transition temperature and dissolution of solid dispersion systems containing primidone and citric acid, 825
——Enever, R. P., and Carless, J. E., influence of crystal form on tensile strength of compacts of pharmaceutical materials, 1172
Sun, S.-R., and Chun, A. H. C., determination of pentobarbital in serum by electron-capture GLC, 477
Sundberg, R. J., Rearick, D. E., and Russell, H. F., synthesis and anticancer screening of 2-indolyl 5-(1,2,3,6-tetrahydropyridyl) ketone, 263

Sved, S., McGilveray, I. J., and Beaudoin, N., bioavailability of three isoniazid formulations, 1761
Swain, H. H., *see* Rice, K. C., 193
Swidler, H. J., *see* Orth, R. E., 279, 437
Szulczewski, D., *see* Hong, W. H., 1703

T

Tackie, A. N., *see* Dwuma-Badu, D., 1242
Takenaka, H., *see* Maeda, T., 69
Takruri, H., Ecanow, B., and Balagot, R., water as a nonpolar partition medium, 283
Tan, H. S. I., Bruemmer, G. A., and Shelton, D., colorimetric assay of benzocaine and some dosage forms, 1037
——Gerlach, E. D., and Dimattio, A. S., sensitive assay procedure for ethambutol hydrochloride *via* charge transfer complex formation, 766
Tansy, M. F., Martin, J. S., Benhaim, S., Landin, W. E., and Kendall, F. M., GI motor inhibition associated with acute exposure to methyl methacrylate vapor, 613
——Martin, J. S., Innes, D. L., Kendall, F. M., Melamed, S., and Moss, J. N., GI pharmacology of polyethyleneimine II: motor activity in anesthetized dogs, 902
——*see* Melamed, S., 899
Tayim, H. A., *see* Bikhazi, A. B., 1515
Taylor, H., *see* Dawson, J. E., 1259
Taylor, T., and Chasseaud, L. F., plasma concentrations and bioavailability of clofibric acid from its calcium salt in humans, 1638
——*see* Assinder, D. F., 775
Telek, L., determination of solasodine in fruits of *Solanum* species, 699
Teng, L., Bruce, R. B., and Dunning, L. K., metoclopramide metabolism and determination by high-pressure liquid chromatography, 1615
Thames, K. E., *see* Johnson, B. J., 427
Theeuwes, F., and Bayne, W., dosage form index: an objective criterion for evaluation of controlled-release drug delivery systems, 1388
Theimer, E. E., and Ciurczak, E. W., quick specific assay for aspirin, 139
Theodorakis, M. C., *see* Digenis, G. A., 442
Thiessen, J. J., and Rowland, M., kinetics of drug–drug interactions in sheep: tolbutamide and sulfadimethoxine, 1063
Thio, A. P., *see* Kornet, M. J., 1022
Thomas, B. H., and Solomonraj, G., drug interactions with isoniazid metabolism in rats, 1322
——*see* Whitehouse, L. W., 1399
Thomas, D., *see* Skinner, W. A., 1764
Thomas, D. W., *see* Johnson, H. L., 1660
Thompson, B. L., *see* Choong, T.-C., 1340
Thompson, E. D., *see* Valentine, J. L., 1263
Thompson, G., *see* Borodkin, S., 693
Thorstenson, J. H., *see* Kornet, M. J., 1022
Thron, C. D., quick estimation of kinetic parameters for a compartment with exponential absorption rate and first-order elimination rate, 127
Tice, A. D., *see* Greene, D. S., 1508
Tidd, M. J., *see* Clarke, J. M., 1429
Tilton, P. F., *see* Grindel, J. M., 834
Tin-Wa, M., *see* Dobberstein, R. H., 600
Tomcufcik, A. S., *see* Child, R. G., 466
Tong, H. C., *see* Skinner, W. A., 1764
Torrance, S. J., Wiedhopf, R. M., and Cole, J. R., antitumor agents from *Jatropha macrorhiza* (Euphorbiaceae) III: acetylaleuritolic acid, 1348
——*see* Hoffmann, J. J., 883
Tovivich, P., *see* Foye, W. O., 1607
Trager, W. F., see Nelson, S. D., 1180
Tsau, D. Y. J., *see* Wong, C. K., 736
Tse, F. L. S., and Welling, P. G., prednisolone bioavailability in the dog, 1751
Tsilifonis, D. C., *see* Chafetz, L., 1145
Tsou, K. C., *see* Gutin, P. H., 1338
Tsuei, C. T., *see* Lee, J. K., 832
Tsuji, A., Itatani, Y., and Yamana, T., hydrolysis and epimerization kinetics of hetacillin in aqueous solution, 1004
——Kubo, O., Miyamoto, E., and Yamana, T., physicochemical properties of β-lactam antibiotics: oil–water distribution, 1675
——*see* Yamana, T., 747, 861
Tterlikkis, L., Ortega, E., Solomon, R., and Day, J. L., pharmacokinetics of mercaptopurine, 1454
Tuchinda, M., *see* Molokhia, A. M., 1101
Tuckerman, M. M., and Sanchez de Ramos, M. E., direct complexometric titration of calcium phosphates, 1341
——*see* Burns, L. B., 753

U

Uekama, K., Hirayama, F., Ikeda, K., and Inaba, K., utilization of cyclodextrin complexation for separation of E, A, and B prostaglandins by ion-exchange liquid chromatography, 706
Upadhyaya, J. S., *see* Srivastava, P. K., 904

V

Vaitkus, J. W., *see* Dermody, W. C., 386
Valentine, J. L., Bryant, P. J., Gutshall, P. L., Gan, O. H. M., Lovegreen, P. D., Thompson, E. D., and Niu, H. C., high-pressure liquid chromatographic–mass spectrometric determination of Δ^9-tetrahydrocannabinol in human plasma following marijuana smoking, 1263
Valiner, J. J., binding of drugs by albumin and plasma protein, 447
——and Chen, L., β-lipoproteins: possible plasma transport proteins for basic drugs, 420
——*see* Saxena, S. J., 236, 751
van der Graaff, H., *see* de Blaey, C. J., 1696
Vanderlaan, R. K., *see* Kerkhof, N. J., 1528
van Es, T., *see* Fleischner, A. M., 1206
Van Hamme, M. J., Ambre, J. J., and Ghoneim, M. M., mass fragmentographic determination of plasma etomidate concentrations, 1344
Van Vaerenbergh, P. M., *see* De Leenheer, A. P., 1190
Varma, S. D., *see* Segelman, A. B., 1358
Vaughn, D., *see* Born, J. L., 1046
Veng Pedersen, P., new method for characterizing dissolution properties of drug powders, 761
——and Brown, K. F., general class of multiparticulate dissolution models, 1435
——Crooks, M. J., and Brown, K. F., method of obtaining drug–macromolecule binding parameters directly from dynamic dialysis data, 1458
Venturi, F., *see* Antonini, I., 1692
Vilallonga, F. A., Garrett, E. R., and Hunt, J. S., kinetics and mechanisms of monolayer interactions IV: surface activity of alkanols and energies of their interaction with dipalmitoyllecithin and dipalmitoylphosphatidylethanolamine, 1229
Villa, R. F., *see* Benzi, G., 1278
Vincent, P. G., Bare, C. E., and Gentner, W. A., thebaine content of selections of *Papaver bracteatum* Lindl. at different ages, 1716
Visconti, J. A., *see* Kramer, W. G., 1720
Viswanathan, V., *see* Manius, G., 769
Voelimy, C., Speiser, P., and Soliva, M., microencapsulation of phenobarbital by spray polycondensation, 631
Vogin, E. E., renal function testing: differentiation between a nephrotoxic agent and diuretic drugs, 501
Vree, T. B., mass spectrometry of cannabinoids, 1444

W

Wagner, H., *see* Segelman, A. B., 1358
Waksmunski, F. S., see Wu, M. T., 1150
Walkenstein, S. S., *see* Intoccia, A. P., 85
——*see* Randolph, W. C., 1148
Walkling, W. D., *see* Bainbridge, C. A., 480
Wallace, S. M., and Riegelman, S., uptake of acetazolamide by human erythrocytes *in vitro*, 729
——Shah, V. P., and Riegelman, S., GLC analysis of acetazolamide in blood, plasma, and saliva following oral administration to normal subjects, 527
Walny, L. L., *see* Abramson, H. N., 602
Walters, M. J., and Walters, S. M., high-performance liquid chromatographic determination of diethylpropion hydrochloride in tablets: isolation and identification of two decomposition products, 198
Walters, S. M., *see* Ballbach, R. L., 1553
——*see* Walters, M. J., 198
Wan, L. S. C., viscosity and surface tension of dilute salicylic acid–cetrimide systems, 1779
Wander, J. D., *see* Melikian, A. P., 228
Wang, L. Y., *see* Nelson, K. G., 1758
Ward, C. O., *see* Dorato, M. A., 35
Warner, C. R., *see* Chin, D. A., 1143
Warner, V. D., Lynch, D. M., Meszoely, C. A., and Dykstra, W. G., Jr., synthesis and *in vivo* antimalarial evaluation of isopropyl [(4-chlorophenyl)amino]-iminomethylcarbamimidate, 418
——*see* Musto, J. D., 1201
Warren, J. W., Jr., and Price, J. C., drug migration during drying of tablet granulations II: effect of binder solution viscosity and drying temperature, 1409
——and Price, J. C., drug migration during drying of tablet granulations I: effect of particle size of major diluent, 1406
Washington, J. G., *see* Saxena, S. J., 813
Washkuhn, R. J., *see* Brooke, D., 159
Waters, P. F., *see* Karamian, N. A., 723
Watson, J. R., and Lawrence, R. C., selective GLC determination of epinephrine, isoproterenol, and phenylephrine in pharmaceutical dosage forms, 560
Watson, W. C., and Malone, M. H., evaluation of immunosuppressive potential of cryogenine using developing and established adjuvant arthritis in rats, 1304
Webel, S. K., *see* Winkler, V. W., 816
Weber, D. J., high-pressure liquid chromatographic separation of 5,6-*cis*- and *trans*-prostaglandin A_2, 744
Weddle, O. H., and Mason, W. D., rapid determination of procainamide and its *N*-acetyl derivative in human plasma by high-pressure liquid chromatography, 874
Weeks, C. E., and Abdel-Monem, M. M., inhibitors of polyamine biosynthesis V: *in vivo* effects of α-methyl-(±)-ornithine and α-methyl-(±)-ornithine *tert*-butyl ester, 1586
Weiner, N. D., *see* Malick, A. W., 792, 1465
Weinstein, J. D., *see* Gutin, P. H., 1338
Welborn, M. E., *see* Hansen, L. G., 497
Welch, R. M., *see* DeAngelis, R. L., 841
Welling, P. G., Huang, H., Koch, P. A., Craig, W. A., and Madsen, P. O., bioavailability of ampicillin and amoxicillin in fasted and nonfasted subjects, 549
——*see* Dobrinska, M. R., 688
——*see* Kjaer, T. B., 345
——*see* Tse, F. L. S., 1751
Wells, J. E., *see* Hiestand, E. N., 510
Wester, R. C., *see* Hinderling, P. H., 242, 314
White, J. L., *see* Kerkhof, N. J., 1528, 1533
White, R. L., Burrous, S. E., and Schwan, T. J., synthesis and biological activity of a novel analog of nitrofurantoin, 277
Whitehouse, L. W., Paul, C. J., Wong, L. T., and Thomas, B. H., effect of aspirin on a subtoxic dose of ^{14}C-acetaminophen in mice, 1399
Whiteley, J. M., *see* Deits, T. L., 434
Wiebe, J. A., and Moore, D. E., oxidation photosensitized by tetracyclines, 186
Wiedhopf, R. M., *see* Hoffmann, J. J., 586, 883
——*see* Jolad, S. D., 889, 892
——*see* Torrance, S. J., 1348
Wilken, L. O., Jr., *see* Nasir, S. S., 370
Wilkie, S. V., *see* Owen, B. J., 877
Willekens, G. J., rapid and sensitive direct TLC fluorometric method for evaluation of impurities in oxytetracycline, 1419
Willette, R. E., *see* Abbas, R., 1583
Williams, B. B., Jr., *see* McNeil, H. R., 1642
Williams, F. D., *see* Ramachander, G., 1047
Williams, R. L., *see* Meffin, P. J., 135
Wilson, M. C., *see* Borne, R. F., 119
Wilson, W. L., Avdovich, H. W., Hughes, D. W., and Buchanan, G. W., application of proton and ^{13}C-NMR spectroscopy to estimation of diastereoisomer ratio in phenethicillin, 1079
Wingard, L. B., Jr., and Levy, G., comparative pharmacokinetics of coumarin anticoagulants XXXVI: predicted steady-state patterns of prothrombin

complex activity produced by equieffective doses of (*R*)-(+)- and (*S*)-(−)-warfarin in humans, 1790
Winkler, V. W., Borodkin, S., Webel, S. K., and Mannebach, J. T., *in vitro* and *in vivo* considerations of a novel matrix-controlled bovine progesterone-releasing intravaginal device, 816
Wirth, P. W., *see* Borne, R. F., 594
Wittendorf, R. W., *see* Intoccia, A. P., 85
Wittmer, D. P., *see* Sood, S. P., 40
Won, C. M., Zalipsky, J. J., Patel, D. M., and Reavey-Cantwell, N. H., kinetics of hydrolysis of fenclorac, 73
Wong, C. K., Tsau, D. Y. J., Cohen, D. M., and Munnelly, K. P., high-pressure liquid chromatographic analysis of polythiazide in pharmaceutical tablet formulations, 736
Wong, L. T., *see* Whitehouse, L. W., 1399
Wong, P. P., *see* Kent, J. S., 1665
Wood, H. B., Jr., *see* Cheng, C. C., 1781
Wood, P. R., *see* Woolhouse, N. M., 429
Woodford, R., and Barry, B. W., bioavailability and activity of topical corticosteroids from a novel drug delivery system, the aerosol quick-break foam, 99
Woolhouse, N. M., and Wood, P. R., determination of oxamniquine in serum, 429
Wooten, R. S., *see* Oteiza, R. M., 1385
Wormser, H. C., and Abramson, H. N., new compounds: total synthesis of *dl*-3a,4,6a-*cis*-4-(4-carboxybutyl) hexahydropyrrolo [3,4-*d*] imidazol - 2-one hydrochloride (*dl*-azabiotin hydrochloride), 1208
Wu, B.-S., *see* Lee, K.-H., 1194
Wu, M. T., Waksmunski, F. S., Hoff, D. R., Fisher, M. H., Egerton, J. R., and Patchett, A. A., anthelmintic 2-arylhydrazino- and 2-arylazo-2-thiazolines, 1150

X

Y

Yacobi, A., and Levy, G., comparative pharmacokinetics of coumarin anticoagulants XXI: effect of plasma protein binding on distribution kinetics of warfarin in rats, 567
——and Levy, G., comparative pharmacokinetics of coumarin anticoagulants XXIX: elimination kinetics and anticoagulant activity of (*S*)-(−)-warfarin in rats before and after chronic administration, 1275
——and Levy, G., comparative pharmacokinetics of coumarin anticoagulants XXVIII: predictive identification of rats with relatively steep serum warfarin concentration–anticoagulant response characteristics, 145
——and Levy, G., intraindividual relationships between serum protein binding of drugs in normal human subjects, patients with impaired renal function, and rats, 1285
——Lai, C.-M., and Levy, G., comparative pharmacokinetics of coumarin anticoagulants XXXI: effect of plasma protein binding of distribution kinetics of dicumarol in rats, 1741
——Oie, S., and Levy, G., relationship between protein binding of bilirubin, salicylic acid, and sulfisoxazole in serum of unmedicated and phenobarbital-treated rats, 1025
——Slattery, J. T., and Levy, G., comparative pharmacokinetics of coumarin anticoagulants XXIV: effect of treatment with phenobarbital on serum protein binding of warfarin and dicumarol in rats, 941
——*see* Slattery, J. T., 943
Yakatan, G. J., *see* Han, W. W., 573, 795
Yalkowsky, S. H., *see* Flanagan, D. R., 337
Yamahira, Y., *see* Maeda, T., 69
Yamana, T., Tsuji, A., Kiya, E., and Miyamoto, E., physicochemical properties of β-lactam antibacterials: deuterium solvent isotope effect on penicillin G degradation rate, 861
——Tsuji, A., Miyamoto, E., and Kubo, O., novel method for determination of partition coefficients of penicillins and cephalosporins by high-pressure liquid chromatography, 747
——*see* Tsuji, A., 1004, 1675
Yan, S.-J., *see* Cheng, C. C., 1781
Yanchick, V. A., *see* Allen, L. V., Jr., 494
Yankell, S. L., *see* Loux, J. J., 674
Yeh, K. C., kinetic parameter estimation by numerical algorithms and multiple linear regression: theoretical, 1688
Yeh, S. Y., Gorodetzky, C. W., and Krebs, H. A., isolation and identification of morphine 3- and 6-glucuronides, morphine 3,6-diglucuronide, morphine 3-ethereal sulfate, normorphine, and normorphine 6-glucuronide as morphine metabolites in humans, 1288
——McQuinn, R. L., and Gorodetzky, C. W., identification of diacetylmorphine metabolites in humans, 201
Yip, K. F., *see* Gutin, P. H., 1338
Yost, M. T., *see* Kent, J. S., 1051
Young, R. L., *see* Dixon, W. R., 235
Youssef, A. F., Ibrahim, S. A., and Elshabouri, S. R., dihydralazine sulfate analysis using 2-methyl-3-nitropyridine-6-carboxaldehyde, 116
——*see* Farag, H. H., 423
Yu, A. B. C., Nightingale, C. H., and Flanagan, D. R., rapid sensitive fluorometric analysis of cephalosporin antibiotics, 213
Yuen, P. H., and Sokoloski, T. D., kinetics of concomitant degradation of tetracycline to epitetracycline, anhydrotetracycline, and epianhydrotetracycline in acid phosphate solution, 1648
——*see* Sokoloski, T. D., 1159
Yung, D. K., Forrest, T. P., Manzer, A. R., and Gilroy, M. L., reactions of benzenesulfonohydrazides and benzenesulfonamides with hydrogen chloride or hydrogen bromide in acetic acid, 1009

Z

Zalipsky, J. J., *see* Won, C. M., 73
Zappala, A. F., and Post, A., rapid near IR spectrophotometric determination of meprobamate in pharmaceutical preparations, 292
Zarakov, M. S., *see* Orth, R. E., 279, 437
Zatz, J. L., *see* Cleary, G. W., 975
Zee-Cheng, R. K. Y., *see* Cheng, C. C., 1781
——*see* Lee, J. W., 986
Zelenski, S. G., alkaloids of *Nelumbo lutea* (Willd.) pers. (Nymphaeaceae), 1627
Zellers, J. E., and Gautieri, R. F., evaluation of teratogenic potential of codeine sulfate in CF-1 mice, 1727
Ziegler, H. W., *see* Beasley, T. H., Sr., 1749
Zimmerman, J. J., scattered isergonic profiles, 30
Zoglio, M. A., *see* Maulding, H. V., 1175
——*see* Mehta, A., 1462
Zompa, H. A., *see* Lausier, J. M., 1636
Zuleski, F. R., *see* Loh, A., 1056

A

Absorbance calculations—IR spectrophotometric analysis of carbachol, error reported, 1211
Absorption—acetaminophen, effect of aspirin, radiochemical analysis, mice, 1399
food—effect of perfluorooctyl bromide coated on GI tract, rats, 907
GI—griseofulvin, effect of metoclopramide and propantheline preadministration, rats, 1540
GI—griseofulvin, indomethacin, and nalidixic acid, effect of stomach emptying rate, rabbits, 69
GI—niacin, stomach and small intestine compared, humans, 871
GI—procainamide, capsules and sustained-release tablets compared, humans, 981
GI—sulfanilamide, bretylium tosylate, sulfisoxazole acetyl, and riboflavin, effect of γ-radiation on rate, rats, 680
GI—various drugs, effect of cobalt-60 γ-radiation, rats, 361, 366
—isoniazid, effect of various drugs, radiochemical analysis, rats, 1322
—^{14}C-meglumine, rats and dogs, 96
percutaneous—quantitative skin model assuming inactive stratum corneum and viable, enzyme-containing epidermis, 755
—phenolsulfonphthalein, effect of preadministration of sodium deoxycholate, humans, 727
rate constants—data fitted to one- and two-compartment models, relative error evaluated, oral administration of sulfisoxazole, rabbits, 178
rectal—nitrofurantoin, effect of various suppository bases, humans, 955
relative rate—poorly soluble drugs, various formulations evaluated using LD_{50} testing, mice, 1567
—sulfamethazine, various dosage forms compared, cattle, 619
—terbutaline, effect of salicylamide, rats, 1488
vaginal—1-alkanoic acids, rabbits, 781
vaginal—various straight-chain aliphatic alcohols, perfusion system designed, rhesus monkeys, 216
Absorptivity, GI—assessed for analogs of potential drug substances using everted rat intestinal sacs, 1249
Acenocoumarol—double radioisotope derivative analysis, plasma and urine, 997
—GLC analysis, human and dog plasma, 799
Acetaminophen—absorption, excretion, and metabolism, effect of aspirin, radiochemical analysis, mice, 1399
—effects on fetal and placental growth, rats, 111
—GLC analysis in capsules with dichloralantipyrine and isometheptene mucate, 604
—GLC analysis in presence of phenacetin, plasma, 1628
—GLC–mass spectrometric analysis, human plasma, 340
—in vitro adsorption onto activated charcoal, effect of pH, 480
Acetazolamide—GLC analysis, human blood, plasma, and saliva, 527
—in vitro binding to human erythrocytes, effect of plasma drug concentration on steady-state level within erythrocytes, 729
—sustained-release product and 15- and 20-mg/hr GI drug delivery systems compared in humans, dosage form index suggested as evaluating parameter, 1388
Acetohexamide—GLC analysis, human plasma and urine, 635
7-Acetylacroninium perchlorate—hydrolysis mechanism, 1501
Acetylacroninium salts—synthesized as prodrugs for intravenous use, solubilities and kinetics of hydrolysis studied, 628
Acetylaleuritolic acid—isolated from ethanol extract of roots of *Jatropha macrorhiza*, antitumor activity evaluated, 1348
Acid neutralization—aluminum hydroxide gel, pH-stat titration, role of carbonate, 1533
reactivity—magnesium trisilicate, effect of adsorption of chloroquine, 289
Acids, 1-alkanoic—vaginal absorption, rabbits, 781
Aconitine—colorimetric analysis, pharmaceutical formulations in presence of aconine and benzoylaconine, 1331
Acronine prodrug—7-acetylacroninium perchlorate, hydrolysis mechanism, 1501
—quaternary salts of acetyl derivative synthesized as prodrugs for intravenous use, solubilities and kinetics of hydrolysis studied, 628
Adenium obesum—ethanol extract of aboveground parts, various cardenolides and flavonol isolated and identified, evaluated for cytotoxic activity, 1336
Adenosine diphosphate and triphosphate—effect on periodic acid oxidation of various phenothiazines, 1575
monophosphate, cyclic—levels in fetal rat heart in culture, related to rate changes caused by isoproterenol, quinidine, and dysrhythmogenic agent, 1450
triphosphatase, sodium and potassium activated—effect of 3β-thioacetyl-14β-hydroxy-5β-card-20(22)-enolide, 602
Administration routes—uterine intraluminal instillation compared to gastric intubation and subcutaneous injection, progesterone tissue distribution, 1744
Adrenergics—epinephrine and levarterenol, pressor responses, effect of pentazocine, rats, 1652
—epinephrine, high-pressure liquid chromatographic analysis, liquid pharmaceutical preparations, 425
—epinephrine, isoproterenol, and phenylephrine, GLC analyses, pharmaceutical dosage forms, 560
—isometheptene mucate, GLC analysis in capsules with acetaminophen and dichloralantipyrine, 604
—levarterenol and phenylephrine, effect on iris dilator muscle response, roles of neuronal and extraneuronal uptake mechanisms, rabbits, 93
—phenylephrine, effect on methacholine-induced rise in intraocular pressure, dogs, 1013
Adsorption—doxorubicin hydrochloride on solid tribasic calcium phosphate in vitro, 1346
drug—chloroquine by magnesium trisilicate, effect on acid reactivity, 289
in vitro—acetaminophen onto activated charcoal, effect of pH, 480
—morphine onto glassware during fluorometric analysis, effect of siliconization, 1044
—various drugs to activated charcoal in vitro, effect of pH, 1640
Aerosol foam, quick break—betamethasone benzoate bioavailability and activity compared to semisolid dosage form, effect of moisturizer, 99
propellants, fluorocarbon—dichlorodifluoromethane, single and multiple dosing, pharmacokinetic model proposed, dogs, 49
Aerosols, powder inhalation—micronized powders of substituted 2-xanthonecarboxylic acid and sodium salt, effect of lactose concentration, humidity, and temperature, 1254
Aging—aluminum hydroxide gel, monitored with pH-stat titration, compared to other tests, 1528
—direct compression dibasic calcium phosphate tablets, effect of temperature and humidity, 1636
Agitation—effect on particle-size distribution of various large-volume parenterals, 935
Alcohols, aliphatic—solvents for series of alkylparabens, effect of temperature, 42
—ethanol, blood levels, withdrawal reaction, and toxicity, effect of lysine and diethanolamine–rutin, mice, 35
straight-chain aliphatic, various—vaginal absorption, perfusion system, rhesus monkeys, 216
various aliphatic—free energies of adsorption and energies of interaction with phospholipid monolayers at air–water interface, 1229
Aldose reductase, rat lens—effect of three flavone C-glycosides isolated from *Cannabis sativa*, 1358
Aldosterone antagonists—canrenoate potassium, tissue distribution and metabolism, radiochemical study, rabbits, 275
—canrenone and canrenoic acid, automated simultaneous fluorometric analyses, serum, 1131
—canrenone, human milk to serum concentration ratio, 1203
Aliphatic carboxylic acids—colorimetric analysis in solutions, 1403
Alkali metal and alkaline earth cations—effect on binding of histamine to peptide H, association constants determined, 542
Alkaloids—aconitine, colorimetric analysis, pharmaceutical formulations in presence of aconine and benzoylaconine, 1331
antileukemic—coralyne, nitidine, and related compounds, effect on catechol *O*-methyltransferase and tRNA methyltransferase activity, rat liver homogenate, 986
cinchona—quinine and quinidine, colorimetric analyses, pharmaceutical formulations and biological fluids, 1317
ergot—10α-methoxy-$\Delta^{8,9}$-lysergaldehyde, synthesized by oxidation of elymoclavine with manganese dioxide in methanol, 1340
—funiferine *N*-oxide, isolated from extract of roots of *Tiliacora funifera*, structure elucidated, 1242
harmala—cardiovascular activity in dogs, 1244
—identified in *Glaucium flavum* Grantz, populations Isfahan and Kazerun, 873
indole—isolated from *Tabernaemontana holstii* roots, cytotoxic activity evaluated, 1135
—isolated and identified, chloroform extract of seed capsules of *Papaver orientale* L., five chemotypes classified, 1050
—isolated and identified in *Glaucium oxylobum* aerial parts and roots, 593
—isolated from whole plant extract of *Pilosocereus maxonii*, 1485
opium—codeine, morphine, and methadone, binding to human serum proteins, 802
—salsolinol, electron-capture GLC analysis in mouse brain tissue, 893
—thebaine, GLC analysis in root and aboveground portions of various strains of *Papaver bracteatum*, 1716
various—identified in alcoholic extract of petioles of *Nelumbo lutea*, 1627
Alkyltrimethylammonium bromides, various—synthesized, bactericidal activity determined in simple partition systems, compared to cream systems, 696
Aluminum hydroxide gel—acid neutralization, pH-stat titration, role of carbonate, 1533
gel—pH-stat titration evaluated, aging monitored, compared to other tests, 1528
—zero point of charge related to solubility product, 1548
Amines and ammonium salts, various—effect on dissolution rate of cholesterol monohydrate pellets in synthetic bile, 1105
α-Amino acids—lysine, effect on blood levels, withdrawal reaction, and toxicity of ethanol, mice, 35
Amino acids—residues of human IgG1 involved in complement fixing defined, 427
***N*-(Aminoalkyl)acetamides**—dansyl derivatives, TLC and high-pressure liquid chromatographic analysis, human urine, 1195
—determined in human urine, dansyl derivatives synthesized, 1089
Aminobenzoic acid and derivatives—synthesized, evaluated for antistaphylococcal activity in vivo, mice, 844
2-Amino-5*H*-1,3,4-benzotriazepin-5-ones—various derivatives synthesized, 605

4-Aminocyclohexanecarboxylic acid and derivatives—synthesized, evaluated for antistaphylococcal activity *in vivo*, mice, 844
2-Amino-1-*p*-nitrophenylpropane - 1,3-diol—evaluated for smooth muscle relaxant and vasomotor activities, various guinea pig, rat, rabbit, and toad *muscles*, 1239
6-Aminopenicillanic acid—GLC analysis, prepared samples, 1769
—*silyl derivative, preparation and NMR analysis*, 1767
Aminophylline—UV spectrophotometric analysis, commercial capsule in combination with amobarbital and ephedrine hydrochloride, 811
Amitriptyline—GLC–*mass spectrometric analysis*, human plasma, 77
hydrochloride—degradation in aqueous solution, effect of metal-ion contaminants, edetate disodium, and antioxidants, 1087
hydrochloride—high-performance liquid chromatographic analysis, pharmaceutical formulations containing perphenazine, 1117
Ammonium halides—effect on cloud point of octoxynol, various salt concentrations, 165
Amobarbital—UV spectrophotometric analysis, commercial capsule in combination with aminophylline and ephedrine hydrochloride, 811
Amoxicillin—bioavailability, oral administration, effect of fasting and fluid volume, humans, 549
Amphetamine analogs—various sulfur-containing derivatives synthesized, evaluated for central stimulant and anorexic effects, rats, 923
and analogs—with *rigid conformation*, biological disposition, spectrofluorometric analysis in rat tissues, effect of pretreatment with iprindole, 271
and related compounds—reacted with chiral acylating reagent, GLC separation of diastereomeric amide derivatives, 169
—illicit tablets, impurity identified as α-benzylphenethylamine, 443
sulfate—bioavailability, effect of montmorillonite, urinary recovery studies, applied to sustained-release dosage forms, 63
Ampicillin—bioavailability, oral administration, effect of fasting and fluid volume, humans, 549
—partition coefficients in aqueous buffer–octanol systems, effect of pH, 294
—pharmacokinetics, plasma, prostatic fluid, and spinal fluid levels, dogs, 345
—TLC–bioautographic analysis as contaminant in various tetracyclines and peniciliamine, 1646
Analgesic activity—evaluated in fenbufen and various analogs, 466
potential—piperidine derivatives synthesized and evaluated, 1583
—*N*-substituted 5,6-benzo-2-azabicyclo[2.2.2]-octanes evaluated, mice, 594
—various morphine derivatives, monkeys, 285
Analgesics—acetaminophen and dichloralantipyrine, GLC analysis in capsules with isometheptene mucate, 604
—acetaminophen, *in vitro* adsorption onto activated charcoal, effect of pH, 480
—antipyrine, pharmacokinetics, normal subjects and hepatitis patients, plasma and saliva concentration data, 135
—aspirin and propoxyphene, adsorption to activated charcoal *in vitro*, effect of pH, 1640
—aspirin, colorimetric analysis using Schoenemann reaction, pharmaceutical combinations, 139
—2-(3-benzoylphenyl)propionic acid, TLC analysis, plasma, rats, 281
—carbamazepine, time-dependent pharmacokinetics, 1-week infusion, monkeys, 647
—effect of aspirin on absorption, excretion, and metabolism of acetaminophen, radiochemical analysis, mice, 1399
—glafenine, fluorescence characteristics in various solvents, effect of pH, 1771
—indoprofen, GLC analysis in human plasma, 132
—methotrimeprazine and four metabolites, GLC–mass spectral analysis, human plasma and urine, 190
narcotic—codeine, morphine, and methadone, binding to human serum proteins, 802
narcotic—meperidine, GLC analysis, human plasma, 599
narcotic—morphine and codeine, spin labeled in 6-position, effect on binding to brain receptors and analgesic activity, 1054
—pentazocine, effect on pressor responses of epinephrine and levarterenol, rats, 1652
—phenacetin and acetaminophen, GLC–mass spectrometric analyses, human plasma, 340
—phenacetin and acetaminophen, simultaneous GLC analyses in plasma, 1628
—propoxyphene hydrochloride, different formulations, bioavailability compared, 1713
—salicylamide, effect on absorption and metabolism of terbutaline, rats, 1488
—sodium acetylsalicylate buffered formulations, various dosage forms, effect on GI microbleeding, dogs, 124
topical—aconitine, colorimetric analysis, pharmaceutical formulations in presence of aconine and benzoylaconine, 1331
Anaphalis morrisonicola—whole plant chloroform extract, antitumor activity evaluated, helenalin isolated, 1194
Anesthetics, local—lidocaine and various metabolites, chemical-ionization mass spectrometric and stable isotope labeling analyses, human plasma and urine, 1180
local—lidocaine, GLC analysis in human plasma, pharmacokinetics, 1383
topical—benzocaine, colorimetric analysis, bulk drug and commercial dosage forms, 1037
Anhydrotetracycline—epimerization, kinetics and mechanism in acid solution, high-performance liquid chromatographic and circular dichroism study, 1159
Anorexic activity—various sulfur-containing amphetamine derivatives evaluated, 923
agents—diethylpropion hydrochloride, high-performance liquid chromatographic analysis in tablets, identification of two decomposition products, 198
agents, potential—3-(*p*-chlorophenyl)-2-ethyl-2,3,5,6-tetrahydroimidazo[2,1-*b*]thiazol -3- ol, kinetics of degradation in aqueous media, effect of temperature, pH, and ionic strength, 1175
Antacids—aluminum hydroxide gel, acid neutralization, pH-stat titration, role of carbonate, 1533
—aluminum hydroxide gel, pH-stat titration evaluated, aging monitored, compared to other tests, 1528
—magnesium trisilicate, adsorption of chloroquine, effect on acid reactivity, 289
Anthelmintic activity—evaluated in series of substituted dihydroquinoxalino[2,3-*b*]quinoxalines, 1349
—evaluated in various substituted thiazolines in sheep, 1150
Anthracenecarboxamides, *N*-substituted—binding to DNA, electronic absorption and fluorescence spectral study, 1473
Anthranilic acid—GLC analysis in plasma, 1645
Antiacetylcholine activity—evaluated in series of substituted indolizines, 1692
Antiadrenergics—bunolol, metabolism in dogs, metabolites and conjugates identified in urine, 1570
—nadolol, fluorometric analysis in human serum and urine, 1168
Antiamebic agents—iodochlorhydroxyquin, TLC analysis, biological fluids, 1334
Antiarrhythmics—procainamide, bioavailability of intravenous infusion, capsules, and sustained-release tablets, absorption of oral forms compared, humans, 981
—quinidine, spectrofluorometric analysis, human plasma and urine, effect of alkaline washings, 591
—tocainide, high-pressure liquid chromatographic analysis, plasma or blood, 583
Antibacterial activity—evaluated in various rhodanine derivatives, 1607
—substituted 2,4-imidazolidinedione evaluated, 277
—substituted isoxazolium salts, correlated with polar contribution of 5-aryl substituents, polarographic reduction, 597
—*various pyrroles, furans, and thiophenes evaluated*, 1052
—various substituted imidazo[4,5-*f*]quinolines screened, 1204
—various tetracyclines, related to partition coefficients, resistant and sensitive microorganisms, structure–activity relationships, 88
Antibacterial intermediates—6-aminopenicillanic and *7-amino-3-methyl-Δ^3-cephem-4-carboxylic acid*, GLC analyses, prepared samples, 1769
Antibacterial intermediates—6-aminopenicillanic and *substituted cephemcarboxylic acids, silyl derivatives* prepared, NMR analyses, 1767
Antibacterials—ampicillin and amoxicillin, bioavailability, oral administration, effect of fasting and fluid volume, humans, 549
—*ampicillin and hetacillin methoxymethyl ester*, pharmacokinetics, plasma, prostatic fluid, and spinal fluid levels, dogs, 345
—ampicillin, partition coefficients in aqueous buffer–octanol systems, effect of pH, 294
—cefamandole nafate, polarographic analysis, prepared samples, 379
—cefazolin, protein binding, effect of hemodialysis, 1508
—cefazolin, rate and extent of binding to serum protein, dogs, 1663
—cephapirin, spectrophotometric analysis, bulk drug and pharmaceutical formulations, 1108
—clindamycin palmitate hydrochloride, GLC analysis after acetylation catalyzed by 4-(dimethylamino)pyridine, 273
coccidiostatic—lasalocid and bromo analog, GLC analysis, various preparations and dosage forms, 769
—dapsone, contaminants identified in commercial samples, 1723
—ethambutol, spectrophotometric analysis using charge transfer complex formation, prepared samples and commercial tablets, 766
—hetacillin, epimerization and hydrolysis in aqueous solution, effect of pH and temperature, 1004
—oxytetracycline and impurities, TLC fluorometric analyses in prepared solutions, 1419
—oxytetracycline, factors affecting serum levels, calves, 1198
—oxytetracycline, tetracycline, and chlortetracycline, high-pressure liquid chromatographic analyses, urine, 1319
—penicillin G and related compounds, complexation with nickel(II) ions, reaction kinetics, 533
—penicillin G degradation in aqueous solution, deuterium solvent isotope effect, pH 4–10, 861
—phenethicillin, proton and ^{13}C-NMR spectral analysis of diastereoisomer ratio, bulk drug and commercial formulations, 1079
—sulfacetamide, sulfathiazole, and sulfabenzamide, high-pressure liquid chromatographic analyses of mixtures, 1784
—sulfadiazine, bioavailability of tablets prepared by direct compression and fluidized-bed techniques compared to commercial product, rabbits, 1438
—sulfadimethoxine, interaction with tolbutamide, kinetic analysis, sheep, 1063
—sulfamethazine, absorption, metabolism, and excretion, various dosage forms compared, cattle, 619
—sulfathiazole, disposition in tissue, urine, and plasma of sheep following intravenous administration, pharmacokinetic model, 1297
—sulfathiazole, spectrophotometric analysis in mixtures with sulfadiazine and sulfamerazine, 1413
—sulfisoxazole, oral administration, interpretation of plasma concentration–time curves, rabbits, 178
—tetracycline, bioavailability, different commercial capsules, effect of sleep, humans, 1000
—tetracycline degradation, epimerization of anhydrotetracycline in acid solution, 1159

—tetracycline, kinetics of degradation at pH 1.5, effect of temperature, 1648
—TLC–bioautographic analysis of penicillin G and ampicillin as contaminants in various tetracyclines and penicillamine, 1646
—trimethoprim and sulfamethoxazole, NMR spectroscopic analysis, synthetic mixtures and commercial formulations, 121
urinary—methenamine, GLC analysis, commercial tablets, 589
urinary—nitrofurantoin, aqueous solubility, effect of pyridoxine hydrochloride, 1357
urinary—nitrofurantoin, rectal absorption, effect of various suppository bases, humans, 955
—various cephalosporins, fluorometric analysis, commercial samples in aqueous solutions, 213
—various penicillins and cephalosporins, GLC analysis of *N,N*-dimethylaniline as contaminant in commercial samples, 1634
—various penicillins and cephalosporins, high-pressure liquid chromatographic determination of lipophilic indexes, correlated to partition coefficients, 747
—various sulfonamides, binding of povidone, fluorescent probe study, 1157
—various tetracyclines, ac polarographic analysis, electrode processes identified, 1564
—various tetracyclines, photosensitized oxidation, reaction kinetics followed using polarographic oxygen electrode, effect of pH and copper(II) ions, 186
various—thermal decomposition of amorphous samples, effect of water content and temperature, 1312
Antibiotics—litomycin, effect on viral DNA polymerase activity *in vitro*, reaction kinetics and mechanism, 130
—microbiological turbidimetry assays, procedures devised to linearize curved calibration lines, 1520
various—apparent partition coefficients in octanol–water and 2-methylpropanol–water at various pH values, 1675
Anticancer activity—various cyclic *N*-hydroxyureas evaluated, 1556
Anticholinergic activity—evaluated in series of oxime *O*-(α- and β-methylcholinyl) ethers, 1120
—evaluated on rat ileum for isomers of various oxime *O*-dimethylaminoethyl ethers, 1602
Anticholinergics—atropine sulfate, GLC analysis in solutions and tablets containing diphenoxylate hydrochloride, 1553
—homatropine methylbromide, spectrophotometric analysis in pharmaceutical formulations, 123
—propantheline, effect of preadministration on GI absorption of griseofulvin, rats, 1540
—propantheline, hexocyclium, and isopropamide, antisecretory and antimotility effects compared, humans, 1433
—propantheline, quantitative analysis and *in vitro* dissolution, regular and sustained-release tablets compared, 1777
Anticoagulant action—warfarin, effect of ibuprofen, rats, 943
Anticoagulants—acenocoumarol, double radioisotope derivative analysis in plasma and urine, 997
—acenocoumarol, GLC analysis, human and dog plasma, 799
—dicumarol, chelate with magnesium prepared, structure elucidated, 1124
—dicumarol, distribution kinetics, effect of plasma protein binding, rats, 1741
—dicumarol, effect of serum protein binding on elimination kinetics, rats, 1739
—serum warfarin concentration related to response characteristics, rats, 145
—(*R*)-(+)- and (*S*)-(−)-warfarin, activity at steady state compared, 1790
—warfarin and dicumarol, serum protein binding, effect of phenobarbital, rats, 941
—warfarin, distribution kinetics, effect of plasma protein binding, rats, 567
—warfarin, elimination kinetics and activity, effect of chronic administration, rats, 1275
—warfarin, high-pressure liquid chromatographic analysis, human plasma, 142
—warfarin, serum protein binding, effect of ibuprofen, humans, 1060
—warfarin, tissue binding, rats with intrinsic high and low plasma binding ability compared, 1211
Anticomplement activity—two factors isolated by ion-exchange chromatography from cobra venom, effect of neuraminidase digestion, 947
—sulindac and metabolites, combined isotope dilution–radioimmunoassay, human plasma and urine, 414
—tiaprofenic acid, pharmacokinetics in humans, rats, dogs, mice, and rabbits, 1030
drugs—complement inhibitors, review, 1367
Anticonvulsant activity—1-diphenylmethyl-4-[(6-methyl-2-pyridyl)methyleneamino]piperazine, effect of various solvents and dosage forms, oral administration, mice, 82
—evaluated in various thiosemicarbazides, mercaptotriazoles, and triazolethioglycolic acids, rats, 971
Anticonvulsants—clonazepam, radioimmunoassay, human plasma, 235
—ethosuximide, circadian rhythm in steady-state plasma levels, monkeys, 650
—methsuximide and metabolite, pharmacokinetics in dogs after single intravenous doses, GLC analysis in plasma, 688
—nitrazepam in solid state in microcrystalline cellulose, decomposition, effect of temperature and humidity, 676
—nitrazepam, kinetics and mechanisms of hydrolysis, 795
—phenytoin, GLC analysis in plasma, 1510
—phenytoin, GLC and GLC–mass spectrometric analyses and identification of catechol and methylcatechol metabolites in human, monkey, and dog urine, 1596
—phenytoin, solubility and ionization characteristics in various buffers and hydroalcoholic solutions, 994
—phenytoin, tissue binding, normal, nephrotic, and uremic humans compared, 1211
—primidone, solid dispersion systems with citric acid, effect of concentration on glass transition temperature and dissolution, 825
—valproic acid, steady-state plasma levels, time-dependent kinetics, monkeys, 1154
Antidepressants—amitriptyline, adsorption to activated charcoal *in vitro*, effect of pH, 1640
—amitriptyline and nortriptyline, GLC–mass spectrometric analyses, human plasma, 77
—amitriptyline hydrochloride, high-performance liquid chromatographic analysis, pharmaceutical formulations containing perphenazine, 1117
—imipramine and desipramine tablets, TLC, GLC, and mass spectral analysis of impurities, 1015
—imipramine, effect of pregnenolone-16α-carbonitrile on pharmacological activity, distribution, and *in vivo* metabolism, rats, 1492
—lithium carbonate, bioavailability, calculations based on perturbation of renal clearance, commercial dosage form, 609
—nortriptyline, radiochemical GLC analysis in human plasma, 1056
Antidiabetic agents—acetohexamide, GLC analysis, human plasma and urine, 635
—tolbutamide, interaction with sulfadimethoxine, kinetic analysis, sheep, 1063
Antiemetics—meclizine hydrochloride, spectrophotometric analysis using ion-pair extraction with methyl orange, pharmaceutical dosage forms and biological fluids, 710
—metoclopramide and various metabolites, high-pressure liquid chromatographic analyses in rat, dog, and human urine, 1615
—metoclopramide, effect of preadministration on GI absorption of griseofulvin, rats, 1540
Antifungal activity—screened in various bis(propynyloxy)benzenes and monoamino derivatives, 431
agents—alkylparabens, solubility and thermodynamics in aliphatic alcohols, 42
agents—benzoic acid, reversed-phase high-pressure liquid chromatographic analysis, pharmaceutical formulations, 110
agents—griseofulvin dispersed in polyethylene glycol 6000, X-ray diffraction study, aqueous solubility, 989
agents—griseofulvin, GI absorption, effect of metoclopramide and propantheline preadministration, rats, 1540
Antihistamines—triprolidine, TLC analysis, human and rat plasma, pharmacokinetic profile, 841
Antihistaminic activity—evaluated in series of substituted indolizines, 1692
Anti-5-hydroxytryptamine *activity—evaluated in* series of substituted indolizines, 1692
Antihyperlipidemic activity—substituted tetrahydrocarbazole evaluated, rats, 348
agents—clofibric acid, bioavailability from various formulations compared, humans, 1638
agents, potential—various substituted tetrahydrocarbazoles, spectrofluorometric analysis, human blood and urine, 353
Antihypertensives—dihydralazine sulfate, colorimetric analysis in prepared samples, 116
—hydroflumethiazide prepared samples and tablets, high-pressure liquid chromatographic analysis of its precursor 2,4-disulfamyl-5-trifluoromethylaniline, 877
—methyldopa, fluorometric analysis in biological fluids, 1632
—minoxidil, radioimmunoassay in human serum, 1266
—polythiazide, high-pressure liquid chromatographic analysis in pharmaceutical formulations, 736
—sodium nitroprusside, effect on body temperature, various routes of administration, various ambient temperatures, mice, 1658
Anti-infectives, topical—silver sulfadiazine, solubility as a function of pH, potentiometric study, 519
Anti-inflammatory activity—cryogenine evaluated in developing and established adjuvant arthritis, rats, 1304
—evaluated in fenbufen and various analogs, 466
Anti-inflammatory agents—fenclorac and metabolite, spectrophotometric analysis in serum, 832
—fenclorac, kinetics of hydrolysis, stability in aqueous solution, various pH's and temperatures, liquid chromatographic analysis, 73
—ibuprofen, effect on pharmacokinetics and anticoagulant action of warfarin, rats, 943
—ibuprofen, effect on protein binding of warfarin, human serum, 1060
—ibuprofen, GLC analysis in human serum, 749
—indomethacin and congeners, effect on binding of L-tryptophan by defatted human serum albumin, 950
—indomethacin, degradation in alkaline aqueous solutions, various temperatures, kinetics, 27
—indomethacin, degradation kinetics in presence of ionic and nonionic surfactants in alkaline solutions, 1259
—indomethacin, effect on lysosome and protein stability *in vitro*, compared to other drugs, 1651
—indomethacin, radioimmunoassay, human plasma and urine, 486
—naproxen, fluorometric analysis, human serum, 433
—4-nitro-2-phenoxymethanesulfonanilide, high-speed liquid chromatographic analysis in plasma, 1700
Antileukemic agents—coralyne and related compounds, mutagenicity evaluated, compared to 7,12-dimethylbenz[*a*]anthracene, 1781
Antimalarial activity—screened in substituted carbamimidate ester, turkeys, 418
—sulfonates of substituted phenols and quinolinols evaluated, 440
Antimalarials—chloroquine, adsorption by magnesium trisilicate, effect on acid reactivity, 289
—mefloquine, high-pressure liquid chromatographic analysis in whole blood, plasma, and urine, 834
—quinine, colorimetric analysis, pharmaceutical formulations and biological fluids, 1317
Antimicrobial activity—compound 48/80 evaluated

in protozoa, bacteria, fungi, and viruses, 702
activity—screened in thiosulfonates formed by reaction of benzenesulfonohydrazides and benzenesulfonamides with hydrogen chloride in acetic acid, 1009
agents, potential—cudranone, isolated and identified from stems and roots of *Cudrania chochinchinensis*, 908
Antimotility effects—propantheline, hexocyclium, and isopropamide compared, humans, 1433
Antineoplastic activity, potential—substituted glutarimides synthesized and screened, mice, 232
—preliminary evaluation of sphyrnastatins isolated from hammerhead shark, 757
Antineoplastic agents—acronine, quaternary salts of acetyl derivative synthesized as prodrugs for intravenous use, solubilities and kinetics of hydrolysis studied, 628
—carmustine, degradation rate in aqueous media, effect of pH and temperature, 1073
—carmustine, degradation rate in mixed solvents and nonaqueous media, effect of temperature, 1076
—doxorubicin and dacarbazine, alone and with high blood glucose levels, mice, 279
—doxorubicin and dacarbazine, combined with hyperglycemia and hyperthermia, effect on survival of tumor-transplanted mice, 437
—doxorubicin, electronic absorption and fluorescence spectrophotometric determination of dissociation constants and protolytic equilibria, 958
—floxuridine, entrapment within sphingomyelin and lecithin liposomes, compared to fluorouracil, 984
—fluorouracil, ion-pair extraction from aqueous solutions with quaternary alkylammonium ions into organic solvents, 1190
—fluorouracil, microbial kinetic analysis in biological fluids, pharmacokinetics in humans, 1422
—ftorafur, GLC analysis in biological fluids, 1497
—mercaptopurine, pharmacokinetics in rats, 1454
—mercaptopurine, polymorphic form, dissolution rate, differential thermographic and X-ray diffraction analyses, 608
—methotrexate, high-pressure liquid chromatographic analysis in commercial preparations, 1219
potential—organoboron carboxamido derivative of tetracycline synthesized, UV, IR, and NMR spectral data and hydrolytic stability evaluated, 1505
Antiobesity agents, potential—perfluorooctyl bromide, coated on GI tract, effect on food absorption and weight gain, rats, 907
Antioxidants—sodium bisulfite, effect on aspirin hydrolysis, various pH values, 1775
various—effect on degradation of amitriptyline hydrochloride in aqueous solution, 1087
Antiparasitic activity—various substituted thiazoles screened, 423
Antiperistaltic agents—diphenoxylate hydrochloride, spectrophotometric analysis in solutions and tablets containing atropine sulfate, 1553
Antipruritics—phenol, high-pressure liquid chromatographic analysis in pharmaceutical preparations, 1201
Antipyretic activity—aspirin, four commercial formulations evaluated and compared to powder, effect of particle size, rats, 674
Antipyrine—high-pressure liquid chromatographic analysis, commercial combination with benzocaine, 897
—pharmacokinetics, normal subjects and hepatitis patients, plasma and saliva concentration data, 135
Antiradiation agents—cysteamine, thiazolidine, and derivatives, NMR conformational study in aqueous solutions, 483
Antirheumatic agents—phenylbutazone, four polymorphic forms identified, thermal and compressional behavior and solubilities compared, 669
—phenylbutazone, stability in presence of various pharmaceutical colors, effect of light, 733
Antischistosomals—oxamniquine, GLC analysis, human serum or plasma, 429
Antisecretory effects—propantheline, hexocyclium, and isopropamide compared, humans, 1433
Antistaphylococcal activity—4-aminocyclohexanecarboxylic acid, aminobenzoic acid, and various derivatives evaluated, 844
Antituberculosis activity—screened in various thiocarboxamide derivatives, 1332
agents, potential—various thiosemicarbazones synthesized, 904
Antitumor activity—bromoacetylcholine evaluated, mouse neuroblastoma, 837
—evaluated in acetylaleuritolic acid isolated from ethanol extract of roots of *Jatropha macrorhiza*, 1348
—evaluated in *Eupatorium altissimum* aqueous ethanol whole plant extract and isolated flavones, 600
—evaluated in substituted hydrazines and phthalazines, 849
—evaluated in various substituted triazenes, mice, 1416
—whole plant chloroform extract of *Anaphalis morrisonicola* evaluated, 1194
Antitussives—cough syrup ingredients analyzed by high-pressure liquid chromatography, colorimetry, and spectrophotometry, 895
—dextromethorphan hydrobromide, bioavailability evaluated using fluorometric analysis of dextrorphan in human plasma, 1047
Antiviral activity—evaluated in various rhodanine derivatives, 1607
agents—idoxuridine, metabolism in cerebrospinal fluid, effect of rapid perfusion and molecular modification, dogs, 1338
Apparatus, dissolution—effect of sampling depth, temperature, and time on results, 607
Aquadichloro(2,6 - diaminopyridine)palladium(II)—degradation kinetics in acidic and acid halide media, 1515
D-Arabinofuranosylurea derivatives—synthesis described, 1206
Aristolochia taliscana—ethanol–water extract of aboveground parts, dehydrodiisoeugenol isolated and identified, 1489
Ascaricides, veterinary—anthranilic acid, GLC analysis in plasma, 1645
Aspirin—colorimetric analysis using Schoenemann reaction, pharmaceutical combinations, 139
—compacts, effect of crystal form on tensile strength, 1172
—effect on absorption, excretion, and metabolism of acetaminophen, radiochemical analysis, mice, 1399
—effects on fetal and placental growth, rats, 111
—four commercial formulations evaluated for antipyretic activity, compared to powder, effect of particle size, rats, 674
—hydrolysis, effect of sodium bisulfite, various pH values, 1775
sodium salt—buffered formulations, various dosage forms, effect on GI microbleeding, dogs, 124
—tablets, stability, porosity and pore-size distribution determined, effect of colloidal silicon dioxide, 407
Association constants—determined for binding of histamine to peptide H, effect of alkali metal and alkaline earth cations, 542
Atropine sulfate—GLC analysis in solutions and tablets containing diphenoxylate hydrochloride, 1553
Autocondensation—3-quinuclidinone, products identified, 890
Automated analyses—simultaneous fluorometric analyses of canrenone and canrenoic acid, serum, 1131
counter—particle analysis, intravenous pharmaceutical preparations, proposed as quality control method, 181
systems—dissolution testing of six samples simultaneously, system designed and evaluated, 1665
Azabiotin—synthesized in seven-step sequence, 1208
Azaperone and oxide—fluorescence characteristics, effect of pH, 1787
Aziridines, fluorene-9-spiro—synthesized, hydrolyzed to 9-chlorofluorene-9-carboxanilides, 1653

B

Bacterial endotoxins, various—UV spectrophotometric analysis, prepared solutions, wide concentration range, 723
Bactericidal agents—various alkyltrimethylammonium bromides synthesized, activity determined in simple partition systems, compared to cream systems, 696
Baeocystin—isolated from extracts of *Psilocybe semilanceata*, identified by mass spectrometry and UV spectroscopy, 113
Bamethan—effect on muscular enzyme activity, rats, 1278
Barbaloin derivatives—cascarosides A and B, electron-impact and field desorption mass spectrometric and NMR and circular dichroism spectroscopic structural identification, 1300
Barbital—compacts, effect of crystal form on tensile strength, 1172
Barbiturates, various—electron-capture GLC retention times, 477
various—partition coefficients, coacervates as nonpolar phases in equilibrium with polar water phases, 283
Benz[*a*]anthracene—binding to human serum albumin, fluorometric analysis, 209
Benzenesulfonohydrazides and benzenesulfonamides—reaction with hydrogen chloride or bromide in acetic acid, pharmacological activity of thiosulfonates formed, 1009
Benzilates—*N*-ethyl-3-piperidyl ester, metabolism in rats, 931
5,6-Benzo-2-azabicyclo[2.2.2]octanes, *N*-substituted—synthesized, analgesic activity evaluated, mice, 594
Benzocaine—colorimetric analysis, bulk drug and commercial dosage forms, 1037
—high-pressure liquid chromatographic analysis, commercial combination with antipyrine, 897
—release from aqueous gels through silicone rubber membranes *in vitro*, mathematical models extended, 926
Benzodiazepines, various—hydroxylation by rat and mouse liver microsomal enzymes *in vitro*, 1482
1,4-Benzodiazepines—nitrazepam, kinetics and mechanisms of hydrolysis, 795
—oxazepam and diazepam, kinetics and mechanism of hydrolysis, effect of pH, 573
Benzoic acid—reversed-phase high-pressure liquid chromatographic analysis, pharmaceutical formulations containing salicylic acid, 110
Benzomorphans, *N*-substituted—synthesized, pharmacological activity and opiate-receptor binding evaluated, 193
Benzophenone derivative—cudranone isolated and identified from stems and roots of *Cudrania chochinchinensis*, antimicrobial activity evaluated, 908
Benzo[*a*]pyrene—binding to human serum albumin, fluorometric analysis, 209
***p*-Benzoquinone** complexes—with proline and histamine, effect of various triazolopyrazines, kinetic spectrophotometric study, 205
Benzotriazepinones, substituted—various derivatives synthesized, 605
Benzoyl peroxide—stability in pharmaceutical gels, effect of temperature, pH, and various gel ingredients, 718
2-(3-Benzoylphenyl)propionic acid—TLC analysis, plasma, rats, 281
α-Benzylphenethylamine—identified as impurity in illicit amphetamine tablets, 443
Betamethasone benzoate—bioavailability and activity, quick-break aerosol foam and semisolid dosage forms, various corticosteroids in foam concentrates compared, effect of moisturizer, 99
—UV photometric analysis, bulk drug and pharmaceutical formulations, 1145

Bile acids—effect of type and concentration on dissolution of cholesterol monohydrate pellets in simulated bile, 1094
salts—sodium deoxycholate, effect of preadministration on absorption and excretion of phenolsulfonphthalein, humans, 727
synthetic—dissolution rate of cholesterol monohydrate pellets, effect of various nitrogen-containing compounds and surfactants, 1105
Biles, various—dissolution kinetics of cholesterol monohydrate pellets in human, animal, and simulated bile, effect of interfacial resistance, 1101
Bilirubin—protein binding, relationship to binding of salicylic acid and sulfisoxazole, effect of phenobarbital, rat serum, 1025
Binders—polyethylene glycol in direct compression of tablets, various drugs, stability evaluated, 1551
Binding—acetazolamide to human erythrocytes *in vitro,* effect of plasma drug concentration on steady-state level within erythrocytes, 729
competitive—cocaine and various drugs to synthetic levodopa melanin, 1544
cooperative protein—log *Q* plot used to estimate free energy change associated with conformational transition, 146
drug–macromolecule—parameters obtained directly from dynamic dialysis data, 1458
—L-glutamic acid dehydrogenase to nonionic detergent, 876
—histamine to peptide H, effect of alkali metal and alkaline earth cations, association constants determined, 542
opiate–receptor—various *N*-substituted benzomorphans evaluated, 193
plasma protein—effect on distribution kinetics of dicumarol, rats, 1741
plasma protein—effect on warfarin distribution kinetics, rats, 567
protein—benz[*a*]anthracene and benzo[*a*]pyrene to human serum albumin, fluorometric analysis, 209
protein—bilirubin, salicylic acid, and sulfisoxazole, effect of phenobarbital, rat serum, 1025
protein—cefazolin, effect of hemodialysis, 1508
protein—codeine, morphine, and methadone to human serum, 802
protein—L-tryptophan binding by defatted human serum albumin, effect of indomethacin and congeners, 950
protein—various drugs to albumin and plasma proteins, pharmacokinetics, drug displacement, and clinical significance, review, 447
serum protein—cefazolin, rate and extent, dogs, 1663
serum protein—dicumarol, effect on elimination kinetics, rats, 1739
serum protein—phenytoin, salicylic acid, sulfisoxazole, and warfarin compared, normal and renally impaired humans, rats, 1285
serum protein—warfarin and dicumarol, effect of phenobarbital, rats, 941
spectral—pyridine and derivatives to cytochrome P-450, constants determined, 1046
—*N*-substituted anthracenecarboxamides to DNA, electronic absorption and fluorescence spectral study, 1473
tissue—phenytoin compared in normal, nephrotic, and uremic humans, warfarin in rats with intrinsic high and low plasma binding ability, 1211
—various phenolic preservatives to polysorbate 80, effect of sorbitol, 1470
—various sulfonamides to povidone, fluorescent probe study, 1157
—warfarin to serum protein, effect of ibuprofen, humans, 1060
Bioavailability—ampicillin and amoxicillin, oral administration, effect of fasting and fluid volume, humans, 549
—analyses based on pharmacological response data, situations producing misleading results determined, 580
—betamethasone benzoate, quick-break aerosol foam and semisolid dosage forms, effect of moisturizer, 99
—clofibric acid, various formulations compared, humans, 1638
—dextromethorphan hydrobromide evaluated using fluorometric analysis of dextrorphan in human plasma, 1047
—digoxin, commercial tablets and soft gelatin capsules compared, dogs and humans, 267
—digoxin–hydroquinone complex compared to other digoxin dosage forms, humans, 644
—digoxin, various formulations compared, proposed guidelines evaluated, humans, 1720
—ferrous sulfate delayed-release capsule compared to solution, piglets, 85
—formulation effects, absorption alteration and pharmacokinetics of pharmaceutical salts, review, 1
—isoniazid, three commercial formulations compared, 1761
—lithium carbonate, calculations based on perturbation of renal clearance, commercial dosage form, 609
ocular—pilocarpine, effect of vehicle composition and pH, rabbits, 1222
—oral β-methyldigoxin, humans, radiochemical–TLC study, 314
—pilocarpine nitrate, effect of instilled volume, 1058
—prednisolone, various dosage forms compared, dogs, 1751
—procainamide, intravenous infusion, capsules, and sustained-release tablets compared, humans, 981
—propoxyphene hydrochloride, different formulations compared, 1713
—quinidine sulfate, four commercial tablets compared, humans, 539
—spironolactone in humans, related to *in vitro* dissolution, various tablet formulations compared, 1429
—sulfadiazine, tablets prepared by direct compression and fluidized-bed techniques compared to commercial product, rabbits, 1438
—tetracycline, different commercial capsules, effect of sleep, humans, 1000
topical—model and equations developed permitting *in vitro* assessment, assuming simultaneous metabolism and drug transport in skin, 1525
topical—quantitative skin model assuming inactive stratum corneum and viable, enzyme-containing epidermis, 755
Biotin analog—substituted pyrroloimidazolone synthesized in seven-step sequence, 1208
trimethylsilyl derivative—structure determined, 1212
Biphenyls, polychlorinated—effects on pharmacokinetics of pentobarbital, rats, 238
—tissue distribution, dilution by growth, and elimination, swine, 497
Bis(propynyloxy)benzenes and monoamino derivatives—synthesized, screened for antifungal activity, 431
Bisulfite ion—nucleophilic addition to dinoprostone and prostaglandin A_2, effect on aqueous stability, 149
Blood glucose—high levels, alone and with doxorubicin or dacarbazine, effect on survival of tumor-transplanted mice, 279
—high levels, combined with hyperthermia and doxorubicin or dacarbazine, effect on survival of tumor-transplanted mice, 437
Blood levels—ethanol, effect of lysine and diethanolamine–rutin, mice, 35
Blue tetrazolium—kinetics of reaction with various corticosteroids, effect of temperature, mechanism proposed, 1385
Books
Abrégé de Pharmacie Galénique. Excipients, Opérations et Formes Pharmaceutiques. Second Ed., 1366
Actualités Pharmacologiques, 1792
Acute Diarrhoea in Childhood, 1366
Advances in Chromatography. Vol. 15, 1366
Advances in the Drug Therapy of Mental Illness, 1366
Advances in Mass Spectrometry in Biochemistry and Medicine. Vol. 1, 446
Advances in Mass Spectrometry in Biochemistry and Medicine. Vol. II, 1792
Advances in Modern Toxicology. Vol. 1, Part 1: New Concepts in Safety Evaluation, 1214
Alicyclic Chemistry. Vol. 4, 759
Aliphatic Chemistry. Vol. 4, 910
The Alkaloids, Vol. 6, 612
AMA Drug Evaluations. 3rd Ed., 1512
Aminergic Hypotheses of Behavior: Reality or Cliche?, 912
Amino-Acids, Peptides, and Proteins. Vol. 7, 446
Amino-Acids, Peptides, and Proteins. Vol. 8, 1364
Analytical Profiles of Drug Substances. Vol. 5, 1061
The Anesthesiologist's Handbook, 1366
Annual Reports in Medicinal Chemistry. Vol. 11, 1213
Antibiotics. A Critical Review, 911
Aromatic and Heteroaromatic Chemistry. Vol. 4, 1062
Arzneiformenlehre. Ein Lehrbuch für Pharmazeuten, 296
Assessing Drug Reactions—Adverse and Beneficial. Vol. 7: Philosophy and Technology of Drug Assessment, 1512
Basic Medical Microbiology, 1366
Basic Neurochemistry. Second Ed., 912
Biochemical Fluorescence: Concepts. Vol. 2, 296
The Biochemistry of the Tissues, 1366
Biology of Cholinergic Function, 1366
Biosynthesis. Vol. 4, 296
Birth Defects and Drugs in Pregnancy, 1366
Breast-Feeding and the Mother. Ciba Foundation Symposium 45 (new series), 1366
British National Formulary 1976–78, 296
Calculations in Pharmacy. 3rd Ed., 445
Carbohydrate Chemistry. Vol. 8, 296
The *Catharanthus* Alkaloids, 295
Chemical Pharmacology of the Synapse, 1792
Chinese Herbs: Their Botany, Chemistry, and Pharmacodynamics, 1213
Clinical Chemistry. Principles and Procedures. 4th Ed., 759
Clinical Pharmacy and Clinical Pharmacology, 1366
Clinical Pharmacy Sourcebook. Key Articles from the American Journal of Hospital Pharmacy, 610
Colorimetric and Fluorimetric Analysis of Steroids, 1364
Conservation of Resources, 1366
Contemporary Liquid Chromatography, 1364
Contemporary Organic Chemistry, 296
Current Developments in Psychopharmacology. Vol. 3, 1366
Dental Practitioners' Formulary 1976–78, 296
Dermatotoxicology and Pharmacology: Advances in Modern Toxicology. Vol. 4, 1792
Dictionnaire Pratique de Pharmacologie Clinique, 296
Dimethyl Sulphoxide, 912
Disinfection, Sterilization, and Preservation. 2nd Ed., 1792
Dispensing of Medication. 8th Ed., 1061
Drug Assessment in Ferment: Multinational Comparisons. Vol. 6, 1366
Drug Design. Vol. VII, 1366
Drug Fate and Metabolism: Methods and Techniques. Vol. 1, 1664
Drug Interactions, 1792
Drug Metabolism: Chemical and Biochemical Aspects, 758
Drug Metabolism Reviews. Vol. 4, 445
Drug Misuse . . . . Human Abuse, 912
Drug Regulation and Innovation: Empirical Evidence and Policy Options, 911
Drugs and Therapy. A Psychotherapist's Handbook of Psychotropic Drugs, 912
Drug Therapy Reviews. Vol. 1, 1366
Drug Treatment. Principles and Practice of Clinical Pharmacology and Therapeutics, 759
The Effect of Disease States on Drug Pharmacokinetics, 295
Embryogenesis in Mammals, 1366
Encyclopaedia of Antibiotics, 1366

Encyclopedia of Electrochemistry of the Elements. Vol. V, 1366
Essays in Neurochemistry and Neuropharmacology. Vol. 1, 1366
Essentials of Medicinal Chemistry, 910
Ethical Safeguards in Research on Humans. Vol. 5. Philosophy and Technology of Drug Assessment, 445
Experimental Pharmaceutics. 4th Ed., 1514
The Fate of Drugs in the Organism: A Bibliographic Survey. Vol. 4, 1366
A Flexible Design for Health Professions Education, 611
Fluorocarbon and Related Chemistry. Vol. 3, 912
Foams, 1792
Frontiers of Pharmacology. Journal of Pharmacy and Pharmacology: Special Supplement, 912
Genetic and Biochemical Aspects of the Development of Datura. Monographs in Developmental Biology. Vol. 12, 912
A Guide to the Vitamins. Their Role in Health and Disease, 1366
Handbook of Analysis of Organic Solvents, 1062
Handbook of Basic Pharmacokinetics, 912
Handbook of Intermediary Metabolism of Aromatic Compounds, 912
Handbook of Ocular Toxicity, 296
A Handbook of Treatment, 1366
Hazards in the Chemical Laboratory. 2nd Ed., 1792
Health Care in a Changing Setting: the UK Experience, 1366
The Heroin Epidemics. A Study of Heroin Use in the United States, 1965–1975, 296
Hormone–Receptor Interaction: Molecular Aspects, 1366
Hormones, Behavior and Psychopathology, 296
Immunopharmacology, 296
Index of Reviews in Organic Chemistry. Second Cumulative Volume, 1366
Inhibition and Inactivation of Vegetative Microbes, 1792
Innovative Medical-Psychiatric Therapies, 296
Interactions of Drugs of Abuse. Annals of the New York Academy of Sciences. Vol. 281, 1365
International Nonproprietary Names (INN) for Pharmaceutical Substances, 1214
Introduction to Pharmaceutical Dosage Forms, 1061
An Introduction to Phytopharmacy, 1513
Introduction to the Spectroscopy of Biological Polymers, 1366
An Introduction to Veterinary Pharmacology, 1366
Kremers and Urdang's History of Pharmacy, 912
Lehrbuch der Pharmazeutischen Chemie, 8th Ed., 1365
Lipid Chromatographic Analysis. Vol. 2, 911
Liquid Scintillation Counting, 611
Lung Liquids. Ciba Foundation Symposium 38 (new series), 912
The Lymphocyte: Structure and Function. Part 1, 1792
Manual of Clinical Immunology, 910
Marihuana: An Annotated Bibliography, 909
Marihuana. Chemistry, Biochemistry and Cellular Effects, 612
Martindale: The Extra Pharmacopoeia. 27th Ed., 1664
Medication Law and Behavior, 147
Methods in Receptor Research. Part I, 912
Methods in Receptor Research. Part II, 1366
Microbiological Hazards of Infusion Therapy, 1366
Microbiology–1975, 612
Microencapsulation, 148
Molecular Connectivity in Chemistry and Drug Research, 1214
Narcolepsy (Advances in Sleep Research, Vol. 3), 912
Narcotic Antagonists: The Search for Long-Acting Preparations, NIDA Research Monograph Series 4, 1791
The National Formulary and the USP Guide to Select Drugs, 1062
Newburger's Manual of Cosmetic Analysis. 2nd Ed., 1792
Organic Chemistry, Series Two. Vol. 3: Aromatic Compounds, 912
Organic Chemistry, Series Two. Vol. 4: Heterocyclic Compounds, 912
Organic Chemistry of Drug Synthesis, 1512
Organophosphorus Chemistry. Vol. 7, 912
Pesticides in the Environment. Vol. 3, 1366
Pharmaceutics of Solids and Solid Dosage Forms, 1513
Pharmacognosy. 7th Ed., 1061
Pharmacokinetics of Psychoactive Drugs: Blood Levels and Clinical Response, 759
Pharmacology of Behavior and Memory, 912
Pharmacology of Marihuana. Vols. 1 and 2, 912
Photochemistry. Vol. 7, 912
Physical Chemistry for the Life Sciences, 1514
Physiologic Disposition of Drugs of Abuse, 911
The Plasma Membrane: Models for Structure and Function, 1792
Platelets in Biology and Pathology, 1366
Polypeptide Hormones: Molecular and Cellular Aspects, 1366
Practical Pharmaceutical Chemistry. 3rd Ed.—Part 1, 148
Practical Pharmaceutical Chemistry. 3rd Ed.,—Part 2, 296
Pro-drugs as Novel Drug Delivery Systems, 295
Progress in Drug Metabolism. Vol. 1, 1364
Progress in Drug Research. Vol. 20, 1366
Progress in Toxicology. Special Topics. Vol. 2, 760
Psychotherapeutic Drugs, Part 1—Principles, 1366
Psychotropic Action of Hormones, 912
Quantum Mechanics of Molecular Conformations, 1366
Radiopharmacy, 611
Radiotracer Techniques and Applications. Vol. 1, 1792
Receptors and Mechanism of Action of Steroid Hormones. Part I, 1366
Receptors and Mechanism of Action of Steroid Hormones. Part II, 1792
Receptors and Recognition. Series A, Vol. 1, 296
Receptors and Recognition. Series A, Vol. 2, 1366
Research and Medical Practice: Their Interaction, 1366
Reviews of Physiology, Biochemistry and Pharmacology. Vol. 74, 296
Reviews of Physiology, Biochemistry and Pharmacology. Vol. 75, 1366
Reviews of Physiology, Biochemistry and Pharmacology. Vol. 77, 1792
Reviews of Physiology, Biochemistry and Pharmacology. Vol. 79, 1792
Separation and Purification Methods. Vol. 4, 912
Special Topics in Heterocyclic Chemistry. Vol. 30 of The Chemistry of Heterocyclic Compounds, 1791
Stylebook/Editorial Manual of the AMA. 6th Ed., 912
Synthetic Methods for Carbohydrates, ACS Symposium Series 39, 1513
Synthetic Peptides. Vol. 4, 1366
Terpenoids and Steroids. Vol. 6, 760
Textbook of Organic Medicinal and Pharmaceutical Chemistry. 7th Ed., 1511
Thiamine, 296
Tissue Responses to Addictive Drugs, 1366
Topics in Infectious Diseases. Vol. 1. Drug Receptor Interactions in Antimicrobial Chemotherapy, 147
Toxicology of Trace Elements: Advances in Modern Toxicology. Vol. 2, 1792
Trace Amines and the Brain, 1366
Venous Thromboembolism. Prevention and Treatment, 1365
Visceral Muscle. Its Structure and Function, 296
Yeasts and Yeast-Like Microorganisms in Medical Science, 1792
Bottles, screw capped—method of testing hermetic seals developed for large numbers, 333
Bretylium tosylate—GI absorption, effect of cobalt-60 γ-radiation, rats, 361, 366
—GI absorption, effect of γ-radiation on rate, rats, 680
Brine shrimp larvae—toxicity of various phorbol esters related to cocarcinogenic potency, 1362
Bromoacetylcholine—*in vitro* cytotoxic and *in vivo* antitumor activity, mice, 837
Bronchodilators—pirbuterol, stability of aqueous solutions, effect of pH and temperature, 819
—terbutaline, absorption and metabolism, effect of salicylamide, rats, 1488
Bunolol—metabolites and conjugates identified, dog urine, 1570
Bursera kluglii—sapelins A and B isolated from ethanol extract of leaves, cytotoxic activity evaluated, 889
Bursera morelensis—deoxypodophyllotoxin and 5′-desmethoxy derivative isolated from dried exudate, cytotoxic activity evaluated, 892
Butamben—permeation rate through dimethicone membrane, convective diffusion model, 137

C

Caffeine—effect on muscular enzyme activity, rats, 1278
Calcium—complexometric analysis in dibasic and tribasic calcium phosphates, bulk drug and tablets, 1341
ions—aggregation with prostaglandin E_1 and dinoprost, effect on liquid–water partition coefficients and uptake by isolated rabbit intestine, 1308
phosphate, dibasic—direct compression tablets, aging, effect of temperature and humidity, 1636
phosphate, tribasic—adsorption of doxorubicin hydrochloride *in vitro*, 1346
transport, intestinal—effect of chronic administration of parathion or paraoxon, rats, 879
Cannabinoids—GLC analysis, device using a surface-coated open tube column, 114
various—mechanism of mass spectrometric fragmentation, 1444
Cannabis sativa—three flavone C-glycosides isolated, effect on rat lens aldose reductase evaluated, 1358
Canrenoate potassium—tissue distribution and metabolism, radiochemical study, rabbits, 275
Canrenone and canrenoic acid—automated simultaneous fluorometric analyses, serum, 1131
—human milk to serum concentration ratio, 1203
Capsule-filling machine, automatic—instrumentation for monitoring compression and ejection forces described, 504
automatic—strain gauges, explanation of action, 1507, 1508
Capsules—containing lubricants, effect of shear mixing on *in vitro* dissolution, 1215
Carbachol—IR spectrophotometric analysis, absorbance calculation, error reported, 1211
—IR spectrophotometric analysis, commercial ophthalmic preparations, 439
Carbamazepine—time-dependent pharmacokinetics, 1-week infusion, monkeys, 647
Carbamimidate ester, substituted—synthesized, screened for antimalarial activity, turkeys, 418
Carbonate—role in acid neutralization of aluminum hydroxide gel, pH-stat titration, 1533
Carbonic anhydrase inhibitors—acetazolamide, GLC analysis, human blood, plasma, and saliva, 527
—acetazolamide, sustained-release product and 15- and 20-mg/hr GI drug delivery systems compared, humans, 1388
—chlorthalidone, spectrophotometric analysis, urine, 1735
—*in vitro* binding to human erythrocytes, effect of plasma drug concentration on steady-state level within erythrocytes, 729
Carboxylic acids, aliphatic—colorimetric analysis in solutions, 1403
Carboxymethylcellulose, various types—effect on permeation rate of salicylate across a dialysis membrane, 1611
Carcinogens—benz[*a*]anthracene and benzo[*a*]pyrene, binding to human serum albumin, fluo-

rometric analysis, 209
—7,12-dimethylbenz[*a*]anthracene, mutagenicity compared to coralyne and related compounds, 1781
Cardenolides, various—isolated from ethanol extract of aboveground parts of *Adenium obesum,* evaluated for cytotoxic activity, 1336
Cardiac depressants—procainamide and *N*-acetyl derivative, high-pressure liquid chromatographic analyses, human plasma, 874
—propranolol, GLC analysis in human plasma, 1490
—quinidine, colorimetric analysis, pharmaceutical formulations and biological fluids, 1317
—quinidine sulfate, bioavailability of four commercial tablets compared, humans, 539
Cardiac glycosides—β-methyldigoxin, intravenous, pharmacokinetics in humans, radiochemical–TLC study, 242
—β-methyldigoxin, oral and intravenous, effect on left ventricular ejection time and heart rate correlated with pharmacokinetic parameters, humans, 326
—β-methyldigoxin, oral and intravenous, pharmacokinetics, radioimmunoassay compared to radiochemical spectrometric assays, human plasma, 806
—β-methyldigoxin, oral, pharmacokinetics and bioavailability in humans, radiochemical–TLC study, 314
Cardioactive agents—isoproterenol, quinidine, and dysrhythmogenic agent, effect on fetal rat heart rate related to levels of cyclic adenosine monophosphate, organ culture, 1450
Cardiopulmonary effects—polyethyleneimine, oral and intravenous administrations compared, dogs, 902
Cardiotonic activity—screened in 3β-thioacetyl-14β-hydroxy-5β-card-20(22)-enolide, 602
Cardiotonic agents—digoxin, bioavailability of various formulations compared, proposed guidelines evaluated, humans, 1720
—digoxin–hydroquinone complex, bioavailability compared to other digoxin dosage forms, humans, 644
—digoxin, *in vitro* dissolution and bioavailability, commercial tablets and soft gelatin capsules compared, dogs and humans, 267
—digoxin, pharmacokinetic model for disposition in dog developed, applied to humans, 1679
—digoxin, pharmacokinetic model for distribution and elimination, effect of ligation of bile duct or ureter, rats, 1138
—ouabain and digitoxin, reaction with 1,3,5-trinitrobenzene or 2,4,6-trinitroanisole, NMR spectral characterization of products, 753
Cardiovascular activity—three harmala alkaloids in dogs, 1244
effects—mescaline on isolated rat atria, 938
system—effects of intravenous administration of dimethyl sulfoxide, anesthetized rabbits, 269
Carmustine—degradation rate in aqueous media, effect of pH and temperature, 1073
—degradation rate in mixed solvents and nonaqueous media, effect of temperature, 1076
Cascarosides A and B—electron-impact and field desorption mass spectrometric and NMR and circular dichroism spectroscopic structural identification, 1300
Catalytic activity—enzymes spread as a monomolecular film at an air–water interface, surface exchange technique developed, 792
Catechol and methylcatechol metabolites—of phenytoin, GLC and GLC–mass spectrometric analyses and identification, human, monkey, and dog urine, 1596
O-methyltransferase—activity, effect of coralyne, nitidine, and related compounds, rat liver homogenate, 986
Cefamandole nafate—polarographic analysis, prepared samples, 379
Cefazolin—protein binding, effect of hemodialysis, 1508
—rate and extent of binding to serum protein, dogs, 1663
Cephalosporins, various—fluorometric analysis, commercial samples in aqueous solutions, 213
—GLC analysis of *N,N*-dimethylaniline as contaminant in commercial samples, 1634
—high-pressure liquid chromatographic determination of lipophilic indexes, correlated to partition coefficients, 747
—thermal decomposition of amorphous samples, effect of water content and temperature, 1312
zwitterionic—ionization constants, error in equations corrected, 1357
Cephapirin—spectrophotometric analysis, bulk drug and pharmaceutical formulations, 1108
Cephemcarboxylic acids substituted—GLC analysis, prepared samples, 1769
—silyl derivatives, preparation and NMR analyses, 1767
Cetrimide–salicylic acid—aqueous solutions, viscosity and surface tension, 1779
Charcoal, activated—adsorption of various drugs *in vitro,* effect of pH, 1640
—*in vitro* adsorption of acetaminophen, effect of pH, 480
Charge transfer complex formation—spectrophotometric analysis of ethambutol in prepared samples and commercial tablets, 766
Chelates—dicumarol–magnesium, prepared, structure elucidated, 1124
—pyrrolidone-5-hydroxamic acid with iron(III), mono, bis, and tris, stability constants in aqueous solutions, 330
various—with zinc, effect on serum zinc levels, rats, 391
Chelating agents—1,10-phenanthroline, alone and complexed with zinc, teratogenic effects evaluated in mice, 1755
Chemical-ionization mass spectrometry—analyses, lidocaine and various metabolites, human plasma and urine, 1180
—various phenothiazines and oxygenated analogs, 228
Chemosensitivity—skeletal muscle in culture, review, 913
Chiral acylating reagents—(−)-α-methoxy-α-(trifluoromethyl)phenylacetyl chloride, reacted with amphetamine and related compounds, GLC separation of diastereomeric amide derivatives, 169
Chloramphenicol and hydrolytic product—evaluated for smooth muscle relaxant and vasomotor activities, various guinea pig, rat, rabbit, and toad muscles, 1239
Chlordiazepoxide—and related impurities, high-performance liquid chromatographic analysis, commercial formulations, 684
Chloroquine—adsorption by magnesium trisilicate, effect on acid reactivity, 289
Chlorpromazine metabolites—oxidation pathways, electrochemical study, pH 3–8, 357
Chlortetracycline—high-pressure liquid chromatographic analysis, urine, 1319
Chlorthalidone—GLC analysis in urine, 1732
—spectrophotometric analysis based on inhibition of carbonic anhydrase, urine, 1735
Cholesterol and various esters—solid solutions with hydrocortisone, dissolution into simulated intestinal fluid, effect on surface tension, 1536
—implant pellets containing progesterone, *in vivo* and *in vitro* release and biological effectiveness, rabbits and rats, 490
monohydrate—pellets, dissolution kinetics in human, animal, and simulated bile, effect of interfacial resistance, 1101
monohydrate—pellets, dissolution kinetics in simulated bile, effect of bile acid type and concentration, ratio to lecithin, and added electrolytes, 1094
monohydrate—pellets, dissolution rate in synthetic bile, effect of various nitrogen-containing compounds and surfactants, 1105
—monolayers, pure and mixed with lecithin, interaction with hydrocortisone, 975
Cholinergics—bromoacetylcholine, *in vitro* cytotoxic and *in vivo* antitumor activity, mice, 837
—methacholine, mechanism of induced rise in intraocular pressure, effect of phenylephrine, dogs, 1013
ophthalmic—carbachol, IR spectrophotometric analysis, absorbance calculation, error reported, 1211
ophthalmic—carbachol, IR spectrophotometric analysis, commercial preparations, 439
ophthalmic—physostigmine, quantitative analysis by measurement of duration of cholinesterase inhibition, human blood, 389
Cholinesterase—duration of inhibition by physostigmine measured, related to physostigmine concentration, human blood, 389
Chromatography, column—isolation of various morphine metabolites from human urine, 1288
Chronotropic effects—isoproterenol, quinidine, and dysrhythmogenic agent, fetal rat heart in culture, related to levels of cyclic adenosine monophosphate, 1450
—mescaline on isolated rat atria, 938
Cimetidine—high-pressure liquid chromatographic analysis, blood and urine, 1148
Cinnamylidenes, various—structural requirements for fluorescence in strong acid, 1478
Circadian rhythm—in steady-state plasma levels of ethosuximide, monkeys, 650
—valproic acid, steady-state plasma levels, time-dependent kinetics, monkeys, 1154
Circular dichroism spectroscopy—structural identification of cascarosides A and B, 1300
—study of epimerization of anhydrotetracycline in acid solution, 1159
Citric acid—solid dispersion systems with primidone, effect of primidone concentration on glass transition temperature and dissolution, 825
Clays—montmorillonite, complex with amphetamine sulfate, effect on bioavailability, 63
Clindamycin palmitate hydrochloride—GLC analysis after acetylation catalyzed by 4-(dimethylamino)-pyridine, 273
Clofibric acid—bioavailability from various formulations compared, humans, 1638
Clonazepam—radioimmunoassay, human plasma, 235
Cloud point—octoxynol, effect of tetraalkylammonium salts and ammonium halides, various salt concentrations, 165
CNS activity—substituted 1,4,2-dioxazoles screened, 772
Coacervates—gelatin–acacia, medicated and unmedicated microglobules prepared, physical parameters evaluated for use as dosage forms, 1327
—nonpolar phases in equilibrium with polar water phases, partition coefficients, various barbiturates and xanthines, 283
Cobra venom—two anticomplement factors isolated by ion-exchange chromatography, effect of neuraminidase digestion, 947
Cocaine—competitive binding with various drugs to synthetic levodopa melanin, 1544
derivatives—norcocaine synthesized, pharmacological activity evaluated, monkeys, 119
Cocarcinogenic potency—various phorbol esters, related to toxicity to brine shrimp larvae, 1362
Coccidiostatic antibacterials—lasalocid and bromo analog, GLC analysis, various preparations and dosage forms, 769
Codeine—binding to human serum proteins, 802
phosphate—high-pressure liquid chromatographic analysis, cough syrup, 895
—radioimmunoassay–GLC analysis, human urine, 66
—spin labeled in 6-position, effect on binding to brain receptors and analgesic activity, 1054
sulfate—teratogenic activity evaluated, mice, 1727
Colchicine derivatives—X-ray diffraction determination of crystal and molecular structures, 1127
Color stability—tablets coated with FD&C Yellow No. 6, effect of sunscreening agents and various coating methods, 107
Colors, various pharmaceutical—effect on stability of phenylbutazone, effect of light, 733
Colorimetry—analyses, quinine and quinidine, pharmaceutical formulations and biological fluids, 1317
—analysis, aconitine, pharmaceutical formulations

in presence of aconine and benzoylaconine, 1331
—analysis, aliphatic carboxylic acids in solutions, 1403
—analysis, benzocaine, bulk drug and commercial dosage forms, 1037
—analysis, dihydralazine sulfate in prepared samples, 116
—analysis, isoniazid, hydrazones formed with 4-nitrobenzaldehyde or pyridoxal, prepared samples, 291
—analysis, pheniramine maleate, cough syrup, 895
—analysis using Schoenemann reaction, aspirin in pharmaceutical combinations, 139
Column chromatography—identification, diacetylmorphine metabolites, human urine, 201
Complement fixing—human IgG1, effect of chemical modifications on active site, 427
—mechanism of activation, associated biological effects, role in human diseases, inhibitory drugs, review, 1367
Complex formation—penicillin G and related compounds with nickel(II) ions, reaction kinetics, 533
Complexes—p-benzoquinone with proline and histamine, effect of various triazolopyrazines, kinetic spectrophotometric study, 205
—digoxin–hydroquinone, bioavailability compared to other digoxin dosage forms, humans, 644
—phenobarbital with ephedrine, preparation, chemical and spectroscopic analysis, 1019
—various prostaglandins with cyclodextrins, ion-exchange liquid chromatographic analysis, prepared samples, 706
various—with zinc, effect on serum zinc levels, rats, 391
Complexometry—analysis, calcium in dibasic and tribasic calcium phosphates, bulk drug and tablets, 1341
Compound 48/80—antimicrobial activity evaluated in protozoa, bacteria, fungi, and viruses, 702
Compression cycle—tablet formation, effect of duration and maximum force on tablet tensile strength, 155
forces—in automatic capsule-filling machine, instrumentation described, 504
Compressional behavior—four polymorphic forms of phenylbutazone compared, 669
Computer curve-fitting method—pharmacokinetic model constants estimated, drug concentration data obtained during repetitive drug administration, 530
Conformational transition—unbound to complexed proteins, log Q plot used to estimate free energy change, 146
Conformations—cysteamine, thiazolidine, and derivatives, NMR study in aqueous solutions, 483
—various hydroxyureas in octanol–water, effect of solvent equilibration, 1040
Contact angles—various pharmaceutical powders, 1480
Contaminants—α-benzylphenethylamine identified in illicit amphetamine tablets, 443
—N,N-dimethylaniline, GLC analysis in various penicillins and cephalosporins, commercial samples, 1634
environmental—polychlorinated biphenyls, effects on pharmacokinetics of pentobarbital, rats, 238
—identified in commercial samples of dapsone, 1723
inhibitory—presence in various commercial preparations of human chorionic gonadotropin, 1773
Cooperative protein binding—log Q plot used to estimate free energy change associated with conformational transition, 146
Coordination compounds—aquadichloro(2,6-diaminopyridine)palladium(II), degradation kinetics in acidic and acid halide media, 1515
Copolymers—methyl vinyl ether–maleic anhydride–acid, potentiometric characterization of composition and measurement of dissolution profiles, 713
Coralyne and related compounds—mutagenicity evaluated, compared to 7,12-dimethylbenz[a]-anthracene, 1781
—effect on catechol O-methyltransferase and tRNA methyltransferase activity, rat liver homogenate, 986
Corticosteroids, topical—betamethasone benzoate, bioavailability and activity of quick-break aerosol foam and semisolid dosage forms, effect of moisturizer, 99
various—glass dispersions using sugar carriers, dissolution rates compared to plain powder, 494
various—kinetics of reaction with blue tetrazolium, effect of temperature, mechanism proposed, 1385
Costunolide—isolated from ethanol extract of bark of Michelia champaca and petroleum ether extract of roots of Talauma ovata, cytotoxic activity evaluated, 883
Coumarin anticoagulants—dicumarol, effect of serum protein binding on elimination kinetics, rats, 1739
—warfarin, elimination kinetics and anticoagulant activity, effect of chronic administration, rats, 1275
—warfarin, (R)-(+)- and (S)-(−)-enantiomers, steady-state anticoagulant activity compared, 1790
Creatine phosphokinase—serum levels correlated with myocardial damage caused by infarction, rats, 1483
Cryogenine—immunosuppressive activity evaluated in developing and established adjuvant arthritis, rats, 1304
Crystal and molecular structures—various thiocolchicines, X-ray diffraction determination, 1127
form—effect on tensile strength of compacts of aspirin, sulfathiazole, and barbital, 1172
Cudranone—isolated and identified from stems and roots of Cudrania chochinchinensis, antimicrobial activity evaluated, 908
Cyclocytidine—pharmacokinetics in humans, mathematical model, 1441
Cyclodextrin complexation—with various prostaglandins, ion-exchange liquid chromatographic analysis, prepared samples, 706
Cycloheptylsulfamate—metabolism, rabbits and rats, 881
Cysteamine—and derivatives, NMR conformational study in aqueous solutions, 483
Cytochrome P-450—spectral binding to pyridine and derivatives, constants determined, 1046
Cytotoxic activity—bromoacetylcholine evaluated mouse neuroblastoma cell culture, 837
—deoxypodophyllotoxin and 5′-desmethoxy derivative evaluated, 892
—evaluated in Eupatorium altissimum aqueous ethanol whole plant extract and isolated flavones, 600
—evaluated in latentiated derivatives of 3-methyleneoxindole, 1022
—evaluated in various cardenolides and flavonol isolated from ethanol extract of aboveground parts of Acenium obesum, 1336
—evaluated in various indole alkaloids isolated from Tabernaemontana holstii roots, 1135
—lignan isolated from chloroform fraction of extract of aerial parts of Polygala macradenia evaluated, 586
—plant constituents parthenolide and costunolide evaluated, 883
—sapelins A and B evaluated, 889
—various furans and thiophenes evaluated, 1052
—various 2-indolyl 5-pyridyl ketone derivatives screened, 263

D

Dacarbazine—combined with high blood glucose levels, effect on survival of tumor-transplanted mice, 279
—combined with hyperglycemia and hyperthermia, effect on survival of tumor-transplanted mice, 437
Dansyl chloride—derivatizing reagent in high-pressure liquid chromatographic analysis of tocainide, 583
derivatives—N-(monoaminoalkyl)- and N-(polyaminoalkyl)acetamides, TLC and high-pressure liquid chromatographic analysis, human urine, 1195
derivatives—of N-(monoaminoalkyl)- and N-(polyaminoalkyl)acetamides synthesized, 1089
Dantrolene sodium—high-pressure liquid chromatographic analysis, biological fluids, 751
—high-pressure liquid chromatographic analysis, commercial dosage forms, 286
Dapsone and related compounds—high-speed liquid chromatographic analyses, bulk drug, pharmaceutical formulations, and biological fluids, 1618
—commercial samples, contaminants identified, 1723
Decomposition—nitrazepam in solid state in microcrystalline cellulose, effect of temperature and humidity, 676
products—of diethylpropion hydrochloride, identification, high-performance liquid chromatographic analysis in tablets, 198
thermal—amorphous samples of various antibacterials, effect of water content and temperature, 1312
thermal—1,3-dimethyl derivative of phenobarbital, in gas chromatograph, major products identified by mass spectrometry, 578
Degradation—amitriptyline hydrochloride in aqueous solution, effect of metal-ion contaminants, edetate disodium, and antioxidants, 1087
hydrolytic—pirbuterol, effect of pH and temperature, 819
—indomethacin in alkaline aqueous solutions, various temperatures, kinetics, effect of ionic strength, 27
kinetics—aquadichloro(2,6 - diaminopyridine)-palladium(II) in acidic and acid halide media, 1515
kinetics—indomethacin in presence of ionic and nonionic surfactants in alkaline solutions, 1259
kinetics—pentobarbital sodium in propylene glycol-based solutions, in vivo effects in laboratory animals, 693
kinetics—phenothiazine and 10-methyl derivative, oxidation in acidic oxygen-saturated medium, effect of pH, 1392
kinetics—substituted thiazol-3-ol, in aqueous media, effect of temperature, pH, and ionic strength, 1175
kinetics—tetracycline at pH 1.5, effect of temperature, 1648
—penicillin G in aqueous solution, deuterium solvent isotope effect, pH 4–10, 861
—phenothiazine in ethanol–water mixtures, mechanism suggested, 1395
—prostaglandin E_1 and dinoprostone at pH extremes, 1590
rate—carmustine in aqueous media, effect of pH and temperature, 1073
rate—carmustine in mixed solvents and nonaqueous media, effect of temperature, 1076
Dehydrodiisoeugenol—isolated from ethanol–water extract of aboveground parts of Aristolochia taliscana, 1489
Delivery, drug—zero-order system, geometric factors considered, experimental device tested, 159
—zero-order system, theoretical behavior, equations developed, 163
4′-Demethyldeoxypodophyllotoxin—isolated from chloroform fraction of extract of aerial parts of Polygala macradenia, evaluated for cytotoxic and tumor inhibitory activity, 586
Densities—various pharmaceutical powders, 1480
2′-Deoxy-5-fluorouridylate ester—fluorescent derivatives synthesized, inhibition of thymidylate synthetase evaluated, 434
Deoxypodophyllotoxin—and 5′-desmethoxy derivative, isolated from dried exudate of Bursera morelensis, cytotoxic activity evaluated, 892
Desipramine tablets—impurities, TLC, GLC, and mass spectral analysis, 1015

Detergents, nonionic—binding to L-glutamic acid dehydrogenase, 876
Deuterium-labeled compounds—(+)-, (−)-, and (±)-$^{2}H_{5}$-methadones synthesized, 1579
***Deuterium oxide**—solvent isotope effect on penicillin* G degradation in aqueous solution, pH 4–10, 861
Dextroamphetamine—alone and combined with *fenfluramine, sex-based differences in psychomotor* and physiological effects, humans, 739
Dextromethorphan hydrobromide—bioavailability evaluated using fluorometric analysis of dextrorphan in human plasma, 1047
***Dextrorphan**—fluorometric analysis, human plasma,* 1047
Dextrose infusion—alone and with doxorubicin or *dacarbazine, effect on survival of tumor-transplanted* mice, 279
—combined with *hyperthermia* and doxorubicin or dacarbazine, effect on survival of tumor-transplanted mice, 437
Diacetylmorphine—metabolites identified using TLC, GLC, and column chromatography, human urine, 201
Dialysis data, dynamic—drug–macromolecule binding parameters obtained directly, 1458
Diastereoisomers—phenethicillin, proton and ^{13}C-NMR spectral analysis of ratio, bulk drug and commercial formulations, 1079
***Diazepam**—kinetics and mechanism of hydrolysis,* effect of pH, 573
Dichloralantipyrine—GLC analysis in capsules with acetaminophen and isometheptene mucate, 604
Dichlorodifluoromethane—single and multiple dosing, *pharmacokinetic model proposed, dogs, 49*
Dicumarol—chelate with magnesium prepared, structure elucidated, 1124
—*distribution kinetics, effect of plasma protein* binding, rats, 1741
—*effect of serum protein binding on elimination* kinetics, rats, 1739
—serum protein binding, effect of phenobarbital, *rats, 941*
Diethanolamine–rutin—effect on blood levels, withdrawal reaction, and toxicity of ethanol, mice, 35
Diethylpropion hydrochloride—high-performance liquid chromatographic analysis in tablets, identification of two decomposition products, 198
Diethylstilbestrol effects—antagonism by 5-substituted 2-oxazolidinethiones evaluated, rats, 887
***Diethyltoluamide**—protection time, effect of skin* surface lipids, humans, 1764
Diffusion coefficients—benzocaine in aqueous gel *vehicle, calculations derived from mathematical* drug release models, 926
convective—model applied to permeation rate of butamben through dimethicone membrane, 137
drug—quantitative skin model assuming inactive stratum corneum and viable, enzyme-containing epidermis, 755
—suspended drug in semisolid vehicle, mathematical model based on physicochemical principles, *654, 662*
—three *p*-aminobenzoate esters through tubular dimethyl polysiloxane membrane into a flowing *liquid, 337*
Digitoxin—reaction with 1,3,5-trinitrobenzene or 2,4,6-trinitroanisole, NMR spectral characterization of products, 753
Digoxin—bioavailability of complex with hydroquinone *compared to other digoxin dosage forms,* humans, 644
—bioavailability, various formulations compared, *proposed guidelines evaluated, humans, 1720*
—*in vitro* dissolution and bioavailability, commercial tablets and soft gelatin capsules, dogs and humans, *267*
—pharmacokinetic model for disposition in dog *developed, applied to humans, 1679*
—pharmacokinetic model for distribution and elimination, effect of ligation of bile duct or ureter, *rats, 1138*
Dihydralazine sulfate—colorimetric analysis using *2-methyl-3-nitropyridine-6-carboxaldehyde,* prepared samples, 116
Dihydroquinoxalino[2,3-*b*]quinoxalines, substituted—synthesized, anthelmintic activity evaluated, 1349
Dihydroxy compounds—clindamycin palmitate hydrochloride, GLC analysis after acetylation cata*lyzed by 4-(dimethylamino)pyridine, 273*
3,4-Dimethoxyphenethylamine and *N*-methyl homologs—effect on monoamine oxidase-catalyzed *deamination of tyramine and tryptamine, 1048*
***O*-Dimethylaminoethyl** oxime ethers, various—isomers synthesized, anticholinergic activity of methylhalide salts evaluated on rat ileum, 1602
4-(Dimethylamino)pyridine—catalyst for acetylation *of clindamycin palmitate hydrochloride preparatory* to GLC assay, 273
***N,N*-Dimethylaniline**—GLC analysis in various peni*cillins and cephalosporins, commercial samples,* 1634
7,12-Dimethylbenz[*a*]anthracene—mutagenicity compared to coralyne and related compounds, 1781
2,4-Dimethylbenzo[*g*]quinoline—NMR spectrum, chemical shifts of methyl groups defined, effect of concentration, 1200
1,3-Dimethyl derivative of phenobarbital—thermal decomposition in gas chromatograph, major prod*ucts identified by mass spectrometry, 578*
Dimethyl sulfoxide—intravenous administration, cardiovascular and neuromuscular effects, anes*thetized rabbits, 269*
Dinoprost—aggregation with calcium ions, effect on lipid–water partition coefficients and uptake by isolated rabbit intestine, 1308
C-15 alkyl esters, various—monomolecular film *compression–relaxation behavior compared,* 823
Dinoprostone—nucleophilic addition of bisulfite ion, *effect on aqueous stability, 149*
—stability of pH extremes, 1590
1,4,2-Dioxazoles, substituted—synthesis, general pharmacological screening, 772
Diphenoxylate hydrochloride—spectrophotometric *analysis in solutions and tablets containing atropine* sulfate, 1553
Disinfectants—triclocarban, GLC analysis, rat and human blood, 725
—triclosan, free and conjugated, GLC analysis, human plasma and urine, 1166
Disintegration—tablets, time course determined using numerical analysis of dissolution profile, 1758
*time—tablets with enteric film coating of meth*acrylic acid–methyl methacrylate copolymer, mathematical model, 1070
***Dispersions,** solid—griseofulvin–polyethylene glycol* 6000, X-ray diffraction study, aqueous solubility, *effects of pulverization and aging,* 989
Displacement, drug—various drugs, binding to albumin and plasma proteins, review, 447
***Dissociation** constants—doxorubicin, electronic ab*sorption and fluorescence spectrophotometric determination, 958
Dissolution apparatus—effect of sampling depth, temperature, and time on results, 607
data, in vitro—predictive conversion into in vivo drug response–time profiles, plasma warfarin levels, 297
—*from a horizontal surface, mathematical analysis* of solute velocities in descending column, 741
—hydrocortisone into simulated intestinal fluid from solid solutions with cholesterol or various esters, 1536
in vitro—capsules containing lubricants, effect of shear mixing, 1215
in vitro—digoxin, commercial tablets and soft *gelatin capsules compared, 267*
in vitro—propantheline regular and sustained-release tablets compared, 1777
in vitro—spironolactone, *related to human bio*availability, various tablet formulations com*pared, 1429*
kinetics—cholesterol monohydrate pellets in human, animal, and simulated bile, effect of in*terfacial resistance, 1101*
kinetics—cholesterol monohydrate pellets in simulated bile, effect of bile acid type and concentration, ratio to lecithin, and added electrolytes, 1094
kinetics—soluble nondisintegrating disks, equation developed, related to cube root law, 1696
—methyl vinyl ether–maleic anhydride–acid copolymers, potentiometric measurement of pro*files, 713*
—micronized glyburide, various multiparticulate models fit to data, rate and size distribution pa*rameters evaluated, 761*
model—multiparticulate systems under sink and nonsink conditions, generally applicable equations derived, 1435
—multisized drug particles, approximate expres*sions for weight fraction undissolved, 553*
—multisized suspensions of prednisolone acetate, effect of particle size, 557
—*oxytetracycline tablets, effect of various* formulation and processing factors, 852
—*primidone–citric acid solid dispersion systems,* effect of primidone concentration, 825
profile—numerical analysis used to determine time course of tablet disintegration, 1758
rate—cholesterol monohydrate pellets, effect of various nitrogen-containing compounds and *surfactants,* 1105
rate, *in vitro*—used to predict plasma time profiles, validity evaluated, 1359
rate—polymorphic form of mercaptopurine, differential thermographic and X-ray diffraction *analyses, 608*
rate—various corticosteroids, glass dispersions using sugar carriers compared to plain powder, 494
—solid in a solvent, energy changes determined, *961*
—suspended drug in semisolid vehicle, mathematical model based on physicochemical prin*ciples, 654, 662*
testing—six samples simultaneously, automated *system designed and evaluated,* 1665
Distribution, biological—amphetamine and analogs with rigid conformation, spectrofluorometric *analysis in rat tissues, effect of pretreatment with* iprindole, 271
biological—^{14}C-meglumine salicylate, oral ad*ministration, humans, 536*
biological—mercaptopurine in rats, 1454
biological—sulfathiazole in tissue, urine, and plasma of sheep following intravenous administration, pharmacokinetic model, 1297
biological—^{99m}Tc- and ^{57}Co-labeled fatty acid analogs containing chelating agents, compared to ^{3}H-palmitic acid, rabbits, 225
—*dichlorodifluoromethane, single and multiple* dosing, pharmacokinetic model proposed, dogs, 49
drug—ampicillin and hetacillin methoxymethyl ester, plasma, prostatic fluid, and spinal fluid *levels, dogs, 345*
drug—aqueous chamber drug volume, inulin, pilocarpine, and 1-hexanoic acid, rabbit eyes, 219
drug—triamterene, radiochemical analysis, rats, 53
—*imipramine, effect of pregnenolone-16α-car*bonitrile, rats, 1492
kinetics—dicumarol, effect of plasma protein *binding, rats, 1741*
—^{14}C-meglumine, rats and dogs, 96
—pharmacokinetic parameters, effect of plasma *protein binding, rats, 567*
tissue—canrenoate potassium, radiochemical *study, rabbits, 275*
tissue—digoxin, pharmacokinetic model, effect of ligation of bile duct or ureter, rats, 1138
*tissue—isoniazid, effect of various drugs, radio*chemical analysis, rats, 1322
tissue—progesterone, different routes of admin*istration compared, 1744*
tissue—various polychlorinated biphenyls, swine, 497
2,4 - Disulfamyl - 5 - trifluoromethylaniline—high-pressure liquid chromatographic analysis in hy*droflumethiazide samples and tablets, 877*
Diuretics—chlorthalidone, GLC analysis in urine, 1732
—*chlorthalidone, spectrophotometric analysis* based on inhibition of carbonic anhydrase, urine,

1735
—polythiazide, high-pressure liquid chromatographic analysis in pharmaceutical formulations, 736
—spironolactone, bioavailability in humans related to *in vitro* dissolution, various tablet formulations *compared*, 1429
—triamterene, distribution and pharmacokinetics, radiochemical analysis, rats, 53
various—effects on urine and plasma osmolality compared to nephrotoxic agent, dogs, 501
DNA—*binding to N-substituted anthracenecarboxamides*, electronic absorption and fluorescence spectral study, 1473
polymerase, viral—effect of litmomycin on in vitro activity, reaction kinetics and mechanism, 130
Dosage form index—suggested as evaluating parameter for drug delivery systems, sustained-release product and 15- and 20-mg/hr GI acetazolamide *systems compared in humans*, 1388
Dosage forms—aspirin tablets, stability, porosity and pore-size distribution determined, effect of *colloidal silicon dioxide*, 407
—buffered sodium acetylsalicylate, effect on GI microbleeding, dogs, 124
—*capsules containing lubricants*, effect of shear mixing on in vitro dissolution, 1215
—*compressed tablets, effect of duration of lubricant–excipient mixing* on physical properties, 1377
—*digoxin tablets and soft gelatin capsules, in vitro* dissolution and bioavailability, dogs and humans, 267
—*direct compression tablets*, dibasic calcium phosphate, aging, effect of temperature and humidity, 1636
—directly compressed tablets of various drugs, gluconolactone as excipient, effect on physical *characteristics*, 370
—enteric-coated pellets, theoretical analysis of effect of dispersion in stomach on blood level *profiles*, 1495
—intravenous pharmaceutical preparations, automated counter particle analysis, *proposed as* quality control method, 181
—large-volume parenterals, particle-size *distributions characterized, cleanliness factor developed*, 1083
—molded nitroglycerin tablets, sorption by *thermoplastic polymers and stability in various strip* packages, 1293
—oxytetracycline tablets, tensile strength and *dissolution*, effect of various formulation and processing factors, 852
parenteral—timed-release microcapsules formulated, evaluated *in vitro* and *in vivo*, mice, 172
potential—medicated and unmedicated *microglobules prepared from gelatin–acacia coacervates*, physical parameters evaluated, 1327
—powder inhalation aerosols, micronized powders *of substituted 2-xanthonecarboxylic acid* and sodium salt, effect of lactose concentration, humidity, and temperature, 1254
—quick-break aerosol foam and semisolid, betamethasone benzoate bioavailability and activity *compared, effect of moisturizer*, 99
—regular and sustained-release tablets of propantheline, quantitative analysis and *in vitro dissolution*, 1777
—spray granulations, effect of liquid flow rate on particle-size distribution, 1462
—*sustained-release drug–clay complex*, effect of montmorillonite on bioavailability of amphetamine sulfate, 63
—sustained-release progesterone–cholesterol implant pellets, in vivo and in vitro release and *biological effectiveness of progesterone*, rabbits and rats, 490
—tablets, aspirin, sulfathiazole, and barbital, effect *of crystal form on tensile strength*, 1172
—tablets, effect of binder solution viscosity and temperature on drug migration during drying, 1409
—tablets, effect of duration of compression cycle and maximum compressive force on tensile strength, 155
—*tablets, effect of particle size of major diluent on* drug migration during drying, 1406
—tablets, formulation prediction factors developed, *applied to manufacturing procedures*, 254
—tablets, fracture caused by shear stresses during decompression, effect of plastic deformation, 510
—tablets, imipramine and desipramine, TLC, GLC, *and mass spectral analysis of impurities*, 1015
—tablets, various drugs, polyethylene glycol as binder for direct compression, stability evaluated, 1551
—tablets with enteric film coating of methacrylic acid–methyl methacrylate copolymer, disintegration time, mathematical model, 1070
various—digoxin and digoxin–hydroquinone complex, *bioavailability compared, humans*, 644
various—effect on anticonvulsant activity of a substituted piperazine after oral administration, *mice*, 82
—various large-volume parenterals, particle-size distribution, effect of different degrees of agitation, 935
—wet-processed granulations, relationships among *volumetric powder flow rates, angles of repose*, and particle size, 1235
Dosage regimens—simultaneous intravenous priming *and infusion doses, pharmacokinetic parameters* determined from postinfusion blood level data, 1499
Doxorubicin—combined with high blood glucose levels, effect on survival of tumor-transplanted *mice*, 279
—combined with hyperglycemia and hyperthermia, effect on survival of tumor-transplanted mice, 437
—electronic absorption and fluorescence spectrophotometric determination of dissociation *constants and protolytic equilibria*, 958
hydrochloride—adsorption on solid tribasic calcium phosphate *in vitro*, 1346
Dragendorff's reagent—several modifications, effect on relative TLC sensitivities of compounds con*taining various functional groups*, 1656
Drug–biomolecule interactions—various acidic and basic drugs with β-lipoproteins, 420
Drug delivery—*progesterone from silicone matrixes, in vitro* system compared to bovine intravaginal device *in vitro*, 816
systems—quick-break aerosol foam, betamethasone benzoate bioavailability and activity compared *to semisolid dosage form, effect of* moisturizer, 99
systems—sustained-release product and 15- and *20-mg/hr GI acetazolamide systems compared* in humans, dosage form index suggested as evaluating parameter, 1388
vaginal—in situ absorption of 1-alkanoic acids, rabbits, 781
vaginal—membrane surface pH *determined*, compared to bulk solution pH, rabbits, 778
—zero-order system, geometric factors considered, *experimental device tested*, 159
—zero-order system, theoretical behavior, equations developed, 163
Drug interactions—*tolbutamide and sulfadimethoxine*, kinetic analysis, sheep, 1063
Drug levels, serum—oxytetracycline, factors causing variance, calves, 1198
Drug–macromolecule binding—parameters obtained *directly from dynamic dialysis data*, 1458
Drug release—benzocaine from aqueous gels through silicone rubber membranes *in vitro*, mathemat*ical models extended*, 926
—*from suspensions*, diffusion model based on physicochemical principles, 654, 662
Drug response *profiles, in vivo*—plasma warfarin levels, predicted from in vitro dissolution data, 297
Drug transport—permeation rate of salicylate across a dialysis membrane in presence of various types *of carboxymethylcellulose*, 1611
Drying temperature—tablet granulations, effect on drug migration, 1409
Dyes—*FD&C Yellow No. 6 tablet coating*, effect of sunscreening agents and various coating methods *on color stability*, 107
Dysrhythmogenic agent—effect on fetal rat heart rate related to levels of cyclic adenosine monophosphate, organ culture, 1450

E

Edetate *disodium—effect on degradation of amitriptyline* hydrochloride in aqueous solution, 1087
Editorials
Cancer in the Kitchen? (August)
The "Dumb Cops" Image (January)
Fifty More FDAs? (November)
Getting to Know the FDA (October)
Has Justice Been Served? (June)
How Much Is "Enough"? (March)
Impeding Metric Conversion (May)
Keeping "Basics" in Balance (September)
A New Kind of "Drug Lag" (July)
Prediction: New Drug Law Coming (December)
Reliability of Scientific Data *(February)*
"Zero-Based" Drug Standards (April)
Ejection forces—in automatic capsule-filling machine, *instrumentation described*, 504
Electrochemistry—study of oxidation pathways of hydroxylated chlorpromazine metabolites, 357
Electrolytes—*effect on dissolution kinetics of cholesterol monohydrate* pellets in simulated bile, 1094
Electronic absorption spectrometry—binding of *N*-substituted anthracenecarboxamides to DNA, 1473
Electrophysiology—skeletal muscle in culture, review, 913
Elimination—*digoxin, pharmacokinetic model, effect* of ligation of bile duct or ureter, rats, 1138
kinetics—dicumarol, effect of serum protein binding, rats, 1739
kinetics—warfarin, effect of chronic administration, *rats*, 1275
renal—tetraethylammonium bromide, effect of sodium salicylate, rats, 56
—*various polychlorinated biphenyls, swine*, 497
Elymoclavine—oxidized with manganese dioxide in methanol to 10α-methoxy-$\Delta^{8,9}$-lysergaldehyde, 1340
Endotoxins, various—UV spectrophotometric analysis, *prepared solutions, wide concentration range*, 723
Energy changes—determined for dissolution of a solid *in a solvent*, 961
transfer—*Limulus* hemocyanin, fluorometric study, 1684
Enteric-coated pellets—theoretical analysis of effect of dispersion in stomach on blood level profiles, 1495
Enzyme activity—catechol *O*-methyltransferase and tRNA methyltransferase, effect of coralyne, ni*tidine, and related compounds, rat liver homog*enate, 986
activity—effect of training time and treatment with *various vasodilators, rats*, 1278
activity—histidine decarboxylase, conversion of D,L-α-^{13}C-histidine to histamine, ^{13}C-NMR and GLC–mass spectral study, 1660
activity—pig heart mitochondrial malate dehydro*genase, monomolecular films, effect of lipids*, 1465
cofactors—pyridoxal phosphate, spectrophoto*metric analysis in biological fluids*, 1503
hydrolysis—for GLC analysis of conjugated estrogens, commercial formulations, 523
inducers—phenobarbital, effect on serum protein binding of warfarin and dicumarol, rats, 941
inhibitors—*fluorescent derivatives of 2'-deoxy*-5-fluorouridylate ester synthesized, effect on thymidylate synthetase, 434
Enzymes—*carbonic anhydrase, inhibition by chlor*thalidone, spectrophotometric analysis, urine, 1735
—*creatine phosphokinase, serum levels* correlated with myocardial damage caused by infarction, rats, 1483
—L-glutamic acid dehydrogenase, binding to nonionic detergent, 876

—mitochondrial malate dehydrogenase spread as a monomolecular film at an air–water interface, surface exchange technique developed, 792
—monoamine oxidase, deamination of tyramine and tryptamine, effect of 3,4-dimethoxyphenethylamine and *N*-methyl homologs, 1048
—ribonucleotide reductase, effect of various hydroxyureas on activity *in vitro*, 1040
—tyrosine hydroxylase activity, effect of various tetrazole analogs of phenylalanine derivatives, 1642
—viral DNA polymerase, effect of litmomycin on *in vitro* activity, reaction kinetics and mechanism, 130

Ephedrine—complex with phenobarbital prepared, chemical and spectroscopic analysis, 1019
hydrochloride—UV spectrophotometric analysis, commercial capsule in combination with aminophylline and amobarbital, 811

Epimerization—anhydrotetracycline in acid solution, kinetics and mechanism, high-performance liquid chromatographic and circular dichroism study, 1159
—hetacillin in aqueous solution, effect of pH and temperature, 1004

Epinephrine—GLC analysis, pharmaceutical dosage forms, 560
—high-pressure liquid chromatographic analysis, liquid pharmaceutical preparations, 425
—pressor responses, effect of pentazocine, rats, 1652

Equilibrium—various pyrazolodiazepinones in aqueous solution, effect of pH and methyl substitution, 1703

Erythrocytes, human—binding of acetazolamide *in vitro*, effect of plasma drug concentration on steady-state level within erythrocytes, 729

Escherichia coli—resistant and sensitive, inhibition by various tetracyclines, related to partition coefficient, structure–activity relationships, 88

Estrogens, conjugated—enzyme hydrolysis and GLC analysis, commercial formulations, 523
various—aqueous solubilities, pKa values, effects of structural differences on ionization, 624

Ethambutol—spectrophotometric analysis using charge transfer complex formation, prepared samples and commercial tablets, 766

Ethanol—blood levels, withdrawal reaction, and toxicity, effect of lysine and diethanolamine–rutin, mice, 35

Ethinamate and hydroxy derivative—GLC analysis in biological fluids, bioavailability from tablets and capsules, humans, 992

Ethosuximide—circadian rhythm in steady-state plasma levels, monkeys, 650

Ethylene oxide—and reaction products, GLC analysis, sterilized bulk drugs and formulations, 789

***N*-Ethyl-3-piperidyl benzilate**—metabolism in rats, 931

Etomidate—mass fragmentographic analysis, human plasma, 1344

Eupatorium altissimum—aqueous ethanol whole plant extract, two flavones isolated, cytotoxic and antitumor activity evaluated, 600

Eustoma grandiflorum—methanol extract of roots, six polyoxygenated xanthones isolated, 828

Excipients—gluconolactone in directly compressed tablets of various drugs, effect on physical characteristics, 370

Excretion—acetaminophen, effect of aspirin, radiochemical analysis, mice, 1399
—isoniazid, effect of various drugs, radiochemical analysis, rats, 1322
kinetics, capacity limited—iodipamide in dogs, 1670
—^{14}C-meglumine, rats and dogs, 96
—^{14}C-meglumine salicylate, oral administration, humans, 536
—phenolsulfonphthalein, effect of preadministration of sodium deoxycholate, humans, 727
—sulfamethazine, various dosage forms compared, cattle, 619
urinary—cycloheptylsulfamate and metabolites, rabbits and rats, 881
urinary—hydromorphone and metabolites, humans, rats, dogs, guinea pigs, and rabbits, 1709

F

Factor analysis techniques—used to determine therapeutic classes of various drugs, 304

Fatty acid analogs, ^{99m}Tc- and ^{57}Co-labeled—containing chelating agents, biological distribution, compared to ^{3}H-palmitic acid, rabbits, 225

FD&C Yellow No. 6—tablet coating, effect of sunscreening agents and various coating methods on color stability, 107

Fenbufen—and various analogs, synthesized and evaluated for anti-inflammatory and analgesic activity, 466

***Fenclorac* and metabolite**—spectrophotometric analyses, serum, 832
—kinetics of hydrolysis, stability in aqueous solution, various pH's and temperatures, liquid chromatographic analysis, 73

Fenfluramine—alone and combined with dextroamphetamine, sex-based differences in psychomotor and physiological effects, humans, 739

***Ferrous* ion**—spectrophotometric analysis, pharmaceutical formulations, 140
sulfate—bioavailability, delayed-release capsule compared to solution, piglets, 85

Fetal growth—effects of aspirin and acetaminophen, rats, 111

***Film coating,* enteric**—with methacrylic acid–methyl methacrylate copolymer, tablet disintegration time, mathematical model, 1070

Films, monomolecular—of enzymes at an air–water interface, surface exchange technique developed, 792
—pig heart mitochondrial malate dehydrogenase, effect of lipids on activity, 1465
—various dinoprost C-15 alkyl esters, compression–relaxation behavior compared, 823

Flavone C-glycosides, various—isolated from *Cannabis sativa*, effect on rat lens aldose reductase, 1358

Flavones—isolated from *Eupatorium altissimum* aqueous ethanol whole plant extract, cytotoxic and antitumor activity evaluated, 600

Flavonols—3,3′-bis(*O*-methyl)quercetin isolated from ethanol extract of aboveground parts of *Adenium obesum*, evaluated for cytotoxic activity, 1336

Flow rates, liquid—effect on particle-size distribution in spray granulations, 1462
powder—relationship to angles of repose and particle size in wet-processed granulations, 1235

Floxuridine—entrapment within sphingomyelin and lecithin liposomes, compared to fluorouracil, 984

Fluorene-9-spiro-2′-aziridines, various—synthesized, hydrolyzed to 9-chlorofluorene-9-carboxanilides, 1653

Fluorescence characteristics—azaperone and oxide, effect of pH, 1787
characteristics—glafenine in various solvents, effect of pH, 1771
spectrometry—binding of *N*-substituted anthracenecarboxamides to DNA, 1473
—study of reaction product of 17α-methyltestosterone with trichloroacetic acid, 1478

Fluorescent probes—study of binding of various sulfonamides to povidone, 1157

Fluorocarbon aerosol propellants—dichlorodifluoromethane, single and multiple dosing, pharmacokinetic model proposed, dogs, 49

Fluorometry—analysis, dextrorphan in human plasma, 1047
—analysis, methyldopa in biological fluids, 1632
—analysis, nadolol in human serum and urine, 1168
—analysis, naproxen in human serum, 433
—analysis, various cephalosporins, commercial samples in aqueous solutions, 213
—automated simultaneous analyses, canrenone and canrenoic acid, serum, 1131
—binding of benz[*a*]anthracene and benzo[*a*]pyrene to human serum albumin, 209
—study of *Limulus* hemocyanin oxygen binding and energy transfer, 1684
TLC—analyses, oxytetracycline and impurities in prepared solutions, 1419

Fluorouracil—ion-pair extraction from aqueous solutions with quaternary alkylammonium ions into organic solvents, 1190
—microbial kinetic analysis in biological fluids, pharmacokinetics in humans, 1422

Folic acid—TLC and high-pressure liquid chromatographic analyses, bulk drug, 1112

Formazans—of blue tetrazolium and triphenyltetrazolium, stability, effect of laboratory light, various solvents, 965

Ftorafur—GLC analysis, biological fluids, 1497

Funiferine *N*-oxide—isolated from extract of roots of *Tiliacora funifera*, structure elucidated, 1242

Furans, various—synthesized, evaluated for antibacterial and cytotoxic activity, 1052

G

Gallstones, model—cholesterol monohydrate pellets, dissolution kinetics in human, animal, and simulated bile, effect of interfacial resistance, 1101
—cholesterol monohydrate pellets, dissolution kinetics in simulated bile, effect of bile acid type and concentration, ratio to lecithin, and added electrolytes, 1094
—cholesterol monohydrate pellets, dissolution rate in synthetic bile, effect of various nitrogen-containing compounds and surfactants, 1105

Gas–solid chromatography—analysis, salicylic acid in commercial plaster pads, 731

Gastric emptying—effect of various polyethyleneimines, phenolsulfonphthalein and resin bead methods compared, rats, 899
rate—scintigraphic determination using ^{99m}Tc-labeled triethylenetetramine–polystyrene resin, humans, 442

Gelatin–acacia—coacervates, medicated and unmedicated microglobules prepared, physical parameters evaluated for use as dosage forms, 1327

Gels—aluminum hydroxide, acid neutralization, pH-stat titration, role of carbonate, 1533
—aluminum hydroxide, pH-stat titration evaluated, aging monitored, compared to other tests, 1528
—stability of benzoyl peroxide, effect of temperature, pH, and various gel ingredients, 718

GI absorption—effect of coating with perfluorooctyl bromide, rats, 907
—griseofulvin, effect of metoclopramide and propantheline preadministration, rats, 1540
—griseofulvin, indomethacin, and nalidixic acid, effect of stomach emptying rate, rabbits, 69

GI absorptivity—assessed for analogs of potential drug substances using everted rat intestinal sacs, 1249

GI effects—polyethyleneimine, oral and intravenous administrations compared, dogs, 902

GI microbleeding—buffered sodium acetylsalicylate, effect of various dosage forms, dogs, 124

GI motor activities—effect of pulmonary exposure to monomeric methyl methacrylate vapor, dogs, 613

Glafenine—fluorescence characteristics in various solvents, effect of pH, 1771

Glass dispersions—various corticosteroids, sugar carriers, dissolution rates compared to plain powder, 494
transition temperature—primidone–citric acid solid dispersion systems, effect of primidone concentration, 825

***Glaucium flavum* Grantz**—populations Isfahan and Kazerun, major alkaloids identified, 873

Glaucium oxylobum—aerial parts and roots, alkaloids isolated and identified, 593

GLC—analyses, acetaminophen, dichloralantipyrine, and isometheptene mucate in combination capsules, 604
—analyses, aceiohexamide and hydroxyhexamide, human plasma and urine, 635
—analyses, 6-aminopenicillanic acid and 7-amino-3-methyl-Δ^3-cephem-4-carboxylic acid, prepared samples, 1769
—analyses, epinephrine, isoproterenol, and phenylephrine, pharmaceutical dosage forms, 560

—analysis, acenocoumarol, human and dog plasma, 799
—analysis, acetazolamide, human blood, plasma, and saliva, 527
—analysis, anthranilic acid in plasma, 1645
—analysis, atropine sulfate in solutions and tablets containing diphenoxylate hydrochloride, 1553
—analysis, cannabinoids, device using a surface-coated open tube column, 114
—analysis, chlorthalidone in urine, 1732
—analysis, clindamycin palmitate hydrochloride, after acetylation catalyzed by 4-(dimethylamino)pyridine, 273
—analysis, codeine and morphine in human urine, 66
—analysis, conjugated estrogens, commercial formulations, 523
—analysis, *N,N*-dimethylaniline in various penicillins and cephalosporins, commercial samples, 1634
—analysis, ethinamate and hydroxy derivative in biological fluids, 992
—analysis, ethylene oxide and reaction products in sterilized bulk drugs and formulations, 789
—analysis, free and conjugated triclosan, human plasma and urine, 1166
—analysis, ftorafur in biological fluids, 1497
—analysis, glycerin in plasma, 1027
—analysis, ibuprofen in human serum, 749
—analysis, indoprofen in human plasma, 132
—analysis, lasalocid and bromo analog, various preparations and dosage forms, 769
—analysis, lidocaine in human plasma, 1383
—analysis, meperidine, human plasma, 599
—analysis methenamine, commercial tablets, 589
—analysis, methsuximide and metabolite, dog plasma, 688
—analysis, opium alkaloids in papaveretum, prepared samples, 421
—analysis, oxamniquine, human serum or plasma, 429
—analysis, phenytoin in plasma, 1510
—analysis, propranolol in human plasma, 1490
—analysis, Δ^9-tetrahydrocannabinol in biological fluids, 20
—analysis, thebaine in root and aboveground portion of various strains of *Papaver bracteatum*, 1716
—analysis, triclocarban, rat and human blood, 725
and GLC–mass spectrometry—analyses and identification of phenytoin metabolites in human, monkey, and dog urine, 1596
–chemical-ionization mass spectrometry—analysis, methadone in plasma and urine, 1579
electron capture—analysis, isosorbide dinitrate and metabolites, plasma, 1143
electron capture—analysis, isosorbide dinitrate, human plasma, 384
electron capture—analysis, pentobarbital in human serum, retention times, various barbiturates, 477
electron capture—analysis, salsolinol in mouse brain tissue, 893
—identification, diacetylmorphine metabolites, human urine, 201
–mass spectrometry—analyses, amitriptyline and nortriptyline in human plasma, 77
–mass spectrometry—analyses, phenacetin and acetaminophen, human plasma, 340
–mass spectrometry—analysis, methotrimeprazine and four metabolites, human plasma and urine, 190
–mass spectrometry—analysis, methylphenidate in biological fluids, pharmacokinetic study in rats, 866
–mass spectrometry—analysis, psilocin and psilocybin in extract of mushroom *Psilocybe cubensis*, 743
–mass spectrometry—analysis, trimethylsilyl derivatives of biotin, structure determined, 1212
–mass spectrometry—study of conversion of D,L-α-^{13}C-histidine to histamine by histidine decarboxylase, 1660
–mass spectrometry—thermal decomposition of 1,3-dimethyl derivatives of phenobarbital, major products identified, 578
radiochemical—analysis, nortriptyline in human plasma, 1056
retention indexes—attempted correlation with molecular connectivity indexes of various alcohols, ethers, esters, and ketones, 1630
—separation of diastereomeric amide derivatives of amphetamine and related compounds after reaction with chiral acylating reagent, 169
—simultaneous analyses, phenacetin and acetaminophen in plasma, 1628
Glucocorticoids—hydrocortisone, dissolution into simulated intestinal fluid from solid solutions of cholesterol or various esters, effect on surface tension, 1536
—prednisolone acetate, multisized suspensions, dissolution profiles and particle-size measurements, 557
—prednisolone, bioavailability and pharmacokinetics, various dosage forms compared, dogs, 1751
various—kinetics of reaction with blue tetrazolium, effect of temperature, mechanism proposed, 1385
various—UV photometric analysis, bulk drug and pharmaceutical formulations, 1145
Gluconolactone—excipient in directly compressed tablets of various drugs, effect on physical characteristics, 370
Glucose transport, intestinal—effect of chronic administration of parathion or paraoxon, rats, 879
L-Glutamic acid dehydrogenase—binding of nonionic detergent, 876
Glutarimides, substituted—various derivatives synthesized, antineoplastic activity evaluated, mice, 232
Glyburide, micronized—dissolution, various multiparticulate models fit to data, rate and size distribution parameters evaluated, 761
Glycerin—GLC analysis, plasma, 1027
Gonadotropin, human chorionic—various commercial preparations, presence of inhibitory contaminants, 1773
Granulations, spray—effect of liquid flow rate on particle-size distribution, 1462
wet processed—relationships among volumetric powder flow rates, angles of repose, and particle size, 1235
Griseofulvin—dispersed in polyethylene glycol 6000, X-ray diffraction study, aqueous solubility, effects of pulverization and aging, 989
—GI absorption, effect of metoclopramide and propantheline preadministration, rats, 1540
—GI absorption, effect of stomach emptying rate, rabbits, 69
Guaifenesin—high-pressure liquid chromatographic analysis, cough syrup, 895

H

Hallucinogenics—psilocin and psilocybin, GLC–mass spectral analysis in extract of mushroom *Psilocybe cubensis*, 743
Harmaline—cardiovascular activity in dogs, 1244
Harmalol—cardiovascular activity in dogs, 1244
Harmine—cardiovascular activity in dogs, 1244
Helenalin—isolated from whole plant chloroform extract of *Anaphalis morrisonicola*, 1194
Hematinics—ferrous ion, spectrophotometric analysis in pharmaceutical formulations, 140
—ferrous sulfate, bioavailability, delayed-release capsule compared to solution, piglets, 85
Hemocyanin, *Limulus*—oxygen binding energy transfer, fluorometric study, 1684
Hemodialysis—effect on protein binding of cefazolin, 1508
Hetacillin—epimerization and hydrolysis in aqueous solution, effect of pH and temperature, 1004
methoxymethyl ester—pharmacokinetics, plasma, prostatic fluid, and spinal fluid levels, dogs, 345
Heterocycles—various pyrroles, furans, and thiophenes synthesized, evaluated for antibacterial and cytotoxic activity, 1052
1-Hexanoic acid—aqueous chamber volume of distribution, rabbit eyes, 219
Hexocyclium—antisecretory and antimotility effects compared to propantheline and isopropamide, humans, 1433
High-performance liquid chromatography—analyses, perphenazine and amitriptyline hydrochloride, two-component pharmaceutical formulations, 1117
—analysis, chlordiazepoxide and related impurities, commercial formulations, 684
—analysis, diethylpropion hydrochloride in tablets, identification of two decomposition products, 198
—analysis, isoniazid, tablets and injectables, 564
—analysis, methadone hydrochloride in liquid pharmaceutical preparation, 1749
—study of epimerization of anhydrotetracycline in acid solution, 1159
High-pressure liquid chromatography—analyses, antipyrine and benzocaine in commercial combination, 897
—analyses, codeine phosphate, guaifenesin, and phenylpropanolamine hydrochloride, cough syrup, 895
—analyses, isoniazid and acetyl derivative, plasma and urine, 813
—analyses, metoclopramide and various metabolites in rat, dog, and human urine, 1615
—analyses, oxytetracycline, tetracycline, and chlortetracycline in urine, 1319
—analyses, procainamide and *N*-acetyl derivative, human plasma, 874
—analyses, sulfacetamide, sulfathiazole, and sulfabenzamide in mixtures, 1784
—analysis, cimetidine, blood and urine, 1148
—analysis, dansyl derivatives of *N*-(monoaminoalkyl)- and *N*-(polyaminoalkyl)acetamides, human urine, 1195
—analysis, dantrolene sodium, biological fluids, 751
—analysis, dantrolene sodium, commercial dosage forms, 286
—analysis, 2,4-disulfamyl-5-trifluoromethylaniline in hydroflumethiazide prepared samples and tablets, 877
—analysis, epinephrine, liquid pharmaceutical preparations, 425
—analysis, folic acid bulk drug, 1112
—analysis, mefloquine in whole blood, plasma, and urine, 834
—analysis, methotrexate in commercial preparations, 1219
—analysis, phenol in pharmaceutical preparations, 1201
—analysis, polythiazide in pharmaceutical formulations, 736
—analysis, *cis*- and *trans*-prostaglandin A_2, 744
—analysis, Δ^9-tetrahydrocannabinol in biological fluids, 20
—analysis, thimerosal in pharmaceutical formulations, 738
—analysis, tocainide, plasma or blood, 583
—analysis, warfarin in human plasma, 142
—determination, dansyl derivatives of *N*-(monoaminoalkyl)- and *N*-(polyaminoalkyl)acetamides, human urine, 1089
—determination of lipophilic indexes of various penicillins and cephalosporins, correlated to partition coefficients, 747
–mass spectrometry—analysis, Δ^9-tetrahydrocannabinol, human plasma after smoking marijuana, 1263
reversed phase—analysis, benzoic and salicylic acids, pharmaceutical formulations, 110
reversed phase—simultaneous analysis, niacin and niacinamide in multivitamin preparations, 40
High-speed liquid chromatography—analyses, dapsone and related compounds, bulk drug, pharmaceutical formulations, and biological fluids, 1618
—analysis, 4-nitro-2-phenoxymethanesulfonanilide in plasma, 1700
—analysis, pilocarpine in pharmaceutical preparations, 1625
Histamine—binding to peptide H, effect of alkali metal

and alkaline earth cations, association constants determined, 542
H_2-receptor antagonists—cimetidine, high-pressure liquid chromatographic analysis, blood and urine, 1148
D,L-α-^{13}C-Histamine—conversion from histidine by histidine decarboxylase, ^{13}C-NMR and GLC–mass spectral study, 1660
D,L-α-^{13}C-Histidine—conversion to histamine by histidine decarboxylase, ^{13}C-NMR and GLC–mass spectral study, 1660
Homatropine methylbromide—spectrophotometric analysis, pharmaceutical formulations, 123
Hormones—conjugated estrogens, enzyme hydrolysis and GLC analysis, commercial formulations, 523
—luteinizing hormone releasing hormone, various synthetic preparations analyzed by TLC and radioimmunoassay, potencies determined, rat anterior pituitary cells, 386
—progesterone in sustained-release cholesterol implant pellets, *in vivo* and *in vitro* release, biological effectiveness, rabbits and rats, 490
—progesterone, release from silicone matrixes, *in vitro* system compared to bovine intravaginal device *in vivo*, 816
Hydrazides, *N'*-substituted—of indolizine-2-carboxylic acid synthesized, screened for effect on monoamine oxidase activity, 259
—of 2-methyl-3-indolizinecarboxylic acid synthesized, evaluated for effect on monoamine oxidase activity, 1355
Hydrazines, substituted—synthesized, antitumor activity evaluated, 849
Hydrazones—formed by reaction of isoniazid and 4-nitrobenzaldehyde or pyridoxal, colorimetric analysis, 291
Hydrocarbons—benz[*a*]anthracene and benzo[*a*]-pyrene, binding to human serum albumin, fluorometric analysis, 209
Hydrocortisone—dissolution into simulated intestinal fluid from solid solutions with cholesterol or various esters, effect on surface tension, 1536
—interaction with pure and mixed monolayers of lecithin and cholesterol, 975
Hydroflumethiazide—prepared samples and tablets, high-pressure liquid chromatographic analysis of its precursor 2,4-disulfamyl-5-trifluoromethylaniline, 877
Hydrolysis—7-acetylacroninium perchlorate, mechanism determined, 1501
—aspirin, effect of sodium bisulfite, various pH values, 1775
—fenclorac in aqueous solutions, kinetics, various pH's and temperatures, liquid chromatographic analysis, 73
—hetacillin in aqueous solution, effect of pH and temperature, 1004
—nitrazepam, kinetics and mechanisms, 795
—oxazepam and diazepam, kinetics and mechanism, effect of pH, 573
—various fluorene-9-spiro-2'-aziridines to 9-chlorofluorene-9-carboxanilides, 1653
Hydromorphone and metabolites—urinary excretion in humans, rats, dogs, guinea pigs, and rabbits, 1709
Hydroxamic acid derivatives—(pyrrolidone-5-hydroxamato)iron(III) mono, bis, and tris chelates, stability constants in aqueous solutions, 330
Hydroxides, slightly soluble—zero point of charge related to solubility product, 1548
21-Hydroxycorticosteroids, various—UV photometric analysis, bulk drug and pharmaceutical formulations, 1145
Hydroxyhexamide—GLC analysis, human plasma and urine, 635
Hydroxylation—three benzodiazepines by rat and mouse liver microsomal enzymes *in vitro*, 1482
Hydroxyphthalate esters, mono- and bis(2-ethylhexyl)—synthesized and characterized by PMR and mass spectra, 546
Hydroxyureas, various—solvent-dependent conformation in octanol–water, effect on ribonucleotide reductase activity *in vitro*, 1040
***N*-Hydroxyureas,** cyclic—various derivatives synthesized, anticancer activity evaluated, 1556
Hydroxyxanthones—six isolated from methanol extract of roots of *Eustoma grandiflorum*, 828
Hyperosmolar dehydrating agents—glycerin, GLC analysis in plasma, 1027
Hyperthermia—combined with dextrose infusion and doxorubicin or dacarbazine, effect on survival of tumor-transplanted mice, 437
Hypnotics—etomidate, mass fragmentographic analysis, human plasma, 1344
—pentobarbital sodium, degradation kinetics in propylene glycol-based solutions, *in vivo* effects in laboratory animals, 693
Hypothermia—induced by sodium nitroprusside, effect of various routes of administration and various ambient temperatures, mice, 1658

I

Ibuprofen—effect on pharmacokinetics and anticoagulant action of warfarin, rats, 943
—effect on protein binding of warfarin, human serum, 1060
—GLC analysis, human serum, 749
Idoxuridine—metabolism in cerebrospinal fluid, effect of rapid perfusion and molecular modification, dogs, 1338
2,4-Imidazolidinedione, substituted—synthesized, screened for antibacterial activity, 277
Imidazo[4,5-*f*]quinolines, substituted—synthesized, screened for antibacterial activity, 1204
Imipramine—effect of pregnenolone-16α-carbonitrile on pharmacological activity, *in vivo* metabolism, and distribution, rats, 1492
tablets—impurities, TLC, GLC, and mass spectral analysis, 1015
Immunoglobulins—human IgG1, effect of chemical modifications on complement activity, 427
Immunological systems—complement, mechanism of activation, associated biological effects, role in human diseases, inhibitory drugs, review, 1367
Immunosuppressive activity—cryogenine evaluated in developing and established adjuvant arthritis, rats, 1304
Impurities—in imipramine and desipramine tablets, TLC, GLC, and mass spectral analysis, 1015
Indole binding site—on defatted human serum albumin, functional modification with indomethacin and congeners, 950
2-Indolizinecarboxylic acid hydrazides—synthesized, screened for effect on monoamine oxidase activity, 259
Indolizines—various *N'*-substituted hydrazides of 2-methyl-3-indolizinecarboxylic acid synthesized, evaluated for effect on monoamine oxidase activity, 1355
substituted—series synthesized, evaluated for pharmacological activity, 1692
2-Indolyl 5-pyridyl ketone derivatives—synthesized, screened for cytotoxic activity, 263
Indomethacin and congeners—effect on binding of L-tryptophan by defatted human serum albumin, 950
—degradation in alkaline aqueous solutions, various temperatures, kinetics, effect of ionic strength, 27
—degradation kinetics in presence of ionic and nonionic surfactants in alkaline solutions, 1259
—effect on lysosome and protein stability *in vitro*, compared to other drugs, 1651
—GI absorption, effect of stomach emptying rate, rabbits, 69
—radioimmunoassay, human plasma and urine, 486
Indoprofen—GLC analysis, human plasma, 132
Inhibitory contaminants—presence in various commercial preparations of human chorionic gonadotropin, 1773
Inotropic effects—mescaline on isolated rat atria, 938
Insecticides—parathion and paraoxon, chronic administration, effect on intestinal glucose and calcium transport, rats, 879
Instrumentation—automatic capsule-filling machine, explanation of activity of strain gauges, 1507, 1508
—described for monitoring compression and ejection forces in automatic capsule-filling machine, 504
Interactions, drug–biomolecule—various acidic and basic drugs with β-lipoproteins, 420
drug—isoniazid, absorption, tissue distribution, excretion, and metabolism, effect of aspirin, rifampin, ethambutol, ethanol, and phenobarbital, radiochemical analysis, rats, 1322
drug—tolbutamide and sulfadimethoxine, kinetic analysis, sheep, 1063
Interparticulate translocations—polydisperse particulate solids, agitated beds, in terms of Markov chains, 104
Intestinal uptake, isolated—prostaglandin E_1 and dinoprost, effect of aggregation with calcium ions, 1308
Intraocular pressure—mechanism of methacholine-induced rise, effect of phenylephrine, dogs, 1013
Intravenous dosage forms—automated counter particle analysis proposed as quality control method, 181
Inulin—aqueous chamber volume of distribution, rabbit eyes, 219
Iodipamide—capacity-limited excretion kinetics, dogs, 1670
Iodochlorhydroxyquin—and conjugate, TLC analysis, biological fluids, 1334
Ion-exchange chromatography—isolation, two anticomplement factors from cobra venom, 947
liquid chromatography—analysis, various prostaglandins after cyclodextrin complexation, prepared samples, 706
Ionization characteristics—phenytoin in various buffers and hydroalcoholic solutions, 994
constants—cephalosporin zwitterionic compounds, error in equations corrected, 1357
—various estrogens, effects of structural differences, 624
Ion-pair extraction—fluorouracil from aqueous solutions with quaternary alkylammonium ions into organic solvents, 1190
Ion-pairs—meclizine hydrochloride–methyl orange, spectrophotometric analysis, pharmaceutical dosage forms and biological fluids, 710
Iprindole—pretreatment, effect on biological disposition of amphetamine and analogs with rigid conformations, rats, 271
Iris dilator muscle response—effect of levarterenol and phenylephrine, roles of neuronal and extraneuronal uptake mechanisms, rabbits, 93
Iron—bioavailability, ferrous sulfate delayed-release capsule compared to solution, piglets, 85
—ferrous ion, spectrophotometric analysis, pharmaceutical formulations, 140
Iron(III) chelates—mono, bis, and tris, with pyrrolidone-5-hydroxamic acid, stability constants in aqueous solutions, 330
IR spectrophotometry—analysis, carbachol, absorbance calculation, error reported, 1211
—analysis, carbachol, commercial ophthalmic preparations, 439
—analysis, meprobamate, commercial dosage forms, 292
Isergonic profiles, solvation—geometric analysis of scatter as a function of vertical, horizontal, and perpendicular distances from error line, 30
Isometheptene mucate—GLC analysis in capsules with acetaminophen and dichloralantipyrine, 604
Isoniazid—absorption, tissue distribution, excretion, and metabolism, effect of aspirin, rifampin, ethambutol, ethanol, and phenobarbital, radiochemical analysis, rats, 1322
and acetyl derivative—high-pressure liquid chromatographic analyses, plasma and urine, 813
—bioavailability of three commercial formulations compared, 1761
—colorimetric analysis, hydrazones formed with 4-nitrobenzaldehyde or pyridoxal, prepared samples, 291
—high-performance liquid chromatographic analysis, tablets and injectables, 564
Isopilocarpine—^{13}C-NMR analysis in commercial ophthalmic formulations of pilocarpine hydrochloride, 638

Isopropamide—antisecretory and antimotility effects compared to propantheline and hexocyclium, humans, 1433
Isoproterenol—effect on fetal rat heart rate related to levels of cyclic adenosine monophosphate, organ culture, 1450
—GLC analysis, pharmaceutical dosage forms, 560
Isosorbide dinitrate—and metabolites, electron-capture GLC analysis, plasma, 1143
—electron-capture GLC analysis, human plasma, 384
—pharmacokinetics, oral and sublingual administration compared, standard and sustained-release tablets compared, humans, 775
Isotope dilution–radioimmunoassay—analysis of sulindac and metabolites, human plasma and urine, 414
Isoxazolium salts, substituted—polarographic reduction, effect of pH, polar contribution of 5-aryl substituents correlated with antibacterial activity, 597

J

Jatropha macrorhiza—ethanol extract of roots, acetylaleuritolic acid isolated and evaluated for antitumor activity, 1348

K

Keratolytics—benzoyl peroxide, stability in pharmaceutical gels, effect of temperature, pH, and various gel ingredients, 718
—salicylic acid, gas–solid chromatographic analysis in commercial plaster pads, 731
—salicylic acid, reversed-phase high-pressure liquid chromatographic analysis, pharmaceutical formulations, 110
Kinetic parameters—compartment with exponential absorption rate and first-order elimination rate, two methods for quick estimation, 127
—estimated by numerical algorithms and multiple linear regression, 1688
Kinetics—analysis of tolbutamide–sulfadimethoxine interaction, sheep, 1063
degradation—indomethacin in alkaline aqueous solutions, various temperatures, effect of ionic strength, 27
degradation—indomethacin in presence of ionic and nonionic surfactants in alkaline solutions, 1259
degradation—substituted thiazol-3-ol, in aqueous media, effect of temperature, pH, and ionic strength, 1175
dissolution—soluble nondisintegrating disks, equation developed, related to cube root law, 1696
reaction—complexation of nickel(II) with penicillin G and related compounds, 533
time dependent—valproic acid, steady-state plasma levels, monkeys, 1154

L

β-Lactam antibiotics—apparent partition coefficients in octanol–water and 2-methylpropanol–water at various pH values, 1675
Lasalocid and bromo analog—GLC analysis, various preparations and dosage forms, 769
LD_{50} testing—relative absorption rate and toxicity of various formulations of poorly soluble drugs evaluated, mice, 1567
Lecithin—monolayers, pure and mixed with cholesterol, interaction with hydrocortisone, 975
—ratio to bile acid concentration, effect on dissolution kinetics of cholesterol monohydrate pellets in simulated bile, 1094
Leprostatic antibacterials—dapsone and related compounds, high-speed liquid chromatographic analyses, bulk drug, pharmaceutical formulations, and biological fluids, 1618
Levarterenol—effect on iris dilator muscle response, roles of neuronal and extraneuronal uptake mechanisms, rabbits, 93
—pressor responses, effect of pentazocine, rats, 1652
Levodopa melanin, synthetic—competitive binding with cocaine and various drugs, 1544
Lidocaine and various metabolites—chemical-ionization mass spectrometric and stable isotope labeling analyses, human plasma and urine, 1180
—GLC analysis in human plasma, pharmacokinetics, 1383
Lignans—dehydrodiisoeugenol isolated from ethanol–water extract of aboveground parts of *Aristolochia taliscana*, 1489
***Limulus* hemocyanin**—oxygen binding, energy transfer fluorometric study, 1684
Lipid levels, serum—effect of substituted tetrahydrocarbazole, rats, 348
Lipids—cholesterol and various esters, solid solutions with hydrocortisone, dissolution into simulated intestinal fluid, effect on surface tension, 1536
—effect on activity of pig heart mitochondrial malate dehydrogenase monomolecular films, 1465
skin surface—effect on protection time of diethyltoluamide, humans, 1764
Lipophilic indexes—log k' of various penicillins and cephalosporins determined by high-pressure liquid chromatography, correlated to partition coefficients, 747
β-Lipoproteins—interaction with various acidic and basic drugs screened, 420
Liposomes, sphingomyelin and lecithin—entrapment of floxuridine, compared to fluorouracil, 984
Liquid chromatography—analysis, fenclorac in aqueous solutions, 73
Lithium carbonate—bioavailability, calculations based on perturbation of renal clearance, commercial dosage form, 609
Litmomycin—effect on viral DNA polymerase activity *in vitro,* reaction kinetics and mechanism, 130
Lubrication, surface—effect of duration of lubricant–excipient mixing on physical properties of tablets and processing characteristics of powders, 1377
Luteinizing hormone releasing hormone—various synthetic preparations analyzed by TLC and radioimmunoassay, potencies determined, rat anterior pituitary cells, 386
Lysine—effect on blood levels, withdrawal reaction, and toxicity of ethanol, mice, 35
Lysosomes—stability, effect of indomethacin *in vitro,* compared to other drugs, 1651

M

Magnesium—chelate with dicumarol prepared, structure elucidated, 1124
trisilicate—adsorption of chloroquine, effect on acid reactivity, 289
Malate dehydrogenase, mitochondrial—spread as a monomolecular film at an air–water interface, surface exchange technique developed, 792
pig heart mitochondrial—monomolecular films, effect of lipids on activity, 1465
Maleic anhydride–acid copolymers—with methyl vinyl ether, potentiometric characterization of composition and measurement of dissolution profiles, 713
Marijuana constituents—Δ^9-tetrahydrocannabinol, high-pressure liquid chromatographic–mass spectrometric analysis, human plasma after smoking marijuana, 1263
flavonoids—various flavone C-glycosides, effect on rat lens aldose reductase, 1358
—GLC analysis of constituents, device using a surface-coated open tube column, 114
Marine antineoplastic agents, potential—sphyrnastatins isolated from hammerhead shark, 757
Markov chains—polydisperse particulate solids, agitated beds, interparticulate translocations, 104
Mass fragmentography—analysis, etomidate in human plasma, 1344
Mass spectrometry—characterization of mono- and bis(2-ethylhexyl) esters of 3- and 4-hydroxyphthalic acid, 546
chemical ionization—various phenothiazines and oxygenated analogs, 228
electron impact and field desorption—structural identification of cascarosides A and B, 1300
—mechanism of fragmentation of various cannabinoids, 1444
Meclizine hydrochloride—spectrophotometric analysis using ion-pair extraction with methyl orange, pharmaceutical dosage forms and biological fluids, 710
Mefloquine—high-pressure liquid chromatographic analysis, whole blood, plasma, and urine, 834
^{14}C-Meglumine—absorption, distribution, and excretion, rats and dogs, 96
salicylate—synthesized, administered orally, biological distribution and excretion measured, humans, 536
Melanin, synthetic levodopa—competitive binding with cocaine and various drugs, 1544
Membrane permeation—three *p*-aminobenzoate esters through tubular dimethyl polysiloxane membrane into a flowing liquid, 337
transport—convective diffusion model applied to permeation rate of butamben through dimethicone membrane, 137
Membranes, model—pure and mixed monolayers of lecithin and cholesterol, interaction with hydrocortisone, 975
Meperidine—GLC analysis, human plasma, 599
Meprobamate—IR spectrophotometric analysis, commercial dosage forms, 292
Mercaptopurine—pharmacokinetics in rats, 1454
—polymorphic form, dissolution rate, differential thermographic and X-ray diffraction analyses, 608
Mercaptotriazoles, various—synthesized, evaluated for anticonvulsant activity and effect on NAD-dependent oxidations, rats, 971
Mercuric chloride—effect on urine and plasma osmolality compared to various diuretic agents, dogs, 501
Mescaline—chronotropic and inotropic effects on isolated rat atria, 938
Metabolism—acetaminophen, effect of aspirin, radiochemical analysis, mice, 1399
—bunolol in dogs, metabolites and conjugates identified in urine, 1570
—canrenoate potassium, radiochemical study, rabbits, 275
—cycloheptylsulfamate, rabbits and rats, 881
drug—simultaneous with transport in skin, model and equations developed permitting *in vitro* assessment of bioavailability, 1525
drug—topically applied, quantitative skin model assuming inactive stratum corneum and viable, enzyme-containing epidermis, 755
—*N*-ethyl-3-piperidyl benzilate in rats, 931
—idoxuridine in cerebrospinal fluid, effect of rapid perfusion and molecular modification, dogs, 1338
—imipramine, effect of pregnenolone-16α-carbonitrile, rats, 1492
—isoniazid, effect of various drugs, radiochemical analysis, rats, 1322
—sulfamethazine, various dosage forms compared, cattle, 619
—terbutaline, effect of salicylamide, rats, 1488
—three benzodiazepines, hydroxylation by rat and mouse liver microsomal enzymes *in vitro,* 1482
Metabolites—diacetylmorphine, identified using TLC, GLC, and column chromatography, human urine, 201
—hydromorphone, urinary excretion in humans, rats, dogs, guinea pigs, and rabbits, 1709
various—of metoclopramide, isolated and identified, high-pressure liquid chromatographic analyses, rat, dog, and human urine, 1615
Metal-ion contaminants—effect on degradation of amitriptyline hydrochloride in aqueous solution, 1087
Metal ions—nickel(II), complexation with penicillin G and related compounds, reaction kinetics, 533
Metals—alkali metal and alkaline earth cations, effect on binding of histamine to peptide H, 542
—magnesium, chelate with dicumarol prepared, structure elucidated, 1124
—zinc as chloride, alone and complexed with 1,10-phenanthroline, teratogenic effects evaluated in mice, 1755

—zinc, various salts, chelates, and other complexes, effect on serum zinc levels, rats, 391
Methacholine—mechanism of induced rise in intraocular pressure, effect of phenylephrine, dogs, 1013
Methacrylic acid—methyl methacrylate copolymer—enteric film coating of tablets, disintegration time, mathematical model, 1070
Methadone—binding to human serum proteins, 802
—GLC–chemical-ionization mass spectrometric analysis in plasma and urine, deuterium-labeled enantiomers and racemates synthesized, 1579
hydrochloride—high-performance liquid chromatographic analysis, liquid pharmaceutical preparations, 1749
Methenamine—GLC analysis, commercial tablets, 589
Methotrexate—high-pressure liquid chromatographic analysis, commercial preparations, 1219
Methotrimeprazine and metabolites—GLC–mass spectral analysis, human plasma and urine, 190
10α-Methoxy-Δ^{8,9}-lysergaldehyde—synthesized by oxidation of elymoclavine with manganese dioxide in methanol, 1340
Methoxyxanthones, various—NMR spectra and solvent shift data, 884
Methsuximide and metabolite—pharmacokinetics in dogs after single intravenous doses, GLC analysis in plasma, 688
***O*-(α- and β-Methylcholinyl) ether** derivatives of oximes—synthesized, enantiomeric and geometric isomers separated, anticholinergic activity evaluated, 1120
β-Methyldigoxin—intravenous, pharmacokinetics in humans, radiochemical–TLC study, 242
—oral and intravenous, effect on left ventricular ejection time and heart rate correlated with pharmacokinetic parameters, humans, 326
—oral and intravenous, pharmacokinetics, radioimmunoassay compared to radiochemical spectrometric assays, human plasma, 806
—oral, pharmacokinetics and bioavailability in humans, radiochemical–TLC study, 314
Methyldopa—fluorometric analysis, biological fluids, 1632
3-Methyleneoxindole—latentiated derivatives synthesized and evaluated for cytotoxic activity, 1022
Methyl methacrylate monomeric vapor—pulmonary exposure, effects on GI motor activities, dogs, 613
2-Methyl -3- nitropyridine -6- carboxaldehyde—color reagent in analysis of dihydralazine sulfate in prepared samples, 116
α-Methyl-(±)-ornithine—radiochemical study of metabolism in mice, effects on polyamine biosynthesis in leukemic mice, *tert*-butyl ester synthesized, 1586
Methylphenidate—GLC–mass spectrometric analysis in biological fluids, pharmacokinetics in rats, 866
17β-Methyltestosterone—fluorescence of reaction product with trichloroacetic acid, 1478
Methyl vinyl ether–maleic anhydride–acid copolymers—potentiometric characterization of composition and measurement of dissolution profiles, 713
Metoclopramide—effect of preadministration on GI absorption of griseofulvin, rats, 1540
—high-pressure liquid chromatographic analysis, various metabolites isolated and identified, rat, dog, and human urine, 1615
Micellar distribution—ultracentrifugal study of apparent partition coefficients of various drugs between water and micellar pseudophase, 858
Michelia champaca—parthenolide and costunolide isolated from ethanol extract of bark, cytotoxic activity evaluated, 883
Microbial kinetics—analysis, fluorouracil in biological fluids, 1422
Microbiological turbidimetry—antibiotic and vitamin assays, procedures devised to linearize curved calibration lines, 1520
Microcapsules—formulated, potential as timed-release parenteral dosage form and organ-imaging radiopharmaceutical evaluated *in vitro* and *in vivo*, mice, 172
Microencapsulation—of solids by spray polycondensation, effect of composition, pH, and viscosity, 631
Microglobules—medicated and unmedicated, prepared from gelatin–acacia coacervates, physical parameters evaluated for use as dosage forms, 1327
Migration, drug—during drying of tablet granulations, effect of binder solution viscosity and temperature, 1409
—during drying of tablet granulations, effect of particle size of major diluent, 1406
Minoxidil—radioimmunoassay, human serum, 1266
Models, absorption—everted rat intestinal sacs, GI absorptivity assessed for analogs of potential drug substances, 1249
dissolution—multiparticulate systems under sink and nonsink conditions, generally applicable equations derived, 1435
mathematical—cyclocytidine pharmacokinetics in humans, 1441
mathematical—disintegration time of tablets with enteric film coating of methacrylic acid–methyl methacrylate copolymer, 1070
mathematical—extended to fit *in vitro* drug release system where drug concentration is greater than solubility in vehicle, 926
mathematical—kinetic parameters estimated by numerical algorithms and multiple linear regression, 1688
pharmacokinetic—for digoxin disposition in dog, developed, applied to humans, 1679
Moisturizers—effect on bioavailability and activity of betamethasone benzoate in quick-break aerosol foam and semisolid dosage forms, 99
Molecular connectivity indexes—attempted correlation with GLC retention indexes of various alcohols, ethers, esters, and ketones, 1630
—related to structure–activity relationships, various types of molecules, 642
—relationship to E_s parameter used to estimate steric effects in organic reactions, 1352
Molecular modification—idoxuridine to uronic acid derivative, effect on metabolism in cerebrospinal fluid, dogs, 1338
Monoamine oxidase activity—effect of various *N*-substituted hydrazides of indolizine-2-carboxylic acid, 259
activity—effect of various *N*-substituted hydrazides of 2-methyl-3-indolizinecarboxylic acid, 1355
—deamination of tyramine and tryptamine, effect of 3,4-dimethoxyphenethylamine and *N*-methyl homologs, 1048
Monolayer interactions—various aliphatic alcohols, free energies of adsorption and energies of interaction with phospholipids at air–water interface, 1229
Monolayers—lecithin and cholesterol, pure and mixed, interaction with hydrocortisone, 975
Montmorillonite—effect on bioavailability of amphetamine sulfate, urinary recovery studies, applied to sustained-release dosage form, 63
Morphine—adsorption onto glassware during fluorometric analysis, effect of siliconization, 1044
—binding to human serum proteins, 802
—bioavailability analyzed using pupil diameter measurements, 580
derivatives, various—synthesized, analgesic activity evaluated, monkeys, 285
metabolites, various—column chromatographic and TLC isolation from human urine, 1288
—radioimmunoassay–GLC analysis, human urine, 66
—spin labeled in 6-position, effect on binding to brain receptors and analgesic activity, 1054
Multiparticulate systems—dissolution model under sink and nonsink conditions, generally applicable equations derived, 1435
Mutagenicity—evaluated in coralyne and related compounds, compared to 7,12-dimethylbenz[*a*]-anthracene, 1781
Myocardial infarction—damage correlated with serum creatine phosphokinase levels, rats, 1483

N

NAD-dependent oxidations—effect of various thiosemicarbazides, mercaptotriazoles, and triazolethioglycolic acids, rat brain homogenates, 971
Nadolol—fluorometric analysis, human serum and urine, 1168
Nalidixic acid—GI absorption, effect of stomach emptying rate, rabbits, 69
Naproxen—fluorometric analysis, human serum, 433
Narcotic analgesics—codeine sulfate, teratogenic activity evaluated, mice, 1727
—hydromorphone and metabolites, urinary excretion in humans, rats, dogs, guinea pigs, and rabbits, 1709
—methadone, GLC–chemical-ionization mass spectrometric analysis in plasma and urine, deuterium-labeled enantiomers and racemate synthesized, 1579
—methadone hydrochloride, high-performance liquid chromatographic analysis in liquid pharmaceutical preparation, 1749
—morphine, adsorption onto glassware during fluorometric analysis, effect of siliconization, 1044
—various morphine metabolites, column chromatographic and TLC isolation from human urine, 1288
Narcotic anesthetics, topical—cocaine, competitive binding with various drugs to synthetic levodopa melanin, 1544
Narcotics—codeine and morphine, radioimmunoassay–GLC analysis in human urine, 66
—diacetylmorphine, metabolites identified using TLC, GLC, and column chromatography, human urine, 201
—GLC analysis of opium alkaloids in papaveretum, prepared samples, 421
potential—norcocaine synthesized, pharmacological activity evaluated, monkeys, 119
—thebaine, GLC analysis in root and aboveground portions of various strains of *Papaver bracteatum*, 1716
Nelumbo lutea—alcoholic extract of petioles, various alkaloids identified, 1627
Nephrotoxic agents—mercuric chloride, effect on urine and plasma osmolality compared to various diuretic agents, dogs, 501
Nerve impulse transmission—effects of intravenous administration of dimethyl sulfoxide anesthetized rabbits, 269
Neuronal and extraneuronal uptake mechanisms—roles in iris dilator muscle response, effect of levarterenol and phenylephrine, rabbits, 93
Niacin—absorption from stomach and small intestine compared, humans, 871
and niacinamide—simultaneous analysis, reversed-phase high-pressure liquid chromatography, multivitamin preparations, 40
Nicergoline—effect on muscular enzyme activity, rats, 1278
Nickel(II)—complexation with penicillin G and related compounds, reaction kinetics, 533
Nitidine—effect on catechol *O*-methyltransferase and tRNA methyltransferase activity, rat liver homogenate, 986
Nitrazepam—kinetics and mechanisms of hydrolysis, 795
solid—decomposition in microcrystalline cellulose, effect of temperature and humidity, 676
4-Nitroanisole—polarographic analysis in presence of 4-nitrophenol and 4-nitrocatechol, alkaline solutions, 60
Nitro aromatic compounds—1,3,5-trinitrobenzene and 2,4,6-trinitroanisole, NMR spectral characterization of products of reaction with ouabain or digitoxin, 753
4-Nitrocatechol—polarographic analysis in presence of 4-nitroanisole and 4-nitrocatechol, alkaline solutions, 60
Nitrofurantoin analog—synthesized, screened for antibacterial activity, 277
—aqueous solubility, effect of pyridoxine hydrochloride, 1357
—rectal absorption, effect of various suppository bases, humans, 955
Nitroglycerin—sorption by thermoplastic polymers

and stability of molded tablets in various strip packages, effect of povidone, 1293
—volatility, effect of various tablet components, thermogravimetric determination, 265
4-Nitrophenol—polarographic analysis in presence of 4-nitroanisole and 4-nitrocatechol, alkaline solutions, 60
4-Nitro-2-phenoxymethanesulfonanilide—high-speed liquid chromatographic analysis, plasma, 1700
NMR—analyses, silyl derivatives of 6-aminopenicillanic and substituted cephemcarboxylic acids, 1767
—analysis, trimethoprim and sulfamethoxazole, synthetic mixtures and commercial formulations, 121
^{13}C—analysis, pilocarpine hydrochloride and degradation products, commercial ophthalmic formulations, 638
^{13}C—study of conversion of D,L-α-^{13}C-histidine to histamine by histidine decarboxylase, 1660
—characterization of products of reaction of ouabain and digitoxin with 1,3,5-trinitrobenzene or 2,4,6-trinitroanisole, 753
—conformational study of cysteamine, thiazolidine, and derivatives in aqueous solutions, 483
proton and ^{13}C—analysis, diastereoisomer ratio of phenethicillin, bulk drug and commercial formulations, 1079
—spectra and solvent shift data, various methoxyxanthones, 884
—*spectrum, 2,4-dimethylbenzo[g]quinoline*, chemical shifts of methyl groups defined, effect of concentration, 1200
—*structural identification of cascarosides A and B*, 1300
Norcocaine—synthesized, pharmacological activity evaluated, monkeys, 119
Nortriptyline—GLC–mass spectrometric analysis, *human plasma*, 77
—radiochemical GLC analysis, human plasma, 1056
Nucleophilic addition—*bisulfite to dinoprostone and prostaglandin A_2*, effect on aqueous stability, 149
Nucleotides—adenosine diphosphate and triphosphate, effect on periodic acid oxidation of various phenothiazines, 1575

O

Octoxynol—effect of tetraalkylammonium salts and ammonium halides on cloud point, various salt concentrations, 165
Ocular bioavailability—pilocarpine, effect of vehicle composition and pH, rabbits, 1222
volumes of distribution—aqueous chamber, pilocarpine, inulin, and 1-hexanoic acid, rabbit eyes, 219
Ophthalmic cholinergics—pilocarpine, effect of vehicle composition and pH on ocular bioavailability, *rabbits, 1222*
—pilocarpine, high-speed liquid chromatographic analysis, pharmaceutical preparations, 1625
—*pilocarpine nitrate, bioavailability, effect of in*stilled volume, 1058
Ophthalmic formulations, commercial—^{13}C-NMR analysis of pilocarpine hydrochloride and degradation products, 638
Opiate antagonists, *potential—various N-substituted* benzomorphans synthesized, pharmacological activity and opiate-receptor binding evaluated, *193*
Opiates—codeine and morphine, radioimmunoassay–GLC analysis *in human urine*, 66
—morphine and codeine, spin labeled in 6-position, effect on binding to brain receptors and analgesic *activity, 1054*
Opium alkaloids—GLC analysis in papaveretum, prepared samples, 421
Oral administration—*sulfisoxazole*, interpretation of plasma concentration–time curves, rabbits, 178
Organoboron *compounds—carboxamido derivative* of tetracycline synthesized, UV, IR, and NMR spectral data and hydrolytic stability evaluated, *1505*
Osmolality, urine and plasma—effects of nephrotoxic and diuretic agents compared, dogs, 501
Ouabain—reaction with 1,3,5-trinitrobenzene or 2,4,6-trinitroanisole, NMR spectral characterization of products, 753
Oxamniquine—GLC analysis, human serum or plasma, 429
Oxazepam—kinetics and mechanism of hydrolysis, effect of pH, 573
2-Oxazolidinethiones, 5-substituted—synthesized, evaluated for antagonism to diethylstilbestrol effects, rats, 887
2-Oxazolidones, various—synthesized, evaluated as *topical mosquito repellents*, 587
Oxidation—degradation kinetics of phenothiazine and 10-methyl derivative in acidic oxygen-saturated medium, effect of pH, 1392
NAD dependent—effect of various thiosemicarbazides, mercaptotriazoles, and triazolethioglycolic acids, rat brain homogenates, 971
pathways—hydroxylated chlorpromazine metabolites, *electrochemical study, pH 3–8*, 357
—phenothiazine degradation in ethanol–water mixtures, mechanism suggested, 1395
photosensitized—various tetracyclines, reaction kinetics followed using polarographic oxygen electrode, effect of pH and copper(II) ions, 186
—various phenothiazines by periodic acid, effect of adenosine diphosphate and triphosphate, *1575*
Oxime *O*-ethers, various—isomers synthesized, anticholinergic activity of methylhalide salts evaluated *on rat ileum*, 1602
O-(α- and β-methylcholinyl) ethers—synthesized, enantiomeric and geometric isomers separated, anticholinergic activity evaluated, 1120
Oxindoles, substituted—latentiated derivatives synthesized and evaluated *for cytotoxic activity*, 1022
Oxygen binding—*Limulus* hemocyanin, fluorometric *study, 1684*
uptake—various drugs after UV irradiation, oxidation of 2,5-dimethylfuran determined using polarographic oxygen electrode, 1282
Oxytetracycline and impurities—TLC fluorometric *analyses in prepared solutions*, 1419
—factors affecting serum levels, calves, 1198
—high-pressure liquid chromatographic analysis, *urine*, 1319
tablets—tensile strength and dissolution, effect of various formulation and processing factors, *852*
Oxytocic agents—prostaglandin E_1 and dinoprostone, *stability at pH extremes*, 1590

P

Packaging materials, various—sorption by thermoplastic polymers and *stability of molded nitroglycerin tablets*, effect of povidone, 1293
Palladium(II) *coordination compound—degradation* kinetics in acidic and acid halide media, 1515
Papaver bracteatum—various strains, root and *aboveground portions, GLC analysis of thebaine*, 1716
Papaveretum—GLC analysis of opium alkaloids, *prepared samples*, 421
Papaverine—effect on muscular enzyme activity, rats, *1278*
Papaver orientale **L.**—chloroform extract of seed capsules, alkaloids isolated and identified, five *chemotypes classified, 1050*
Parabens, alkyl—solubility and thermodynamics in aliphatic alcohols, *effect of temperature*, 42
Paraoxon—chronic administration, effect on intestinal glucose and calcium transport, rats, 879
Parathion—*chronic administration, effect on intestinal* glucose and calcium transport, rats, 879
Parenterals, large volume—particle-size distribution, *effect of different degrees of agitation, 935*
—particle-size distributions characterized, cleanliness factor developed, 1083
Parthenolide—isolated from ethanol extract of bark of *Michelia champaca*, cytotoxic activity evaluated, *883*
Particles—automated counter analysis, intravenous pharmaceutical preparations, proposed as quality control method, 181
multisized—dissolution profile, approximate expressions for weight fraction undissolved, 553
Particle-size distribution—characterized in large-volume parenteral solutions, cleanliness factor developed, 1083
distribution—spray granulations, effect of liquid flow rate, 1462
distribution—various large-volume parenterals, effect of different degrees of agitation, 935
—effect on antipyretic activity of aspirin, four commercial formulations evaluated and compared to powder, rats, 674
—effect on dissolution of prednisolone acetate suspensions, 557
—of major diluent in tablet granulations, effect on drug migration during drying, 1406
—relationship to volumetric powder flow rates and angles of repose in wet-processed granulations, 1235
Partition coefficients—ampicillin in aqueous buffer–octanol systems, effect of pH, 294
apparent—various drugs between water and micellar pseudophase, ultracentrifugal study, 858
apparent—various β-lactam antibiotics in octanol–water and 2-methylpropanol–water at various pH values, 1675
lipid–water—prostaglandin E_1 and dinoprost, effect of aggregation with calcium ions, 1308
—various barbiturates and xanthines, coacervates as *nonpolar phases in equilibrium with polar* water phases, 283
—various penicillins and cephalosporins, correlated to lipophilic indexes determined by high-pressure liquid chromatography, 747
—*various tetracyclines, related to antibacterial* activity, resistant and sensitive microorganisms, 88
Pattern recognition—*analysis methods used to determine* therapeutic classes of various drugs, 304
Pellets, enteric coated—theoretical analysis of effect of dispersion in stomach on blood level profiles, 1495
Penicillamine—TLC–bioautographic analysis of penicillin G and ampicillin as contaminants, 1646
Penicillin G—*and related compounds, complexation* with nickel(II) ions, reaction kinetics, 533
—degradation in aqueous solution, deuterium solvent isotope effect, pH 4–10, 861
potassium—thermal decomposition of amorphous *samples, effect of water content and temperature*, 1312
—TLC–bioautographic analysis as contaminant in *various tetracyclines and penicillamine*, 1646
various—GLC analysis of *N,N*-dimethylaniline as *contaminant in commercial samples*, 1634
various—high-pressure liquid chromatographic determination of lipophilic indexes, correlated *to partition coefficients*, 747
Pentazocine—effect on pressor responses of epinephrine and levarterenol, rats, 1652
Pentobarbital—electron-capture GLC analysis, human serum, 477
—*pharmacokinetics, effects of polychlorinated* biphenyls, rats, 238
sodium—degradation kinetics in propylene glycol-based solutions, *in vivo effects in laboratory* animals, 693
Peptide H—binding to histamine, effect of alkali metal and alkaline earth cations, association constants determined, 542
Perfluorooctyl bromide—*coated on GI tract, effect* on food absorption and weight gain, rats, 907
Perfusion, rapid—idoxuridine through ventricular *system, effect on metabolism in cerebrospinal* fluid, dogs, 1338
systems—vaginal drug absorption, various straight-chain aliphatic alcohols, rhesus monkeys, 216
Permeation *rate—butamben through dimethicone* membrane, convective diffusion model, 137
rate—salicylate across a dialysis membrane in presence of various types of carboxymethylcellulose, 1611
Perphenazine—high-performance liquid chromato-

graphic analysis, pharmaceutical formulations containing amitriptyline hydrochloride, 1117
pH—effect on partition coefficients of ampicillin in aqueous buffer–octanol systems, 294
—effect on solubility of silver sulfadiazine, potentiometric study, 519
—membrane surface compared to bulk solution, vaginal drug delivery model, rabbits, 778
pH-stat titration—aluminum hydroxide gel, acid neutralization, role of carbonate, 1533
—evaluated for aluminum hydroxide gel, aging monitored, compared to other tests, 1528
Pharmaceutical salts—general pharmacy, physicochemical properties, bioavailability, pharmaceutical properties, toxicology, review, 1
Pharmacodynamics—β-methyldigoxin, oral and intravenous, effect on left ventricular ejection time and heart rate correlated with pharmacokinetic parameters, humans, 326
Pharmacokinetic models—diffusion and dissolution of suspended drug in semisolid vehicle, 654, 662
parameters—determined from postinfusion blood level data after simultaneous intravenous priming and infusion doses, 1499
Pharmacokinetics—ampicillin and hetacillin methoxymethyl ester, plasma, prostatic fluid, and spinal fluid levels, dogs, 345
—analyses based on pharmacological response data, situations producing misleading results determined, 580
—antipyrine, normal subjects and hepatitis patients, plasma and saliva concentration data, 135
—compartment with exponential absorption rate and first-order elimination rate, two methods for quick estimation of kinetic parameters, 127
—cyclocytidine in humans, mathematical model, 1441
—dichlorodifluoromethane, single and multiple dosing, three-compartment open model proposed, dogs, 49
—digoxin, model for disposition in dog developed, applied to humans, 1679
—digoxin, model for distribution and elimination, effect of ligation of bile duct or ureter, rats, 1138
—distribution of dicumarol, effect of plasma protein binding, rats, 1741
—ethosuximide, circadian rhythm in steady-state plasma levels, monkeys, 650
—excretion of iodipamide in dogs, 1670
—fluorouracil in humans, studied using microbial kinetic analysis, 1422
—interpretation of plasma concentration–time curves after oral administration of sulfisoxazole, rabbits, 178
—intravenous β-r ethyldigoxin, humans, radiochemical–TLC study, 242
—intravenous, Δ^9-tetrahydrocannabinol, radiochemical study, dogs, 395
—isosorbide dinitrate, oral and sublingual administration compared, standard and sustained-release tablets compared, humans, 775
—lidocaine in humans, 1383
—mercaptopurine in rats, 1454
—methsuximide and metabolite, after single intravenous doses in dogs, 688
—β-methyldigoxin, oral and intravenous, correlated with effect on left ventricular ejection time and heart rate, humans, 326
—β-methyldigoxin, oral and intravenous, radioimmunoassay compared to radiochemical spectrometric assays, human plasma, 806
—methylphenidate, GLC–mass spectrometric study in rats, 866
—model constants estimated by computer curve-fitting method, drug concentration data obtained during repetitive drug administration, 530
—oral β-methyldigoxin, humans, radiochemical–TLC study, 314
—pentobarbital, effects of polychlorinated biphenyls, rats, 238
—prednisolone, various dosage forms compared, dogs, 1751
—progesterone, tissue distribution, different routes of administration compared, 1744
—sulfamethazine, various dosage forms compared, cattle, 619
—sulfathiazole in sheep following intravenous administration, 1297
—tiaprofenic acid in humans, rats, dogs, mice, and rabbits, 1030
time dependent—carbamazepine, 1-week infusion, monkeys, 647
time dependent—valproic acid, steady-state plasma levels, monkeys, 1154
—triamterene, radiochemical analysis, rats, 53
—triprolidine, humans and rats, 841
—two-compartment open model for tetraethylammonium bromide, rats, 56
—various drugs, binding to albumin and plasma proteins, review, 447
—warfarin distribution, effect of plasma protein binding, rats, 567
—warfarin, effect of ibuprofen, rats, 943
—(*R*)-(+)- and (*S*)-(−)-warfarin, steady-state anticoagulant activity compared, 1790
Pharmacological response data—use in bioavailability and pharmacokinetic analyses, situations producing misleading results determined, 580
Phenacetin—GLC analysis in presence of acetaminophen, plasma, 1628
—GLC–mass spectrometric analysis, human plasma, 340
Phenanthrenones, various—structural requirements for fluorescence in strong acid, 1478
1,10-Phenanthroline—alone and complexed with zinc, teratogenic effects evaluated in mice, 1755
Phenethicillin—proton and ^{13}C-NMR spectral analysis of diastereoisomer ratio, bulk drug and commercial formulations, 1079
Phenethylamine polymers—compound 48/80, antimicrobial activity evaluated in protozoa, bacteria, fungi, and viruses, 702
Phenethylamines—mescaline, chronotropic and inotropic effects on isolated rat atria, 938
β-Phenethylamines, various—isolated from whole plant extract of *Pilosocereus maxonii,* 1485
Pheniramine maleate—colorimetric analysis, cough syrup, 895
Phenobarbital—complex with ephedrine prepared, chemical and spectroscopic analysis, 1019
1,3-dimethyl derivative—thermal decomposition in gas chromatograph, major products identified by mass spectrometry, 578
—effect on protein binding of bilirubin, salicylic acid, and sulfisoxazole, rat serum, 1025
—effects on serum protein binding of warfarin and dicumarol, rats, 941
—microencapsulation by spray polycondensation, effect of composition, pH, and viscosity, 631
Phenol—high-pressure liquid chromatographic analysis, pharmaceutical preparations, 1201
Phenols, substituted—sulfonates synthesized and evaluated for antimalarial activity, 440
Phenolsulfonphthalein—absorption and excretion, effect of preadministration of sodium deoxycholate, humans, 727
Phenothiazine and 10-methyl derivative—oxidative degradation in acidic oxygen-saturated medium, effect of pH, 1392
—electrochemical oxidation degradation in ethanol–water mixtures, mechanism suggested, 1395
—methotrimeprazine and four metabolites, GLC–mass spectral analysis, human plasma and urine, 190
various—and oxygenated analogs, chemical-ionization mass spectra, 228
various—periodic acid oxidation, effect of adenosine diphosphate and triphosphate, 1575
Phenylalanine derivatives—various tetrazole analogs synthesized, effect on tyrosine hydroxylase activity, 1642
Phenylbutazone—four polymorphic forms identified, thermal and compressional behavior and solubilities compared, 669
—stability in presence of various pharmaceutical colors, effect of light, 733
Phenylephrine—effect on iris dilator muscle response, roles of neuronal and extraneuronal uptake mechanisms, rabbits, 93
—effect on methacholine-induced rise in intraocular pressure, dogs, 1013
—GLC analysis, pharmaceutical dosage forms, 560
2-Phenylethylamines, substituted—various sulfur-containing amphetamine derivatives synthesized, evaluated for central stimulant and anorexic effects, rats, 923
Phenylpropanolamine hydrochloride—high-pressure liquid chromatographic analysis, cough syrup, 895
Phenytoin—GLC analysis in plasma, 1510
metabolites—GLC and GLC–mass spectrometric analyses and identification, human, monkey, and dog urine, 1596
—serum protein binding compared to salicylic acid, sulfisoxazole, and warfarin, normal and renally impaired humans, rats, 1285
—solubility and ionization characteristics in various buffers and hydroalcoholic solutions, 994
—tissue binding, normal, nephrotic, and uremic humans compared, 1211
Phorbol esters, various—toxicity to brine shrimp larvae related to cocarcinogenic potency, 1362
Phospholipid monolayers—energies of interaction with various aliphatic alcohols at air–water interface, 1229
Photodecomposition—uric acid in presence of riboflavin, effect of pH and solvent, 1561
Photolytic reactions—substituted tetrahydrocarbazoles sensitized with methylene blue, spectrofluorometric analysis, human blood and urine, 353
Photosensitization—various drugs irradiated, polymerization of acrylamide determined by dilatometry or oxidation of 2,5-dimethylfuran determined using polarographic oxygen electrode, 1282
Photosensitized oxidation—various tetracyclines, reaction kinetics followed using polarographic oxygen electrode, effect of pH and copper(II) ions, 186
Photosensitizing activity, skin—various substituted psoralens evaluated, 1623
Phototransformation—formazans of blue tetrazolium and triphenyltetrazolium, effect of various solvents, 965
Phthalate esters, mono- and bis(2-ethylhexyl)—3- and 4-hydroxy derivatives synthesized and characterized by PMR and mass spectra, 546
Phthalazines, substituted—synthesized, antitumor activity evaluated, 849
Physicochemical properties—dissolution, solubility, stability, and organoleptic properties of pharmaceutical salts, review, 1
Physiological effects—fenfluramine and dextroamphetamine, alone and in combination, sex-based differences, humans, 739
Physostigmine—quantitative analysis by measurement of duration of cholinesterase inhibition, human blood, 389
Pigments—synthetic levodopa melanin, competitive binding with cocaine and various drugs, 1544
Pilocarpine—aqueous chamber volume of distribution, rabbit eyes, 219
— effect of vehicle composition and pH on ocular bioavailability, rabbits, 1222
—high-speed liquid chromatographic analysis, pharmaceutical preparations, 1625
hydrochloride—and degradation products, ^{13}C-NMR analysis, commercial ophthalmic formulations, 638
nitrate—bioavailability, effect of instilled volume, 1058
Pilocarpinic acid—^{13}C-NMR analysis in commercial ophthalmic formulations of pilocarpine hydrochloride, 638
Pilosocereus maxonii—whole plant extract, six alkaloids isolated and identified, 1485
Piperazine, substituted—anticonvulsant activity after oral administration, effect of various solvents and dosage forms, mice, 82
Piperidine derivatives—synthesized, pharmacological activity evaluated, 1583
Pirbuterol—aqueous solutions, stability, effect of pH and temperature, 819
pKa values—various estrogens, effects of structural differences on ionization, 624

—various β-lactam antibiotics, 1675
Placental growth—*effects of aspirin and acetaminophen*, rats, 111
Plasma drug concentration—effect on steady-state *level of acetazolamide within human erythrocytes*, 729
time profiles—predicted *from in vitro dissolution* data, validity evaluated, 1359
transport proteins—β-lipoprotein interactions with *various acidic and basic drugs screened*, 420
Plastic deformation—effect on tablet fracture caused by shear stresses during decompression, 510
flow—during tablet formation, effect of duration of compression cycle and maximum compressive *force on tensile strength*, 155
PMR—characterization of mono- and bis(2-ethylhexyl) esters of 3- and 4-hydroxyphthalic acid, 546
Polarography, *ac—analysis, various tetracyclines*, electrode processes identified, 1564
—analysis, cefamandole nafate, prepared samples, 379
—determination, rate of oxygen uptake by solutions *of various tetracyclines irradiated with UV light*, effect of pH and copper(II) ions, 186
differential pulse—analysis, stannous ion in pyro*phosphate and polyphosphate radiopharmaceutical* kits, 870
—oxygen electrode used to determine oxidation of 2,5-dimethylfuran by various drugs after UV irradiation, 1282
—*reduction, substituted isoxazolium salts*, effect of pH, polar contribution of 5-aryl substituents correlated with antibacterial activity, 597
—*simultaneous analyses, 4-nitrophenol, 4-nitroanisole*, and 4-nitrocatechol, alkaline solutions, 60
Polyamines—effect of α-methyl-(±)-ornithine and its *tert*-butyl ester on biosynthesis in leukemic mice, *TLC–high-pressure liquid chromatographic* analysis of tissue extracts, 1586
—*N*-(monoaminoalkyl)- and *N*-(polyaminoalkyl)-acetamides, dansyl derivatives, TLC and high-pressure liquid chromatographic analysis, human urine, 1195
—*N*-(monoaminoalkyl)- and *N*-(polyaminoalkyl)-acetamides, determined in human urine, dansyl *derivatives synthesized*, 1089
—polyethyleneimine, GI and cardiopulmonary effects, oral and intravenous administrations compared, dogs, 902
—various polyethyleneimines, effect on gastric *emptying, phenolsulfonphthalein and resin bead* methods compared, rats, 899
Polychlorinated biphenyls—tissue distribution, dilution *by growth, and elimination, swine*, 497
Polyelectrolytes—various types of carboxymethylcellulose, *effect on permeation rate of salicylate* across a dialysis membrane, 1611
Polyethylene glycol—as binder for direct compression *of tablets, various drugs, stability evaluated*, 1551
6000—dispersions with griseofulvin, X-ray diffraction study, aqueous solubility, effects of pulverization and aging, 989
Polyethyleneimine—*GI and cardiopulmonary effects*, oral and intravenous administrations compared, dogs, 902
Polyethyleneimines, *various—effect on* gastric emptying, phenolsulfonphthalein and resin bead *methods compared, rats*, 899
Polygala macradenia—chloroform fraction of extract of aerial parts, lignan isolated, evaluated for cyto*toxic and tumor inhibitory activity*, 586
Polymers of phenethylamine—compound 48/80, antimicrobial activity evaluated in protozoa, bacteria, fungi, and viruses, 702
Polymorphic form—of mercaptopurine, dissolution *rate, differential thermographic and X-ray diffraction* analyses, 608
Polymorphism—phenylbutazone, four crystalline *forms identified, thermal and compressional* behavior and solubilities compared, 669
Polyols—sorbitol, effect on binding of various phenolic preservatives to polysorbate 80, 1470
Polysorbate 80—binding to various phenolic pre*servatives, effect of sorbitol*, 1470
Polythiazide—high-pressure liquid chromatographic *analysis, pharmaceutical formulations*, 736
Porosity and pore-size distribution—aspirin tablets, effect of colloidal silicon dioxide, 407
Potentiometry—analysis, solasodine in fruits of *Solanum* species, 699
—*characterization of composition and measurement* of dissolution profiles of methyl vinyl ether–maleic anhydride–acid copolymers, 713
—*study of solubility of silver sulfadiazine as a* function of pH, 519
Povidone—binding to various sulfonamides, fluorescent probe study, 1157
—effect on stability of molded nitroglycerin tablets *in various strip packages*, 1293
Powders—capacity for tablet formulation, prediction factors developed, applied to manufacturing *procedures*, 254
—effect of duration of lubricant–excipient mixing on processing characteristics, 1377
—micronized glyburide, various multiparticulate models fit to dissolution data, rate and size dis*tribution parameters evaluated*, 761
micronized—substituted 2-xanthonecarboxylic acid and sodium salt used in formulating powder in*halation aerosols, effect of lactose concentration*, humidity, and temperature, 1254
various pharmaceutical—contact angles, densities, and surface tensions, 1480
Prednisolone acetate—multisized suspensions, dis*solution profiles and particle-size measurements*, 557
—bioavailability and pharmacokinetics, various dosage forms compared, dogs, 1751
Pregnenolone-16α-carbonitrile—effect on pharmacological activity, distribution, *and in vivo* metabolism of imipramine, rats, 1492
Preservatives, phenolic—*p*-hydroxybenzoic acid, *methylparaben, ethylparaben*, and *propylparaben*, binding to polysorbate 80, effect of sorbitol, 1470
Pressor responses—epinephrine and levarterenol, effect of pentazocine, rats, 1652
Primidone—*solid dispersion systems with citric acid*, effect of concentration of glass transition temperature and dissolution, 825
Procainamide and *N*-acetyl derivatives—high-pressure liquid chromatographic analyses, human plasma, 874
—bioavailability of intravenous infusion, capsules, and sustained-release tablets, absorption of oral *forms compared, humans*, 981
Procarbazine analogs—synthesized, antitumor activity evaluated, 849
Prodrugs—7-acetylacroninium perchlorate, hydrolysis mechanism, 1501
potential—quaternary salts of acetyl derivative of acronine synthesized for intravenous use, solubilities and kinetics of hydrolysis studied, 628
Progesterone—in sustained-release cholesterol implant pellets, *in vivo* and *in vitro* release biological *effectiveness, rabbits and rats*, 490
—release from silicone matrixes, *in vitro* system compared to bovine intravaginal device *in vivo*, 816
—tissue distribution, different routes of administration compared, 1744
Progestins—progesterone, tissue distribution, different routes of administration compared, 1744
Propantheline—*antisecretory and antimotility effects* compared to hexocyclium and isopropamide, humans, 1433
—*effect of preadministration on GI absorption of* griseofulvin, rats, 1540
—*quantitative analysis and in vitro dissolution*, regular and sustained-release tablets compared, 1777
Propoxyphene hydrochloride—*different formulations*, bioavailability compared, 1713
Propranolol—GLC analysis, human plasma, 1490
Prostaglandin A_2—high-pressure liquid chromatographic analysis, *cis*- and *trans*-isomers, 744
Prostaglandin E_1—*aggregation with calcium ions*, effect on lipid–water partition coefficients and uptake by isolated rabbit intestine, 1308
Prostaglandins—*dinoprostone and prostaglandin A_2*, nucleophilic addition of bisulfite ion, effect on *aqueous stability*, 149
—E_1 and dinoprostone, stability at pH extremes, 1590
—ion-exchange liquid chromatographic analysis after cyclodextrin complexation, prepared *samples*, 706
—various dinoprost C-15 alkyl esters, monomolecular film compression–relaxation behavior *compared*, 823
Protein—stability, egg albumin, effect of indomethacin *in vitro*, compared to other drugs, 1651
Protein binding—bilirubin, salicylic acid, and sulfisoxazole, effect of phenobarbital, rat serum, 1025
—cefazolin, effect of hemodialysis, 1508
—codeine, morphine, and methadone to human serum, 802
—log *Q* plot used to estimate free energy change associated with *conformational transition*, 146
plasma—effect on distribution kinetics of dicumarol, rats, 1741
plasma—effect on warfarin distribution kinetics, 567
serum—cefazolin, rate and extent, dogs, 1663
serum—dicumarol, effect on elimination kinetics, rats, 1739
serum—phenytoin, salicylic acid, sulfisoxazole, and warfarin compared, normal and renally impaired humans, rats, 1285
serum—warfarin and dicumarol, effect of phenobarbital, rats, 541
—L-tryptophan binding by defatted human serum albumin, effect of indomethacin and congeners, 950
—*various drugs to albumin and plasma proteins*, pharmacokinetics, drug displacement, and clinical significance, review, 447
Prothrombin complex synthesis—related to serum warfarin concentration, rats, 145
Protolytic equilibria—doxorubicin, electronic absorption and fluorescence spectrophotometric determination, 958
Psilocin—*GLC–mass spectral analysis in extract of* mushroom *Psilocybe cubensis*, 743
Psilocybe semilanceata—extracts of carpophores, baeocystin and psilocybin isolated, identified by mass spectrometry and UV spectroscopy, 113
Psilocybin—*GLC–mass spectral analysis in extract* of mushroom *Psilocybe cubensis*, 743
—isolated from extracts of *Psilocybe semilanceata and P. pelliculosa, identified by* mass spectrometry and UV spectroscopy, 113
Psoralens, substituted—synthesized, evaluated for skin-photosensitizing activity, 1623
Psychomotor effects—fenfluramine and dextroam*phetamine, alone and in combination, sex-based* differences, humans, 739
Psychotomimetics—mescaline, chronotropic and inotropic effects on isolated rat atria, 938
—Δ^9-tetrahydrocannabinol, high-pressure liquid *chromatographic–mass spectrometric analysis*, human plasma after smoking marijuana, 1263
—Δ^9-tetrahydrocannabinol, intravenous, radio*chemical study of pharmacokinetics*, dogs, 395
Pupil diameter—*measurements used to assess* morphine bioavailability, 580
Pyrazolodiazepinones, various—equilibrium reaction *in aqueous solution, effect of pH and methyl* substitution, 1703
Pyridine and derivatives—spectral binding to cytochrome P-450, constants determined, 1046
Pyridoxal phosphate—spectrophotometric analysis, *biological fluids*, 1503
Pyridoxine hydrochloride—effect on aqueous solubility of nitrofurantoin, 1357
Pyrilamine maleate—spectrophotometric analysis, cough syrup, 895
Pyrogens, various—UV spectrophotometric *analysis*, prepared solutions, wide concentration range, 723
Pyrroles, *various—synthesized, evaluated for* antibacterial activity, 1052
(Pyrrolidone-5-hydroxamato)iron(III)—mono, bis, and tris chelates, stability constants determined in

aqueous solutions, 330
Pyrroloimidazolone, *substituted—synthesized in* seven-step sequence, 1208

Q

Quaternary ammonium bromides, various—synthesized, bactericidal activity determined in simple *partition systems, compared to cream systems,* 696
compounds—tetraethylammonium *bromide,* pharmacokinetic model, effect of sodium salicylate on renal elimination, rats, 56
Quinidine—*colorimetric analysis, pharmaceutical* formulations and biological fluids, 1317
—effect on fetal rat heart rate related to levels of *cyclic adenosine monophosphate,* organ culture, 1450
—spectrofluorometric *analysis, human plasma and* urine, effect of alkaline washings, 591
sulfate—bioavailability of four commercial tablets *compared, humans, 539*
Quinine—colorimetric analysis, pharmaceutical formulations and biological fluids, 1317
Quinoline, substituted—2,4-dimethylbenzo[*g*]quinoline, NMR spectrum, chemical shifts of methyl *groups defined, effect of concentration, 1200*
Quinolinols, substituted—sulfonates synthesized and evaluated for antimalarial activity, 440
Quinoxalines, *substituted—synthesized, anthelmintic* activity evaluated, 1349
Quinuclidines, substituted—synthesized, structures, stereoisomers, and physical properties identified, 890

R

Radiation, gamma—effect on GI absorption of various drugs, rats, 361, 366
—effect on rate of GI absorption of sulfanilamide, bretylium tosylate, sulfisoxazole acetyl, and ri*boflavin, rats, 680*
Radiochemical GLC—analysis, nortriptyline in human plasma, 1056
Radiochemistry—analysis, effect of aspirin on absorption, excretion, and metabolism of *acetaminophen, mice, 1399*
—analysis, isoniazid, effect of various drugs on absorption, tissue distribution, excretion, and *metabolism, rats, 1322*
—analysis, ^{14}C-meglumine, tissues and biological fluids, rats and dogs, 96
—analysis, triamterene distribution, rats, 53
—double radioisotope derivative analysis of ace*nocoumarol in plasma and urine, 997*
—^{14}C-meglumine salicylate synthesized, administered orally, biological distribution and excretion measured, humans, 536
—study of metabolism of α-methyl-(±)-ornithine *in mice, 1586*
—study of pharmacokinetics of intravenous Δ^9-tetrahydrocannabinol, dogs, 395
—*study of tissue distribution and metabolism,* canrenoate potassium, rabbits, 275
—technetium Tc 99*m* as label for fatty acid analogs containing chelating agents, biological distribution, compared to ^{3}H-palmitic acid, rabbits, *225*
–TLC—study of pharmacokinetics and bioavailability of oral β-methyldigoxin in humans, 314
–TLC—study of pharmacokinetics of intravenous β-methyldigoxin in humans, 242
***Radioimmunoassay**—analysis, luteinizing hormone* releasing hormone, various synthetic preparations, 386
—*clonazepam, human plasma, 235*
—combined with isotope dilution, analysis of sulindac and metabolites, human plasma and urine, 414
–GLC—analysis, codeine and morphine in human *urine, 66*
—indomethacin, human plasma and urine, 486
—β-methyldigoxin, pharmacokinetic study after oral *and intravenous administration, compared to* radiochemical spectrometric assays, human *plasma, 806*
—minoxidil in human serum, 1266
Radiopaque media—*iodipamide, capacity-limited* excretion kinetics, dogs, 1670
Radiopharmaceuticals—^{99m}Tc-labeled triethyl*enetetramine–polystyrene resin, scintigraphic* determination of gastric emptying rate, humans, 442
—pyrophosphate and polyphosphate type kits, differential pulse polarographic analysis of *stannous content, 870*
—timed-release microcapsules formulated, potential use in organ imaging evaluated, mice, *172*
Reaction mechanisms—solvation isergonic profiles, geometric analysis of scatter as a function of vertical, horizontal, and perpendicular distances from error line, 30
Relaxants, *skeletal muscle—dantrolene sodium,* high-pressure liquid chromatographic analysis, biological fluids, 751
skeletal muscle—dantrolene sodium, high-pressure liquid chromatographic analysis, commercial dosage forms, 286
smooth muscle—chloramphenicol and its hydrolytic product evaluated, various guinea pig, rat, rabbit, *and toad muscles, 1239*
Renal clearance perturbation—calculations used to determine bioavailability of lithium carbonate, *commercial dosage form,* 609
Renal function testing—differentiation between nephrotoxic and diuretic agents by *urine and plasma* osmolality measurements, dogs, 501
Repellents, insect—diethyltoluamide, protection time, *effect of skin surface lipids, humans, 1764*
mosquito—various 2-oxazolidones synthesized and evaluated, 587
Repetitive drug administration—drug concentration data obtained, model constants estimated by *computer curve-fitting method, 530*
Repose angles—relationship to volumetric powder flow rates and particle size in wet-processed *granulations, 1235*
Review Articles
Binding of Drugs by Albumin and Plasma Protein, 447
Complement: A Host Defense Mechanism Ready *for Pharmacological Manipulation?, 1367*
Electrophysiological and Pharmacological Properties of Skeletal Muscle in Culture, 913
Pharmaceutical Salts, 1
Rhodanine derivatives, various—synthesized, eval*uated for antibacterial and antiviral activities,* 1607
Riboflavin—effect on *in vitro* photodecomposition of *uric acid, various pH's and solvents, 1561*
—GI absorption, effect of cobalt-60 γ-radiation, *rats,* 361, 366
—GI absorption, effect of γ-radiation on rate, rats, 680
***Ribonucleotide reductase**—activity, effect of various* hydroxyureas *in vitro,* 1040

S

Salicylamide—effect on absorption and metabolism of terbutaline, rats, 1488
***Salicylate**—permeation rate across a dialysis mem*brane in presence of various types of carboxymethylcellulose, 1611
Salicylic acid–cetrimide—aqueous solutions, viscosity and surface tension, 1779
—*gas–solid chromatographic analysis, commercial* plaster pads, 731
—protein binding, relationship to binding of bilirubin *and sulfisoxazole, effect of phenobarbital,* rat serum, 1025
—reversed-phase high-pressure liquid chromatographic analysis, pharmaceutical formulations containing benzoic acid, 110
—*serum protein binding compared to phenytoin,* sulfisoxazole, and warfarin, normal and renally impaired humans, rats, 1285
***Salsolinol**—electron-capture GLC analysis, mouse* brain tissue, 893
Salts, pharmaceutical—general pharmacy, physicochemical properties, bioavailability, pharma*ceutical properties, toxicology, review, 1*
zinc—effect on serum zinc levels, rats, 391
Sapelins A and B—isolated from ethanol extract of *leaves of Bursera klugii,* cytotoxic activity evaluated, 889
Scintigraphy, *external—determination of gastric* emptying rate using ^{99m}Tc-labeled triethylenetetramine–polystyrene resin, 442
***Seals,** hermetic—testing method developed for large* numbers of screw-capped bottles, 333
Sedatives—ethinamate and hydroxy derivative, GLC analysis in biological fluids, bioavailability from tablets and capsules, humans, 992
—*glutethimide, methaqualone, diazepam, seco*barbital, pentobarbital, phenobarbital, and amobarbital, adsorption to activated charcoal, *effect of pH, 1640*
—meprobamate, IR spectrophotometric analysis, commercial dosage forms, 292
—pentobarbital, electron-capture GLC analysis in human serum, retention times, various barbiturates, 477
—pentobarbital, pharmacokinetics, effects of polychlorinated biphenyls, rats, 238
—*three benzodiazepines, hydroxylation by rat and* mouse liver microsomal enzymes *in vitro,* 1482
Sex-based differences—fenfluramine and dextroamphetamine, alone and in combination, psy*chomotor and physiological effects, humans, 739*
Shear mixing—effect on *in vitro* disolution of capsules containing lubricants, 1215
***Shelflife**—pharmaceutical preparations, predicted* using linear relationship between log $t_{0.9}$ and reciprocal of absolute temperature, 785
Silicon dioxide, colloidal—effect on stability of aspirin tablets, porosity and pore-size distribution deter*mined, 407*
Silicone matrixes—release of progesterone, *in vitro* system compared to bovine intravaginal device *in vivo,* 816
Siliconization—of glassware, effect on adsorption of *morphine during fluorometric analysis, 1044*
Silver sulfadiazine—solubility as a function of pH, potentiometric study, 519
***Silyl derivatives**—6-aminopenicillanic* and substituted cephemcarboxylic acids, prepared, NMR analyses, 1767
Skeletal muscle in culture—electrophysiological and pharmacological properties, chemosensitivity, re*view, 913*
Sleep—effect on bioavailability of tetracycline, different commercial capsules, humans, 1000
Sodium acetylsalicylate—buffered formulations, various dosage forms, effect on GI microbleeding, dogs, 124
Sodium bisulfite—effect on aspirin hydrolysis, various pH values, 1775
***Sodium deoxycholate**—effect of preadministration* on absorption and excretion of phenolsulfonphthalein, humans, 727
Sodium nitroprusside—effect on body temperature, various routes of administration, various ambient *temperatures, mice, 1658*
Sodium salicylate—effect on renal elimination of tetraethylammonium bromide, rats, 56
***Solanum** species—potentiometric analysis of* solasodine in fruits, 699
Solasodine—potentiometric *analysis in fruits of So*lanum species, 699
Solid dispersions—griseofulvin–polyethylene glycol *6000, X-ray diffraction study, aqueous solubility,* effects of pulverization and aging, 989
dispersions—primidone–citric acid, effect of primidone concentration on glass transition temperature and dissolution, 825
*dispersions—various corticosteroids, sugar car*riers, dissolution rates compared to plain powder, 494
*solutions—hydrocortisone and cholesterol or var*ious esters, dissolution into simulated intestinal fluid, effect on surface tension, 1536
state—decomposition, nitrazepam in microcrys-

talline cellulose, effect of temperature and humidity, 676
Solids—*dissolution in a solvent, energy changes determined*, 961
polydisperse particulate—agitated beds, interparticulate translocations in terms of Markov chains, 104
Solubility—*alkylparabens in aliphatic alcohols, effect of temperature*, 42
aqueous—griseofulvin–polyethylene glycol 6000 *dispersions, X-ray diffraction study*, 989
aqueous—various estrogens, effects of structural differences on ionization, 624
—benzocaine in aqueous gel vehicle, calculations derived from mathematical drug release models, 926
—four polymorphic forms of phenylbutazone compared, 669
—nitrofurantoin in aqueous solutions, effect of pyridoxine hydrochloride, 1357
—phenytoin in various buffers and hydroalcoholic solutions, 994
product—slightly soluble hydroxides, related to zero point of charge, 1548
—silver sulfadiazine as a function of pH, potentiometric study, 519
Solute–micelle interactions—ultracentrifugal study of apparent partition coefficients of various drugs between water and micellar pseudophase, 858
Solute velocities—in descending column during dissolution from a horizontal surface, mathematical analysis, 741
Solvation isergonic profiles—geometric analysis of scatter as a function of vertical, horizontal, and perpendicular distances from error line, 30
Solvents, various—effect on anticonvulsant activity of a substituted piperazine after oral administration, mice, 82
Sorbitol—effect on binding of various phenolic preservatives to polysorbate 80, 1470
Sorption—nitroglycerin by thermoplastic polymers in various packaging materials, 1293
Spectral binding—pyridine and derivatives to cytochrome P-450, constants determined, 1046
Spectrofluorometry—analysis, amphetamine and analogs with rigid conformation, rat tissues, 271
—analysis, quinidine, human plasma and urine, effect of alkaline washings, 591
—analysis, various substituted tetrahydrocarbazoles, human blood and urine, 353
Spectrophotometry—analysis, cephapirin, bulk drug and pharmaceutical formulations, 1108
—analysis, chlorthalidone, based on inhibition of carbonic anhydrase, urine, 1735
—analysis, diphenoxylate hydrochloride in solutions and tablets containing atropine sulfate, 1553
—analysis, fenclorac and metabolite in serum, 832
—analysis, ferrous ion in pharmaceutical formulations, 140
—analysis, homatropine methylbromide in pharmaceutical formulations, 123
—analysis, meclizine hydrochloride using ion-pair extraction with methyl orange, pharmaceutical dosage forms and biological fluids, 710
—analysis, pyridoxal phosphate in biological fluids, 1503
—analysis, pyrilamine maleate, cough syrup, 895
—analysis, sulfathiazole in mixtures with sulfadiazine and sulfamerazine, 1413
—analysis using charge transfer complex formation, ethambutol in prepared samples and commercial tablets, 766
electronic absorption and fluorescence—determination, doxorubicin dissociation constants and protolytic equilibria, 958
—kinetic study, effect of triazolopyrazines on complexes of *p*-benzoquinone with proline and histamine, 205
Sphyrna lewini—hammerhead shark, potential antineoplastic constituents isolated from body fluids, muscle tissue, and liver, identified, 757
Sphyrnastatins—isolated from hammerhead shark, preliminary evaluation of antineoplastic activity, 757
Spin-labeled opiates—morphine and codeine labeled in 6-position, effect on binding to brain receptors *and analgesic activity, 1054*
Spiro compounds—various fluorene-9-spiro-2′-aziridines synthesized, hydrolyzed to 9-chlorofluorene-9-carboxanilides, 1653
Spironolactone—bioavailability in humans related to *in vitro dissolution, various tablet formulations* compared, 1429
metabolite—canrenone, human milk to serum concentration ratio, 1203
metabolites—canrenone and canrenoic acid, automated simultaneous fluorometric analyses, serum, 1131
Spray polycondensation—microencapsulation of solids, effect of composition, pH, and viscosity, 631
Stability—aquadichloro(2,6-diaminopyridine)palladium(II) in acidic and acid halide media, 1515
aqueous—bisulfite adducts of dinoprostone and prostaglandin A_2, 149
—aspirin tablets, porosity and pore-size distribution determined, effect of colloidal silicon dioxide, 407
—benzoyl peroxide in pharmaceutical gels, effect of temperature, pH, and various gel ingredients, 718
—carmustine in aqueous media, effect of pH and temperature, 1073
—carmustine in mixed solvents and nonaqueous media, effect of temperature, 1076
color—tablets coated with FD&C Yellow No. 6, effect of sunscreening agents and various coating methods, 107
constants—mono-, bis-, and tris(pyrrolidone-5-hydroxamato)iron(III) chelates in aqueous solutions, 330
—fenclorac in aqueous solutions, various pH's and temperatures, liquid chromatographic analysis, 73
—formazans of blue tetrazolium and triphenyltetrazolium, effect of laboratory light, various solvents, 965
—lysosome and protein *in vitro*, effect of indomethacin, compared to other drugs, 1651
—molded nitroglycerin tablets in various strip packages, effect of povidone, 1293
—nitrazepam in solid state in microcrystalline cellulose, effect of temperature and humidity, 676
—pentobarbital sodium in propylene glycol-based solutions, *in vivo* effects in laboratory animals, 693
—pharmaceutical preparations, linear relationship between log $t_{0.9}$ and reciprocal of absolute temperature related to shelflife, 785
—phenylbutazone in presence of various pharmaceutical colors, effect of light, 733
—pirbuterol, aqueous solutions, effect of pH and temperature, 819
—prostaglandin E_1 and dinoprostone at pH extremes, 1590
—tablets of various drugs using polyethylene glycol as binder, 1551
Stable isotope labeling—analyses, lidocaine and various metabolites, human plasma and urine, 1180
Stannous ion—differential pulse polarographic analysis in pyrophosphate and polyphosphate radiopharmaceutical kits, 870
Stearic acid—release into ethanol, zero-order drug delivery system, experimental device tested, 159
Stereochemistry—amphetamine and related compounds, reacted with chiral acylating reagent, GLC separation of diastereomeric amide derivatives, 169
Stereoisomers—(+)-, (−)-, and (±)-$^2H_8$-methadones synthesized, 1579
Steric parameters—E_S used to estimate steric effects in organic reactions correlated to molecular connectivity indexes, 1352
Sterilizers—ethylene oxide and reaction products, GLC analysis in bulk drugs and formulations, 789
Steroids—cholesterol monohydrate pellets, dissolution kinetics in human, animal, and simulated bile, effect of interfacial resistance, 1101
—cholesterol monohydrate pellets, dissolution kinetics in simulated bile, effect of bile acid type and concentration, ratio to lecithin, and added *electrolytes, 1094*
—cholesterol monohydrate pellets, dissolution rate in synthetic bile, effect of various nitrogen-containing compounds and surfactants, 1105
—17α-methyltestosterone, fluorescence of reaction *product with trichloroacetic acid, 1478*
—pregnenolone-16α-carbonitrile, effect on pharmacological activity, distribution, and *in vivo* metabolism of imipramine, rats, 1492
—solasodine, potentiometric analysis in fruits of *Solanum* species, 699
Stimulant activity—various sulfur-containing amphetamine derivatives evaluated, 923
Stimulants—amphetamine and related compounds, reacted with chiral acylating reagent, GLC separation of diastereomeric amide derivatives, 169
—amphetamine sulfate, effect of complexing with montmorillonite on bioavailability, 63
central—amphetamine and analogs with rigid conformation, biological disposition, rats, 271
central—methylphenidate, GLC–mass spectrometric analysis in biological fluids, pharmacokinetics in rats, 866
Stomach emptying rate—effect on GI absorption of griseofulvin, indomethacin, and nalidixic acid, rabbits, 69
Structure–activity relationships—alkylparabens, solubility and thermodynamics in aliphatic alcohols, 42
—4-aminocyclohexanecarboxylic acid, aminobenzoic acid, and various derivatives evaluated for antistaphylococcal activity, 844
—compounds containing various functional groups, effect of modification of Dragendorff's reagent on relative TLC sensitivities, 1656
—coralyne and related compounds, mutagenicity evaluated and compared to 7,12-dimethylbenz[*a*]anthracene, 1781
—determined using pattern recognition methods of analysis, various drugs, 304
—3,4-dimethoxyphenethylamine and *N*-methyl homologs, effect on monoamine oxidase-catalyzed deamination of tyramine and tryptamine, 1048
—effect of coralyne, nitidine, and related compounds on catechol *O*-methyltransferase and tRNA methyltransferase activity, rat liver homogenate, 986
—fenbufen and various analogs, evaluated for anti-inflammatory and analgesic activity, 466
—isomers of various oxime *O*-dimethylaminoethyl ethers evaluated for anticholinergic activity on rat ileum, 1602
—latentiated derivatives of 3-methyleneoxindole evaluated for cytotoxic activity, 1022
—norcocaine (cocaine derivative) synthesized, pharmacological activity evaluated, monkeys, 119
—piperidine derivatives, pharmacological activity evaluated, 1583
—series of substituted dihydroquinoxalino[2,3-*b*]quinoxalines evaluated for anthelmintic activity, 1349
—series of substituted indolizines evaluated for pharmacological activity, 1692
—*N*-substituted 5,6-benzo-2-azabicyclo[2.2.2]-octanes synthesized, analgesic activity evaluated, mice, 594
—substituted carbamimidate ester screened for antimalarial activity, turkeys, 418
—substituted 1,4,2-dioxazoles, general pharmacological screening, 772
—*N*′-substituted hydrazides of indolizine-2-carboxylic acid screened for effect on monoamine oxidase activity, 259
—substituted hydrazines and phthalazines evaluated for antitumor activity, 849
—substituted isoxazolium salts, polar contribution of 5-aryl substituents correlated with antibacterial activity, polarographic reduction, 597
—5-substituted 2-oxazolidinethiones evaluated for antagonism to diethylstilbestrol effects, rats, 887
—substituted thiazoles screened for antiparasitic

activity, 423
—sulfonates of substituted phenols and quinolinols evaluated for antimalarial activity, 440
—various bis(propynyloxy)benzenes and monoamine derivatives screened for antifungal activity, 431
—various cyclic *N*-hydroxyureas evaluated for anticancer activity, 1556
—various estrogens, aqueous solubilities and pKa values, 624
—various hydroxyureas, solvent-dependent conformation in octanol–water, effect of ribonucleotide reductase activity *in vitro*, 1040
—various 2-indolyl 5-pyridyl ketone derivatives screened for cytotoxic activity, 263
—various morphine derivatives, analgesic activity evaluated, monkeys, 285
—various 2-oxazolidones evaluated as topical mosquito repellents, 587
—various oxime *O*-(α- and β-methylcholinyl) ethers, anticholinergic activity evaluated, 1120
—various pyrazolodiazepinones, equilibrium reaction in aqueous solution, effect of pH and methyl substitution, 1703
—various pyrroles, furans, and thiophenes evaluated for antibacterial and cytotoxic activity, 1052
—various rhodanine derivatives evaluated for antibacterial and antiviral activities, 1607
—various *N*-substituted benzomorphans synthesized, pharmacological activity and opiate-receptor binding evaluated, 193
—various substituted glutarimides synthesized and screened for antineoplastic activity in mice, 232
—various *N'*-substituted hydrazides of 2-methyl-3-indolizinecarboxylic acid synthesized, evaluated for effect on monoamine oxidase activity, 1355
—various substituted imidazo[4,5-*f*]quinolines screened for antibacterial activity, 1204
—various substituted psoralens evaluated for skin-photosensitizing activity, 1623
—various substituted thiazolines evaluated for anthelmintic activity in sheep, 1150
—various substituted triazenes evaluated for antitumor activity, 1416
—various sulfur-containing amphetamine derivatives evaluated for central stimulant and anorexic activity, 923
—various tetracyclines, antibacterial activity, resistant and sensitive microorganisms, 88
—various tetrazole analogs of phenylalanine derivatives, effect on tyrosine hydroxylase activity, 1642
—various thiocarboxamide derivatives screened for antituberculosis activity, 1332
—various thiosemicarbazides, mercaptotriazoles, and triazolethioglycolic acids evaluated for anticonvulsant activity and effect on NAD-dependent oxidations, rats, 971
—various triazolopyrazines, effect on complexes of *p*-benzoquinone with proline and histamine, 205
—various types of molecules, related to molecular connectivity index, 642
Sugars—dextrose, galactose, and sucrose as carriers in glass dispersions of various corticosteroids, dissolution rates compared to plain powder, 494
Sulfabenzamide—high-pressure liquid chromatographic analysis in mixtures with sulfacetamide and sulfathiazole, 1784
Sulfacetamide—high-pressure liquid chromatographic analysis in mixtures with sulfathiazole and sulfabenzamide, 1784
Sulfadiazine—bioavailability of tablets prepared by direct compression and fluidized-bed techniques compared to commercial product, rabbits, 1438
Sulfadimethoxine—interaction with tolbutamide, kinetic analysis, sheep, 1063
Sulfamethazine—absorption, metabolism, and excretion, various dosage forms compared, cattle, 619
Sulfamethoxazole—NMR spectroscopic analysis, synthetic mixtures and commercial formulations containing trimethoprim, 121
Sulfanilamide—GI absorption, effect of cobalt-60 γ-radiation, rats, 361, 366
—GI absorption, effect of γ-radiation on rate, rats, 680
Sulfathiazole—compacts, effect of crystal form on tensile strength, 1172
—disposition in tissue, urine, and plasma of sheep following intravenous administration, pharmacokinetic model, 1297
—high-pressure liquid chromatographic analysis in mixtures with sulfacetamide and sulfabenzamide, 1784
—spectrophotometric analysis in mixtures with sulfadiazine and sulfamerazine, 1413
Sulfisoxazole acetyl—GI absorption, effect of cobalt-60 γ-radiation, rats, 361, 366
acetyl—GI absorption, effect of γ-radiation on rate, rats, 680
—oral administration, interpretation of plasma concentration–time curves, rabbits, 178
—protein binding, relationship to binding of salicylic acid and bilirubin, effect of phenobarbital, rat serum, 1025
—serum protein binding compared to phenytoin, salicylic acid, and warfarin, normal and renally impaired humans, rats, 1285
Sulfonamides—disposition of sulfathiazole in tissue, urine, and plasma of sheep following intravenous administration, 1297
—sulfamethazine, absorption, metabolism, and excretion, various dosage forms compared, cattle, 619
—sulfathiazole, spectrophotometric analysis in mixtures with sulfadiazine and sulfamerazine, 1413
various—binding to povidone, fluorescent probe study, 1157
various—TLC systems for qualitative determination, evaluation and optimal combination, 1269
Sulfonates—of substituted phenols and quinolinols, synthesized and evaluated for antimalarial activity, 440
Sulindac—and metabolites, combined isotope dilution–radioimmunoassay, human plasma and urine, 414
Sunscreening agents—effect on color stability of tablets coated with FD&C Yellow No. 6, various coating methods, 107
Surface activity—various aliphatic alcohols, energies of interaction with phospholipid monolayers at air–water interface, 1229
exchange technique—enzymes spread as a monomolecular film at an air–water interface, 792
tension—aqueous solutions of salicylic acid and cetrimide, 1779
tension—simulated intestinal fluid, effect of solid solutions of hydrocortisone and cholesterol or various esters, 1536
tensions—various pharmaceutical powders, 1480
Surfactants, ionic and nonionic—effect on degradation kinetics of indomethacin in alkaline solutions, 1259
nonionic—octoxynol, effect of tetraalkylammonium salts and ammonium halides on cloud point, various salt concentrations, 165
nonionic—polysorbate 80, binding to various phenolic preservatives, effect of sorbitol, 1470
various—effect on dissolution rate of cholesterol monohydrate pellets in synthetic bile, 1105
Suspensions—drug release, diffusion model based on physicochemical principles, 654, 662
multisized—prednisolone acetate, dissolution profiles and particle-size measurements, 557
Sustained-release implant pellets—progesterone–cholesterol, *in vivo* and *in vitro* release and biological effectiveness of progesterone, rabbits and rats, 490
Sweeteners—cycloheptylsulfamate, metabolism, rabbits and rats, 881

T

Tabernaemontana holstii—root extract, various indole alkaloids isolated, cytotoxic activity evaluated, 1135
Tablets—aspirin, sulfathiazole, and barbital, effect of crystal form on tensile strength, 1172
—coated with FD&C Yellow No. 6, effect of sunscreening agents and various coating methods on color stability, 107
compressed—effect of duration of lubricant–excipient mixing on physical properties, 1377
direct compression—dibasic calcium phosphate, aging, effect of temperature and humidity, 1636
direct compression—various drugs, gluconolactone as excipient, effect on physical characteristics, 370
—effect of binder solution viscosity and temperature on drug migration during drying, 1409
—effect of particle size of major diluent on drug migration during drying, 1406
—enteric film coating with methacrylic acid–methyl methacrylate copolymer, disintegration time, mathematical model, 1070
formation—fracture caused by shear stresses during decompression, effect of plastic deformation, 510
formulation—prediction factors developed, applied to manufacturing procedures, 254
—imipramine and desipramine, TLC, GLC, and mass spectral analysis of impurities, 1015
molded—nitroglycerin, sorption by thermoplastic polymers and stability in various strip packages, 1293
—nitroglycerin, effect of various tablet components on volatility, thermogravimetric determination, 265
oxytetracycline—tensile strength and dissolution, effect of various formulation and processing factors, 852
—plastic flow during formation, effect of duration of compression cycle and maximum compressive force on tensile strength, 155
—propantheline, regular and sustained release, quantitative analysis and *in vitro* dissolution, 1777
—sulfadiazine, prepared by direct compression and fluidized-bed techniques, bioavailability compared to commercial product, rabbits, 1438
—time course of disintegration determined using numerical analysis of dissolution profile, 1758
—various drugs, polyethylene glycol as binder for direct compression, stability evaluated, 1551
Talauma ovata—costunolide isolated from petroleum ether extract of roots, cytotoxic activity evaluated, 883
Technetium Tc 99m—as radiolabel on triethylenetetramine–polystyrene resin, scintigraphic determination of gastric emptying rate, humans, 442
—label for fatty acids containing chelating agents, biological distribution, compared to ^{3}H-palmitic acid, rabbits, 225
Technology, pharmaceutical—instrumentation described for monitoring compression and ejection forces in automatic capsule-filling machine, 504
—method of testing hermetic seals of large numbers of screw-capped bottles developed, 333
—microencapsulation of solids by spray polycondensation, effect of composition, pH, and viscosity, 631
Temperature, body—effect of sodium nitroprusside, various routes of administration, various ambient temperatures, mice, 1658
Tensile strength—compacts of aspirin, sulfathiazole, and barbital, effect of crystal form, 1172
—oxytetracycline tablets, effect of various formulation and processing factors, 852
—tablets, effect of duration of compression cycle and maximum compressive force, 155
Teratogenicity—codeine sulfate evaluated, mice, 1727
—zinc chloride and 1,10-phenanthroline, alone and complexed, mice, 1755
Terbutaline—absorption and metabolism, effect of salicylamide, rats, 1488
Tetraalkylammonium salts—effect on cloud point of octoxynol, various salt concentrations, 165
Tetracycline—bioavailability, different commercial capsules, effect of sleep, humans, 1000

degradation—kinetics and mechanism of anhydrotetracycline epimerization in acid solution, high-performance liquid chromatographic and circular dichroism study, 1159
—high-pressure liquid chromatographic analysis, urine, 1319
—kinetics of degradation at pH 1.5, effect of temperature, 1648
Tetracyclines—organohoron carboxamido derivative synthesized, UV, IR, and NMR spectral data and hydroiytic stability evaluated, 1505
various—ac polarographic analysis, electrode processes identified, 1564
various—antibacterial activity, related to partition coefficients, resistant and sensitive microorganisms, structure–activity relationships, 88
various—photosensitized oxidation, reaction kinetics followed using polarographic oxygen electrode, effect of pH and copper(II) ions, 186
various—TLC–bioautographic analysis of penicillin G and ampicillin as contaminants, 1646
Tetraethylammonium bromide—pharmacokinetic model, effect of sodium salicylate on renal elimination, rats, 56
Δ-Tetrahydrocannabinol—GLC and high-pressure liquid chromatographic analyses, biological fluids, 20
—high-pressure liquid chromatographic–mass spectrometric analysis, human plasma after smoking marijuana, 1263
—intravenous, radiochemical study of pharmacokinetics, dogs, 395
Tetrahydrocarbazoles, substituted—effect on serum lipid levels in rats, toxicity in rats, mice, and rabbits, 348
substituted—spectrofluorometric analysis, human blood and urine, 353
Tetrahydroisoquinolines, substituted—salsolinol electron-capture GLC analysis in mouse brain tissue, 893
Tetrazole analogs of phenylalanine derivatives—synthesized, effect on tyrosine hydroxylase activity, 1642
Tetrazolium reagents—effect of laboratory light, various solvents, 965
Thebaine—GLC analysis, root and aboveground portions of various strains of *Papaver bracteatum*, 1716
Thermal behavior—four polymorphic forms of phenylbutazone compared, 669
Thermodynamics—alkylparabens in aliphatic alcohols, effect of temperature, 42
Thermogravimetry—determination, effect of various tablet components on nitroglycerin volatility, 265
Thiazoles, substituted—synthesized, screened for antiparasitic activity, rats, 423
Thiazolidine—and derivatives, NMR conformational study in aqueous solutions, 483
Thiazolines, substituted—synthesized, evaluated for anthelmintic activity in sheep, 1150
Thiazol-3-ol, substituted—kinetics of degradation in aqueous media, effect of temperature, pH, and ionic strength, 1175
Thimerosal—high-pressure liquid chromatographic analysis, pharmaceutical formulations, 738
Thiocarboxamides, various—synthesized, screened for antituberculosis activity, 1332
Thiocardenolides—3β-thioacetyl-14β-hydroxy-5β-card-20(22)-enolide synthesized, screened for cardiotonic activity and effect on sodium- and potassium-activated adenosine triphosphatase, 602
Thiocolchicines, various—X-ray diffraction determination of crystal and molecular structures, 1127
Thiophenes, various—synthesized, evaluated for antibacterial and cytotoxic activity, 1052
Thiosemicarbazides, various—synthesized, evaluated for anticonvulsant activity and effect on NAD-dependent oxidations, rats, 971
Thiosemicarbazones, various—synthesized for evaluation as antituberculous agents, 904
Thiosulfonates—formed by reaction of benzenesulfonohydrazides and benzenesulfonamides with hydrogen chloride in acetic acid, pharmacological activity screened, 1009
Thymidylate synthetase—inhibition by fluorescent derivatives of 2′-deoxy-5-fluorouridylate ester evaluated, 434
Tiaprofenic acid—pharmacokinetics in humans, rats, dogs, mice, and rabbits, 1030
Tiliacora funifera—extract of roots, funiferine *N*-oxide isolated and identified, 1242
Time-dependent pharmacokinetics—carbamazepine, 1-week infusion, monkeys, 647
—ethosuximide, circadian rhythm in steady-state plasma levels, monkeys, 650
Tin—stannous ion, differential pulse polarographic analysis in pyrophosphate and polyphosphate radiopharmaceutical kits, 870
Tissue binding—phenytoin compared in normal, nephrotic, and uremic humans, warfarin in rats with intrinsic high and low plasma binding ability, 1211
culture—skeletal muscle, electrophysiological and pharmacological properties, chemosensitivity, review, 913
TLC—analysis, 2-(3-benzoylphenyl)propionic acid, plasma, rats, 281
—analysis, dansyl derivatives of *N*-(monoaminoalkyl)- and *N*-(polyaminoalkyl)acetamides, human urine, 1195
—analysis, folic acid bulk drug, 1112
—analysis, iodochlorhydroxyquin and conjugate, biological fluids, 1334
—analysis, luteinizing hormone releasing hormone, various synthetic preparations, 386
—analysis, triprolidine, human and rat plasma, 841
–bioautography—analysis, penicillin G and ampicillin as contaminants in various tetracyclines and penicillamine, 1646
—determination, dansyl derivatives of *N*-(monoaminoalkyl)- and *N*-(polyaminoalkyl)-acetamides, human urine, 1089
—effect of modifications of Dragendorff's reagent on relative sensitivities of compounds containing various functional groups, 1656
fluorometry—analyses, oxytetracycline and impurities in prepared solutions, 1419
–high-pressure liquid chromatography—analysis, polyamines in tissue extracts, mice, 1586
—identification, diacetylmorphine metabolites, human urine, 201
—isolation of various morphine metabolites from human urine, 1288
—systems, evaluation and optimal combination for qualitative determination of sulfonamides, 1269
Tocainide—high-pressure liquid chromatographic analysis, plasma or blood, 583
Tolbutamide—interaction with sulfadimethoxine, kinetic analysis, sheep, 1063
Topical bioavailability—model and equations developed permitting *in vitro* assessment, assuming simultaneous metabolism and drug transport in skin, 1525
—quantitative skin model assuming inactive stratum corneum and viable, enzyme-containing epidermis, 755
Topological indexes—molecular connectivity indexes correlated with GLC retention indexes of various alcohols, ethers, esters, and ketones, 1630
—molecular connectivity indexes, relationship to E_S parameter used to estimate steric effects in organic reactions, 1352
—molecular connectivity index, related to structure–activity relationships, various types of molecules, 642
Toxicity—dimethyl sulfoxide, intravenous administration, anesthetized rabbits, 269
—ethanol, effect of lysine and diethanolamine–rutin, mice, 35
—monomeric methyl methacrylate vapor, pulmonary exposure, effects on GI motor activities, dogs, 613
—poorly soluble drugs, various formulations evaluated using LD_{50} testing, mice, 1567
—substituted tetrahydrocarbazole, rats, mice, and rabbits, 348
—various phorbol esters to brine shrimp larvae, related to cocarcinogenic potency, 1362
Toxicology—pharmaceutical salts, review, 1
Training time—effect on muscular enzyme activity, rats, 1278
Tranquilizers—azaperone and oxide, fluorescence characteristics, effect of pH, 1787
—chlordiazepoxide, adsorption to activated charcoal *in vitro*, effect of pH, 1640
—chlordiazepoxide and related impurities, high-performance liquid chromatographic analysis, commercial formulations, 684
—chlorpromazine metabolites, electrochemical study of oxidation pathways, 357
—perphenazine, high-performance liquid chromatographic analysis, pharmaceutical formulations containing amitriptyline hydrochloride, 1117
—various phenothiazines, periodic acid oxidation, effect of adenosine diphosphate and triphosphate, 1575
Transport, drug—simultaneous with metabolism in skin, model and equations developed permitting *in vitro* assessment of bioavailability, 1525
—three *p*-aminobenzoate esters through tubular dimethyl polysiloxane membrane into a flowing liquid, 337
Triamterene—distribution and pharmacokinetics, radiochemical analysis, rats, 53
Triazenes, substituted—synthesized, antitumor activity evaluated, mice, 1416
Triazolethioglycolic acids, various—synthesized, evaluated for anticonvulsant activity and effect on NAD-dependent oxidations, rats, 971
Triazolopyrazines, substituted—effect on complexes of *p*-benzoquinone with proline and histamine, kinetic spectrophotometric study, 205
Triclocarban—GLC analysis, rat and human blood, 725
Triclosan—GLC analysis, free and conjugated, human plasma and urine, 1166
Triethylenetetramine–polystyrene resin—^{99m}Tc-labeled, use in scintigraphic determination of gastric emptying rate, humans, 442
Trimethoprim—NMR spectroscopic analysis, synthetic mixtures and commercial formulations containing sulfamethoxazole, 121
Trimethylsilyl derivative of biotin—structure determined, 1212
Triprolidine—TLC analysis, human and rat plasma, pharmacokinetic profile, 841
tRNA methyltransferase—activity, effect of coralyne, nitidine, and related compounds, rat liver homogenate, 986
Tryptamine—monoamine oxidase-catalyzed deamination, effect of 3,4-dimethoxyphenethylamine and *N*-methyl homologs, 1048
L-Tryptophan—binding by defatted human serum albumin, effect of indomethacin and congeners, 950
Tuberculostatic antibacterials—isoniazid, absorption, tissue distribution, excretion, and metabolism, effect of various drugs, rats, 1322
—isoniazid and acetyl derivative, high-pressure liquid chromatographic analyses, plasma and urine, 813
—isoniazid, bioavailability of three commercial formulations compared, 1761
—isoniazid, colorimetric analysis, hydrazones formed with 4-nitrobenzaldehyde or pyridoxal, prepared samples, 291
—isoniazid, high-performance liquid chromatographic analysis, tablets and injectables, 564
Tumor inhibitory activity—lignan isolated from chloroform fraction of extract of aerial parts of *Polygala macradenia* evaluated, 586
Turbidimetry—microbiological antibiotic and vitamin assays, procedures devised to linearize curved calibration lines, 1520
Tyramine—monoamine oxidase-catalyzed oxidative deamination, effect of 3,4-dimethoxyphenethylamine and *N*-methyl homologs, 1048
Tyrosine hydroxylase activity—effect of various tetrazole analogs of phenylalanine derivatives, 1642

U

Ultracentrifugation—determination of apparent partition coefficients of various drugs between water and micellar pseudophase, 858

Ureas, D-arabinofuranosyl—synthesis described, 1206
Uric acid—*in vitro* photodecomposition in presence of riboflavin, effect of pH and solvent, 1561
Urinary recovery studies—effect of montmorillonite on bioavailability of amphetamine sulfate, applied to sustained-release dosage form, 63
UV irradiation—effect on various drugs, polymerization of acrylamide determined by dilatometry or oxidation of 2,5-dimethylfuran determined by polarographic oxygen electrode, 1282
photometry—analysis, betamethasone benzoate and other 21-hydroxycorticosteroids, bulk drug and pharmaceutical formulations, 1145
spectrophotometry—analyses, aminophylline, amobarbital, and ephedrine hydrochloride in combination commercial capsule, 811
spectrophotometry—analysis, various endotoxins, prepared solutions, wide concentration range, 723

V

Vaginal absorption—various straight-chain aliphatic alcohols, perfusion system designed, rhesus monkeys, 216
devices, bovine—progesterone in silicone matrix, compared to *in vitro* system, 816
drug delivery—model, membrane surface pH determined, compared to bulk solution pH, rabbits, 748
Valproic acid—steady-state plasma levels, time-dependent kinetics, monkeys, 1154
Vasodilators—papaverine, caffeine, nicergoline, and bamethan, effect on muscular enzyme activity, rats, 1278
Vasodilators, coronary—isosorbide dinitrate and metabolites, electron-capture GLC analysis, plasma, 1143
—isosorbide dinitrate, electron-capture GLC analysis, human plasma, 384
—isosorbide dinitrate, pharmacokinetics, oral and sublingual administration compared, standard and sustained-release tablets compared, humans, 775
—nitroglycerin, sorption by thermoplastic polymers and stability of molded tablets in various strip packages, effect of povidone, 1293
—nitroglycerin, volatility, effect of various tablet components, thermogravimetric determination, 265
Vasomotor activity—chloramphenicol and its hydrolytic product evaluated, various guinea pig, rat, rabbit, and toad muscles, 1239
Vehicles—effect of composition and pH on ocular bioavailability of pilocarpine, rabbits, 1222
Velocities, solute—in descending column during dissolution from a horizontal surface, mathematical analysis, 741
Viral DNA polymerase—effect of litmomycin on *in vitro* activity, reaction kinetics and mechanism, 130
Viscosity—aqueous solutions of salicylic acid and cetrimide, 1779
binder solution—effect on drug migration during drying of tablet granulations, 1409
Vitamins—biotin, structure of trimethylsilyl derivative determined, 1212
—folic acid, TLC and high-pressure liquid chromatographic analyses, bulk drug, 1112
—microbiological turbidimetry assays, procedures devised to linearize curved calibration lines, 1520
—niacin, absorption from stomach and small intestine compared, humans, 871
—niacin and niacinamide, simultaneous analysis, reversed-phase high-pressure liquid chromatography, multivitamin preparations, 40
—pyridoxine hydrochloride, effect on aqueous solubility of nitrofurantoin, 1357
—riboflavin, effect on *in vitro* photodecomposition of uric acid, various pH's and solvents, 1561
Volatility—nitroglycerin, effect of various tablet components, thermogravimetric determination, 265

W

Warfarin—distribution kinetics, effect of plasma protein binding, rats, 567
—elimination kinetics and anticoagulant activity, effect of chronic administration, rats, 1275
—(*R*)-(+)- and (*S*)-(−)-enantiomers, steady-state anticoagulant activity compared, 1790
—high-pressure liquid chromatographic analysis, human plasma, 142
—pharmacokinetics and anticoagulant action, effect of ibuprofen, rats, 943
—plasma levels predicted from *in vitro* dissolution data, 297
—serum concentration related to anticoagulant response characteristics, rats, 145
—serum protein binding compared to phenytoin, salicylic acid, and sulfisoxazole, normal and renally impaired humans, rats, 1285
—serum protein binding, effect of ibuprofen, humans, 1060
—serum protein binding, effect of phenobarbital, rats, 941
—tissue binding, rats with intrinsic high and low plasma binding ability compared, 1211
Weight fraction undissolved—multisized drug particles, approximate expressions, 553
Withdrawal reactions—ethanol, effect of lysine and diethanolamine–rutin, mice, 35

X

Xanthines, various—partition coefficients, coacervates as nonpolar phases in equilibrium with polar water phases, 283
2-Xanthonecarboxylic acid, substituted—and sodium salt, micronized powders used in formulating powder inhalation aerosols, effect of lactose concentration, humidity, and temperature, 1254
Xanthones, methoxy substituted—NMR spectra and solvent shift data, 884
polyoxygenated—six isolated from methanol extract of roots of *Eustoma grandiflorum,* 828
X-ray diffraction—determination of crystal and molecular structures of various thiocolchicines, 1127
—study, griseofulvin–polyethylene glycol 6000 dispersion, effects of pulverization and aging, 989

Y

Z

Zero point of charge—slightly soluble hydroxides, related to solubility product, 1548
Zinc—serum levels, effect of various salts, chelates, and other complexes, rats, 391
Zinc chloride—alone and complexed with 1,10-phenanthroline, teratogenic effects evaluated in mice, 1755
Zwitterionic cephalosporin compounds—ionization constants, error in equations corrected, 1357